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Colorectal cancer (CRC) is a considerable health burden being the second highest cause of 
cancer deaths globally. While overall cases of CRC have been declining worldwide, there has 
been an increase in the incidence of the disease among patients under 50 years of age. The 
majority of these cancers are sporadic and the increase in incidence may reflect changing 
lifestyle, exposing young people to more and earlier pro-oncogenic factors.   
An early event in the development of CRC is the loss of normal structure of the epithelium and 
key to this is the loss of cell to cell contact. E-cadherin, encoded by the CDH1 gene, is a 
membrane-bound protein whose extracellular domains bind to E-cadherin of neighbouring 
cells forming adherens junctions as the primary event in intercellular contact. Loss of E-
cadherin leads to the breakdown of this organised epithelial structure and can lead to the 
development of cancer.  
The research detailed in this thesis looked at E-cadherin expression status and mutation of the 
CDH1 gene in two separate cohorts. Firstly tumours from young Pakistani patients with early-
onset colorectal signet-ring cell carcinomas (SRCCs), due to their histological similarity to 
SRCCs found in hereditary diffuse gastric cancers where mutation of CDH1 is a common 
causative factor and, secondly a local New Zealand cohort of early-onset CRC cases. 
E-cadherin was found to be absent or weak in the colorectal SRCC samples and in a small 
number of cases this corresponded to germline CDH1 mutation. However, the remaining SRCC 
samples had low levels of CDH1 mutation despite loss of E-cadherin expression, suggesting 
that while E-cadherin loss is common in colorectal SRCC it is not due to CDH1 mutation in 
most cases. Amongst the New Zealand samples, only one tumour, the sole SRCC case in the 
cohort, showed loss of E-cadherin but this was not correlated with CDH1 mutation which was 
not a common feature of this cohort. 
Additionally, APC sequencing was performed on the New Zealand cohort. APC is mutated in 
60-80% of sporadic CRC tumours but with reportedly lower levels in younger patients. 
However 72% of the New Zealand early-onset CRC cohort was found to have a mutation in 
APC, a higher proportion than expected. This may reflect a greater coverage of APC by the 
sequencing methodology employed in this study compared to previous studies with a high 
proportion of mutations occurring outside the commonly studied mutation cluster region of 
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APC. Loss of heterozygosity at the APC locus was found in only three patients, all of whom 
had APC mutations occurring close to codon 1300, reflective of a previous studies in older-
onset CRC. 
While environmental and lifestyle factors are widely considered to have roles in the 
development of sporadic CRC, there is growing evidence of the gut microbiota being a factor 
in colorectal carcinogenesis. One well-studied toxin-producing bacteria is Enterotoxigenic 
Bacteroides fragilis (ETBF) that causes cleavage of E-cadherin in colonic epithelial cells. 
Study of the effect of the B. fragilis toxin (BFT) on colonic epithelial cells has focused on the 
cell line HT29 which shows a rapid morphological change upon incubation with BFT. 
However, HT29 cells only have truncated forms of APC. In the last part of this study one 
mutated APC allele in HT29 was corrected by genome editing in order to study the effects of 
BFT on a cell line expressing full-length APC, and thereby to increase our understanding of 
the role of APC in colorectal carcinogenesis.  
The rapid change in morphology upon exposure to BFT in HT29 cells has been attributed to 
the BFT-mediated cleavage of E-cadherin. However, edited HT29 cells containing full-length 
APC maintained their structure after 6 hours incubation with ETBF supernatant. Moreover, 
fluorescent immunohistochemistry showed that cell morphology was maintained despite the 
cleavage of E-cadherin, suggesting that the structural integrity of the edited cells was due to 
some internal function of APC rather than E-cadherin cleavage. 
In summary, this research found that E-cadherin loss was commonly found in colorectal 
SRCCs but predominantly occurred independently from CDH1 mutations. Furthermore, other 
than in SRCCs, E-cadherin loss was not a common feature of early-onset CRC. Conversely, 
APC mutation was very common, with many mutations being found outside the mutation 
cluster region of APC, suggesting APC sequencing strategies should be targeted more widely 
throughout the gene. These results suggest a role for the APC protein in stabilising the cellular 
morphology of HT29 cells exposed to bacterial toxin, which is independent of E-cadherin. The 
edited HT29 cell line is likely to be a useful tool in the study of bacterial and other 
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1.1 Colorectal Cancer 
Colorectal cancer (CRC) is a considerable health burden globally, being the second most 
diagnosed cancer in women and third in men (Ferlay et al., 2015). New Zealand ranks amongst 
the highest in the world for incidence (Gandhi et al., 2017) and CRC is the second highest cause 
of cancer-related death (Gandhi et al., 2017).  
CRC is influenced by both genetic and environmental factors. While hereditary syndromes 
predisposing patients to CRC, for example hereditary non-polyposis colorectal cancer (Lynch 
et al., 1991) and familial adenomatous polyposis (Groden et al., 1991; Nishisho et al., 1991) 
exist, the majority of CRC cases are sporadic.  
 
1.1.1 Hereditary colorectal cancer syndromes 
1.1.1.1 Hereditary Non-Polyposis Colorectal Cancer 
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is an 
autosomal dominant condition caused by mutations in DNA mismatch repair genes (Lynch et 
al., 1991). DNA damage can occur via errors in DNA replication or by the effects of exogenous 
factors, such as chemicals, cigarette smoke and radiation, or endogenous metabolites including 
reactive oxygen or nitrogen species (G. M. Li, 2008). To prevent such damage affecting the 
integrity of the genome, cells possess multiple mechanisms to repair this damage, an important 
one of which is DNA mismatch repair (MMR). Loss of activity of MMR proteins leads to rapid 
accumulation of DNA replication errors, including within key regulatory genes involved in cell 
control, apoptosis and DNA repair, increasing the potential for tumour formation (Boland et 
al., 2008). The four principal MMR genes mutated in HNPCC are MutL homolog 1 (MLH1), 
post-meiotic segregation 2 (PMS2), MutS homolog 6 (MSH6) and MutS homolog 2 (MSH2) 
(Al-Sohaily et al., 2012). Mutation of a further gene that encodes an epithelial cell adhesion 
molecule Ep-CAM (TACSTD1) has also been implicated in HNPCC due to its silencing effect 
on MSH2 (Ligtenberg et al., 2009).  
The accumulation of DNA replication errors in HNPCC is particularly apparent in 
microsatellites, short regions of repetitive sequences that can acquire losses or gains of the 
2 
 
repeated sequence. This manifests itself as microsatellite instability (MSI) and microsatellite 
testing can be performed by amplifying these short repetitive regions and looking for changes 
in the lengths of the amplicons due to the loss or gain of repeat sequences (Suraweera et al., 
2002). Alternatively, HNPCC can be diagnosed using immunohistochemistry by measuring the 
loss of expression of any of MSH2, MSH6, MLH1 or PMS2 (South et al., 2009). This will also 
be effective in the case of mutation of TACSTD1 as this also results in the loss of MSH2 
expression. 
HNPCC is the most common inherited form of CRC, accounting for 2-3% of all colorectal 
cancer cases (Desai & Barkel, 2008). Tumours occur at an earlier age in HNPCC patients than 
in the general population (Cunningham et al., 2010), and tend to be located on the right side of 
the colon and often occur with synchronous and metachronous colorectal tumours (Vasen, 
2007).  
 
1.1.1.2 Familial Adenomatous Polyposis 
Familial adenomatous polyposis (FAP) accounts for less than 1% of all CRC cases and, despite 
being less common than HNPCC, was the first familial colorectal cancer syndrome identified 
due to its striking clinical characteristics. The disease is typified by the early-onset of hundreds 
to thousands of adenomatous polyps within the colon, and if left untreated almost 100% of 
patients will develop colorectal cancer by the age of 40 years (Bisgaard et al., 1994). Cancer 
can be prevented by rigorous screening and surgical intervention. FAP is an autosomal 
dominant disease caused by mutations in the adenomatous polyposis coli (APC) gene (Groden 
et al., 1991). A detailed analysis of the role of APC in CRC is introduced below. 
Attenuated FAP is a less aggressive form of the disease with a later age of onset and fewer 
adenomatous polyps. While attenuated FAP is also caused by mutations in APC, the causal 
mutations appear confined to three regions of APC: the 5’ region comprising the first 5 exons, 
exon 9 and the 3’ region of the gene (Knudsen et al., 2003). It is estimated around 8% of FAP 






1.1.1.3 Other inherited colorectal cancer syndromes 
A number of other conditions can result in rare inherited forms of CRC. MUTYH-associated 
polyposis is an autosomal recessive sub-type that occurs as a result of mutation of the MUTYH 
gene, which encodes the MYH glycosylase, which is involved in DNA base excision repair. 
Loss of MYH glycosylase leads to the accumulation of DNA mutations in the cell and 
subsequent tumour formation (Poulsen & Bisgaard, 2008). 
Peutz-Jeghers syndrome is an autosomal dominant condition caused by mutation of the 
serine/threonine kinase 11 gene (STK11, also known as LKB1) (Jenne et al., 1998) with an 
incidence of between 1 in 25,000 and 1 in 300,000 people. STK11 is a tumour suppressor gene 
that regulates cell polarity and promotes programmed cell death. Mutation of STK11 is 
associated with uncontrolled epithelial cell growth, leading to the formation of hamartomatous 
polyps and a 41-60% risk of malignant tumours (Vaahtomeri & Makela, 2011). 
Cowden syndrome, an inherited condition affecting approximately 1 in 200,000 people, is 
caused by mutation of the phosphatase and tensin homolog gene (PTEN), and manifests as an 
increased risk of multiple malignancies including colon cancer. Multiple hamartomatous 
polyps are a common feature in Cowden syndrome (Stanich et al., 2011). Interestingly the 
STK11 and PTEN genes implicated in the formation of hamartomatous polyposis syndromes 
in Peutz-Jeghers and Cowden syndromes, respectively, have been shown to interact with each 
other, suggesting these two syndromes may develop through similar pathways (Mehenni et al., 
2005). 
 
1.1.2 Sporadic colorectal cancer pathways 
Approximately 75% of colorectal cancer is sporadic, occurring in patients without a genetic 
predisposition or family history of CRC. Tumour formation is the result of an accumulation of 
genetic and epigenetic alterations (Yamagishi et al., 2016). Over the past few decades three 
pathways of carcinogenesis, comprising different but overlapping patterns of mutated or altered 




Figure 1.1 Sporadic colorectal cancer pathways. Diagram showing the key genetic and epigenetic 
events in each of the three pathways of colorectal cancer development. APC, adenomatous polyposis 
coli gene; KRAS, Kirsten rat sarcoma proto-oncogene; BRAF, v-RAF murine sarcoma viral oncogene 
homolog B; MSI, microsatellite instability; MSS microsatellite stable; CIMP, CpG island methylator 
phenotype. 
 
1.1.2.1 The adenoma-carcinoma pathway 
The genes mutated in familial CRCs are also key to sporadic CRC, with mutation of APC in 
particular being an early event in colorectal carcinogenesis. APC mutations are found in the 
earliest microscopic adenomas (Kinzler & Vogelstein, 1996) and APC mutations in sporadic 
tumours are found at the same rate as in early adenomas (Polakis, 2007). Additionally, both 
alleles of APC appear to require inactivation for carcinogenesis to occur, thereby fulfilling 
Knudsen’s two-hit hypothesis (Kinzler & Vogelstein, 1996). However, APC mutation alone is 
not sufficient in itself for CRC progression as not all adenomas will progress to carcinomas, as 
was evidenced by a study that found no significant difference in APC status between progressed 
and non-progressed adenomas (Hermsen et al., 2002). Those adenomas that do progress to 
CRCs acquire an accumulation of additional genetic aberrations such as mutations of the 
Kirsten rat sarcoma proto-oncogene (KRAS), V-RAF murine sarcoma oncogene homolog B1 
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(BRAF), SMA- and MAD-related proteins 2 and 4 (SMAD2/4), and tumour protein 53 (TP53), 
that occur over time as dysregulation continues (Sameer, 2013). These are often referred to as 
the adenoma-carcinoma sequence (Figure 1.2; (Fearon & Vogelstein, 1990)).  
 
Figure 1.2 The adenoma-carcinoma model of colorectal carcinogenesis. The sequential 
accumulation of genetic aberrations proposed by Fearon and Vogelstein starting with mutation of the 
APC gene. DCC, Deleted in colon cancer (Figure taken from Yalcin, 2014).  
 
An early event following APC mutation in the adenoma-carcinoma pathway is genetic 
disruption in the form of loss or gain of whole arms, or significant portions of arms of 
chromosomes in what is termed chromosomal instability (CIN) (Pino & Chung, 2010). This 
results in an imbalance in chromosome number (aneuploidy) and a high frequency of loss of 
heterozygosity (LOH). Common chromosomal anomalies in CIN include loss of chromosome 
18, partial loss of chromosomes 1, 5, 8 and 17, as well as gains and losses of large parts of 
various chromosomes (Sheffer et al., 2009; Thiagalingam et al., 2001). Of note, loss of 
chromosome 5q, the chromosome arm carrying the APC gene, is seen in 20-50% of colorectal 
cancers (Fearon & Vogelstein, 1990). 
 
1.1.2.2 The microsatellite instability pathway 
While mutation of the APC gene is a hallmark of the adenoma-carcinoma pathway, APC 
mutation per se is not an absolute requirement for CRC progression as alternative pathways of 
CRC exist, as evidenced by the finding that a minority of CRC tumours present with wild type 
APC. This group includes the 15 to 30% of CRC cases that develop from serrated polyps, 
characterised by their saw-tooth appearance (Bettington et al., 2013). Neoplastic lesions arising 
from serrated polyps rarely present with APC mutations but commonly have mutations in 
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BRAF and to a lesser extent KRAS (De Palma et al., 2019). Another common feature of the 
serrated pathway is microsatellite instability (De Palma et al., 2019). 
Microsatellite instability (MSI), the result of mutations in mismatch repair genes, manifests as 
the destabilisation of repetitive tracts of DNA and is the underlying cause of hereditary non-
polyposis colorectal cancer, as detailed above. MSI is also seen in approximately 15% of 
sporadic colorectal cancers (Boland & Goel, 2010). As with familial HNPCC, mutation of 
mismatch repair genes leads to the rapid accumulation of DNA errors, including aberrations in 
key genes that regulate the cell cycle, apoptosis and DNA repair (Boland et al., 2008).  
The presence of MSI in CRCs is associated with an improved prognosis compared to 
microsatellite stable (MSS) tumours (Popat et al., 2005). The reasons for this are unclear. 
Notably, tumours with MSI tend to have less loss of heterozygosity than tumours in the 
chromosomal instability pathway (Soreide et al., 2006). Furthermore, mutations or allele losses 
in KRAS, TP53 and DCC (Deleted in Colon Cancer) are associated with a poorer prognosis and 
mutations within these genes are uncommon in MSI tumours (Soreide et al., 2006). Conversely, 
BRAF V600E mutations are common in MSI tumours while they are not seen in HNPCC 
tumours (G. Deng et al., 2004). In addition, MSI tumours are observed to be associated with 
lymphocyte infiltration, and it is possible that this immune response may contribute to a better 
outcome (Linnebacher et al., 2010). 
 
1.1.2.3 The methylator phenotype pathway 
The discovery during the 1990’s, that multiple suppressor genes are silenced in colorectal 
tumours, led to the development that epigenetic aberrations can define tumour progression as 
a CpG island methylator phenotype (CIMP) (Toyota et al., 1999), where expression of key 
tumour suppressor genes are repressed by promoter methylation (Goel et al., 2007). This led to 
the assertion that CIMP could be used as a classifier and prognostic indicator in CRCs.  While 
the majority of colorectal tumours have genetic aberrations due to either MSI or CIN, the CIMP 
can occur alongside CIN and is often associated with MSI, but appears to arise from an 
independent mechanism of tumour progression (Cheng et al., 2008).  
Tumours exhibiting a CIMP account for about 15-20% of sporadic CRCs, are more common 
in women and older patients, and are often located in the proximal colon (Nosho et al., 2008).  
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CIMP-positive tumours are often associated with MSI and BRAF mutation (Weisenberger et 
al., 2006) and this may be due to methylation of the MLH1 promoter. 
Environmental factors such as smoking (Samowitz et al., 2006) and aging (Toyota & Issa, 
1999) have been shown to correlate with increased methylation. A detailed discussion of 
environmental and lifestyle factors, and their effect on epigenetics and carcinogenesis, is 
presented below (Section 1.7). 
 
1.2 The structure of the colonic epithelium 
The colorectal epithelium consists of a monolayer of polarised cells that act as a barrier, 
keeping the rich microbe community of the gut lumen from infecting the rest of the body. The 
formation of this barrier starts at the base of colonic crypts with continual division of a small 
population of stem cells. At each stem cell division, one cell becomes a transit amplifying cell 
that continues to proliferate, populating first the crypt and then starting to migrate up the crypt 
towards the villus (Boman & Fields, 2013). As numbers increase, cells migrate up the crypt 
where there is a reduction in proliferation as the cells polarise and then differentiate (Pinto & 
Clevers, 2005).  
Central to the establishment of this cell polarity is the formation of adherens junctions (Knust 
& Bossinger, 2002) between adjacent cells where the intracellular protein E-cadherin forms 
homocomplexes with its neighbouring cell (Figure 1.3). The binding of E-cadherin not only 
contacts neighbouring cells but also provides a structural link with intracellular structures via 
catenin proteins (Paredes et al., 2012). The resultant polarised cell monolayer moving up the 
crypt has clearly defined basolateral and apical membranes (Wodarz & Nathke, 2007). Tight 
junctions then form between adjacent cells and integrins bind the basal membrane to the 
basement membrane. The formation of this E-cadherin-mediated barrier not only provides 
structure to the cells, but also acts as a signal to suppress further cell proliferation (Mendonsa 





Figure 1.3 Binding of the extracellular domains of E-cadherin proteins from adjacent cells. E-
cadherin binds adjacent cells at adherens junctions while connecting intracellularly to the actin 
cytoskeleton via catenin molecules (Figure taken from Perry et al., 2009). 
 
The polarised cells continue to migrate up the crypt, gradually differentiating until they are 
shed from the surface of the villus into the lumen of the gut, after a crypt to villous migration 
of approximately five days (Potten et al., 1992).  
 
1.3 The cytoskeleton 
The intracellular domain of E-cadherin binds to β/γ-catenin in a complex with α-catenin which 
attaches to the actin cytoskeleton (Figure 1.3) (Takeichi, 1991). The cytoskeleton is a dynamic 
fibrous network throughout the cytoplasm that regulates cellular architecture as well as 
providing a scaffold for diverse biochemical pathways (S. Kim & Coulombe, 2010). 
Structurally the cytoskeleton is comprised of actin filaments and microtubules made from 
polymerised tubulin. As the cytoskeleton forms a dynamic network across the entire cell it is 
in contact with many cellular components such as the nucleus, various organelles, vesicles and 
proteins, many of which depend on the cytoskeleton for their function. Accordingly, the 
cytoskeleton is a regulator of many cellular processes including cell division, organelle 
positioning, vesicular trafficking, cell migration and adhesion (M. C. Kim et al., 2012). 
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The microtubule component of the cytoskeleton is stabilised by APC binding to its end with 
APC conferring a longer lifespan on microtubules (Kita et al., 2006). APC further strengthens 
the cytoskeleton by facilitating crosstalk between microtubules and actin filaments as a part of 
the cortical microtubule stabilisation complexes (Dogterom & Koenderink, 2019). The 
microtubule binding domain of APC is located near the C-terminal end of the protein which is 
usually lost in the truncated cancer-associated isoforms of APC. Thus disruption of the 
cytoskeletal stabilising role of APC may be one of the key mechanisms by which 
carcinogenesis is promoted by truncated APC (Nathke, 2006), in addition to its role in the 
regulation of Wnt signalling (Section 1.4.1).  
 
1.4 Wnt signalling 
Wnt (Wingless-related integration site) signalling is the dominant force driving epithelial cell 
proliferation in the colon. Wnt ligands bind to the transmembrane receptors Frizzled and 
LRP5/6 (X. He et al., 2004). Binding of the ligands stabilises β-catenin intracellularly which 
then moves to the nucleus where it binds to T-cell factor (TCF) family transcription factors. 
The DNA-binding specificity of TCFs and the transactivation domains of β-catenin allow 
transcription of Wnt target genes such as the MYC oncogene leading to cell proliferation (Pinto 
& Clevers, 2005).  
The effect of Wnt signalling on cell proliferation is desirable in the cells at the bottom of the 
colonic crypts where proliferation is key to the renewal of epithelial cells and cell turnover. 
However, as the cells move up the crypt and mature, Wnt-controlled cellular proliferation is 
less desirable and, accordingly, Wnt signalling becomes gradually inactive towards the top of 
the crypt in the normal epithelium (Daulagala et al., 2019). 
The key intracellular regulator of Wnt signalling is the tumour suppressor protein adenomatous 
polyposis coli (APC). Consequently, the loss of functional APC, as seen in FAP (Groden et al., 
1991) or in 70-80% of sporadic CRC (Fearon, 2011), is associated with dysregulated Wnt 






1.4.1 APC function 
APC is a multi-functional protein in epithelial cells, having roles in Wnt signalling (Boman & 
Fields, 2013), cell structure through interactions with the actin cytoskeleton and microtubules 
(Munemitsu et al., 1994), epithelial cell polarity (Bellis et al., 2012) and apoptosis (Cristofaro 
et al., 2015). As such APC has a number of different binding partners. APC is an important 
regulator of Wnt signalling. In the absence of a Wnt ligand, APC forms a complex with axin 
and GSK3β, recruiting β-catenin to the complex for its phosphorylation by GSK3β, resulting 
in the ubiquitination and, ultimately, proteasomal degradation of β-catenin. This prevents 
excess β-catenin translocating to the nucleus and upregulating oncogenic target genes such as 
MYC (Figure 1.4). 
 
Figure 1.4 The Wnt signalling pathway. In the absence of Wnt ligand (left plate) β-catenin is 
phosphorylated by the APC complex and targeted for degradation. When Wnt ligand binds to its 
receptor (right plate), the phosphorylation of β-catenin is prevented, allowing nuclear translocation of 
β-catenin, its binding to TCF factor, and the transcription of target genes. This figure also highlights the 
interplay between the dual roles of β-catenin in Wnt signalling and intercellular binding via E-cadherin 




The consequent effects of unrestricted upregulation of oncogenic Wnt target genes, caused by 
defects in APC, are exemplified in both hereditary familial adenomatous polyposis (FAP) and 
in sporadic CRCs (Miyoshi et al., 1992), which commonly carry mutations in the APC gene. 
 
Figure 1.5 Wnt and APC gradients in colonic crypts. APC and Wnt are both essential for the 
regulation of cell proliferation and epithelial homeostasis in the gut. Wnt signalling is highest in the 
cells at the bottom of the crypt while APC levels increase as the cells move up the crypt. A sweet spot 
exists where conditions are optimal for balanced growth and cell proliferation. In the case of mutated 
or lost APC, with either one allele (FAP crypt) or both (adenomatous crypt), the sweet spot is higher in 
the crypt leading to uncontrolled proliferation of crypt cells (Figure taken from Boman & Fields, 2013). 
 
The APC gene is located on chromosome 5q21-q22. Although it consists of 15 exons the final 
exon makes up more than 75% of the coding sequence of the gene. This is where the bulk of 
mutations occur, with a mutation cluster region between codons 1286 and 1513 (Miyoshi et 
al., 1992). Mutations in APC predominantly result in truncated proteins that retain some 
function and it appears that the retained functions are essential for the survival of the cells 
(Chandra et al., 2012). The second allele is either mutated as well or is silenced by loss of 
heterozygosity (Lamlum et al., 1999) or epigenetic mechanisms (Esteller et al., 2000). 
The location of the truncating mutation affects the properties of the resultant protein and the 
tumour phenotype (Christie et al., 2013). While familial APC mutations are scattered across 
the 5’ half of the gene, with notable hotspots at codons 1061 and 1309, sporadic mutations tend 
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to occur within the mutation cluster region (MCR). This region contains a number of 20-amino 
acid repeats that act as β-catenin binding sites. The location of a mutation within the MCR 
determines how many of these repeats are included in the truncated protein, with either 1, 2 or 
3 intact 20-amino acid repeats being left. This in turn affects the function of the truncated 
protein, as well as the type and location of the second hit to the APC gene (Christie et al., 2013). 
This is exemplified by evidence that APC mutations in the MCR that result in 2-3 intact 20-
amino acid repeats are more likely to be found in proximal tumours, while mutations leaving 
only 1 or no 20-amino acid repeats tend to be present in distal CRC (Christie et al., 2013). 
However, while the majority of sporadic APC mutations are found in the MCR, other hotspots 
have been found in the 5’ portion of the gene, including codons 213, 216, 232, 283, 876 and 
935, along with a splice-site mutation at c.835-8A>G (Christie et al., 2013). 
 
1.4.2 E-cadherin  
The development of dysplasia from normal epithelium is key to tumour formation in the gut 
(Tjalsma et al., 2012). An important early step is the loss of cell polarity of the epithelium. 
Loss of E-cadherin at the plasma membrane results in loss of intercellular contact at adherens 
junctions, and ultimately loss of cell polarity. This breakdown in the organised structure of the 
epithelium allows dysplastic growth of epithelial cells which can lead to the formation of 





Figure 1.6 Loss of E-cadherin binding results in changes to cellular architecture. A, The normal 
epithelium consists of a monolayer of polar cells joined to neighbouring cells by adherens (green) and 
tight junctions (black) on the lateral membrane. The binding of E-cadherin forms the adherens junctions 
in a ring around the cell (green lines). The apical layer (blue) faces the lumen. B, Loss of E-cadherin 
causes disintegration of the adherens junctions, reduced cell-cell adhesion, loss of cell polarity and 
results in heterogenous cell sizes and shapes (Figure taken from Wodarz & Nathke, 2007). 
 
A further consequence of the loss of cell polarity due to a loss of E-cadherin binding is 
enhanced Wnt signalling. This results in the transcription of pro-oncogenic Wnt target genes, 
in particular MYC, which encodes the transcription factor c-myc, whose upregulation is linked 
to stimulation of polyamine metabolism via upregulation of spermine oxidase (SMO) 
expression. This in turn leads to DNA damage via the production of reactive oxygen species 
(Goodwin et al., 2011). 
E-cadherin, encoded by the CDH1 gene, is a calcium-dependent mediator of cell to cell 
adhesion, facilitating the assembly of intercellular junctions (Gumbiner et al., 1988; Shiozaki 
et al., 1996), an essential step in forming an epithelial cell monolayer and induction of cell 
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polarity (Yap et al., 1995) as described above. Accordingly a loss of E-cadherin activity 
disrupts cell layers (Takeichi, 1990). 
Mutations in the CDH1 gene are rare in CRC but are commonly seen in hereditary diffuse 
gastric cancer (HDGC) (Guilford et al., 1998; Hakkaart et al., 2019). HDGC tumours are 
typified by the presence of diffuse foci of signet-ring cells (Charlton et al., 2004), where a large 
amount of intracellular mucin distorts the cell morphology, pushing the nucleus to the edge of 
the cell giving the classic signet-ring appearance to the cell. Loss of E-cadherin disrupts 
intercellular structure allowing the change in morphology seen in these tumours. Accordingly, 
signet-ring cells show a loss of E-cadherin protein expression (H. C. Kim et al., 2002). 
Loss of E-cadherin has been shown in colorectal cancer, although this is not always as a result 
of reduced expression but rather relocation from the membrane to the cytoplasm (Hiscox & 
Jiang, 1997). In a recent study lower expression of E-cadherin was found to be associated with 
tumour differentiation, stage, invasion depth and lymph node metastasis in advanced CRC 
patients (Gao et al., 2016) and accordingly E-cadherin has been proposed as a possible 
biomarker of CRC prognosis (Christou et al., 2017).  
 
1.5 Risk factors for colorectal cancer 
1.5.1 Gut bacteria 
The human gastrointestinal tract is home to tens of trillions of microbes, with each human 
carrying in excess of 1000 different species (Lozupone et al., 2012). This diverse population is 
acquired by babies from their mothers at birth (Dominguez-Bello et al., 2010) and from the 
environment where they spend the first few years of their life before stabilising (Kostic et al., 
2013). Each individual’s unique microbiome is essential in maintaining a healthy gut, with 
individual species complementing the host cells by digestion of complex carbohydrates (Flint 
et al., 2012), producing essential nutrients such as vitamin K (Conly & Stein, 1992), 
maintaining complex immunological interactions with host cells (Littman & Pamer, 2011), and 
protecting against disease by outcompeting pathogens (Wardwell et al., 2011). However, some 
commensal bacteria can, under the correct conditions, initiate disease.  
The oncogenic potential of bacteria has been known since the discovery of Helicobacter pylori 
as a cause of gastric cancer in the 1980s (Marshall et al., 1985). However, whereas H. pylori 
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inhabits the microbially sparse environment of the stomach and acts alone in carcinogenesis, 
the crowded, diverse microbial community of the colon makes associations and mechanisms 
of bacterial carcinogenesis harder to ascertain.  
The development of dysplasia is influenced by the inflammatory state of the gut, as clearly 
seen in Inflammatory Bowel Disease (IBD)-associated CRC (Beaugerie & Itzkowitz, 2015). 
Thus, sub-clinical inflammation may, over time, contribute to the development of dysplasia in 
an otherwise healthy colon. Moreover, long-term carriage of bacterial species that have the 
potential to cause chronic inflammation are increasingly considered to underlie the 
development of neoplasia (Armstrong et al., 2018). 
One model of microbial initiation of colorectal cancer proposes distinct roles for different 
bacterial species. Initially “driver” bacteria cause inflammation, cell proliferation and/or the 
production of genotoxins that cause mutations in key tumour suppressor genes involved in the 
adenoma-carcinoma pathway such as APC and, later, TP53 (Figure 1.7). The proliferation of 
cells and the breakdown of normal epithelial structure leads to changes in the local 
microenvironment which facilitate the replacement of these “driver” bacteria with other 
opportunistic “passenger” species with competitive advantages in the developing tumour 
(Tjalsma et al., 2012).  
 
 
Figure 1.7 The driver-passenger model of bacterial carcinogenesis. In this model a driver bacterium 
disrupts the epithelial cell monolayer and encourages dysplasia, creating the conditions for a passenger 
bacterium that ultimately outcompetes the initial driver bacterium as the tumour microenvironment 
evolves (Figure taken from Tjalsma et al., 2012). 
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An alternative model postulates that certain bacterial species with unique virulence traits are 
both directly pro-oncogenic and capable of remodelling the microenvironment and local 
microbial community to further induce pro-oncogenic immune responses that also favour its 
own survival. As these bacteria do not work alone but rather co-opt other species this model 
has been termed the alpha-bug model (Sears & Pardoll, 2011). 
A number of bacterial species have been associated with CRC by being found more commonly 
in the mucosa or stools of CRC patients than those of healthy controls, such as Fusobacterium 
nucleatum (Viljoen et al., 2015), colibactin-producing Escherichia coli (Buc et al., 2013) and 
enterotoxigenic Bacteroides fragilis (J. I. Keenan et al., 2016; Toprak et al., 2006). 
Fusobacterium nucleatum binds to colonic epithelial cells via FadA, an adhesin which 
recognises an 11-amino acid region of the extracellular domain of E-cadherin. Binding of FadA 
to E-cadherin upregulates β-catenin signalling leading to upregulation of transcription factors, 
oncogenes, Wnt genes and inflammatory genes (Rubinstein et al., 2013). The toxin produced 
by enterotoxigenic strains of B. fragilis is also associated with perturbation of E-cadherin and, 
while the overall effect is similar, the mechanism relates instead to toxin-mediated perturbation 
of intracellular signalling pathways (Wu et al., 2003). In contrast, strains of E.coli that contain 
a polyketide synthesis (pks) island are shown to cause enterocyte DNA damage in infected 
mice (Cuevas-Ramos et al., 2010). The pks island hosts a number of genes that encode the 
colibactin, a genotoxin that has been shown to promote tumour cell proliferation (Cougnoux et 
al., 2014). Interestingly, the FadA adhesin appears to be constitutively expressed by all F. 
nucleatum strains (Han et al., 2005). In contrast, only a subset of B. fragilis and E. coli strains 
express enterotoxin and colibactin respectively.  
Whether these bacteria, detected in patients with advanced cancer, are important in the 
initiation or progression of cancer, or present as a consequence of favourable conditions in the 
tumour environment, has been a matter of considerable discussion. For example, multiple 
studies have found an association of F. nucleatum with CRC based on an increased presence 
within colorectal tumours (Castellarin et al., 2012; Kostic et al., 2012; McCoy et al., 2013). 
Our research however finds that colonic carriage of F. nucleatum is not associated with the 
subsequent growth of neoplastic lesions (Aitchison, unpublished), suggesting that F. nucleatum 
is more likely to be a passenger rather than a driver of colorectal carcinogenesis (Tjalsma et 
al., 2012).  
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Conversely, in the same patient cohort, our group has shown that long-term carriage of 
enterotoxigenic B. fragilis (ETBF) predisposes patients to early-stage colorectal neoplasia, 
providing evidence of ETBF as an initiator of carcinogenesis (Purcell et al., 2017). 
Accordingly, understanding how these toxin-producing colonic bacteria have the potential to 
drive this process is integral to our ongoing research. 
 
1.5.1.1 Enterotoxigenic Bacteroides fragilis 
Bacteroides fragilis are obligate anaerobes that are commonly found in the healthy human 
colon where they are particularly good at adhering to the mucosa (Sears et al., 2014), 
constituting about 1-2% of the normal microflora (Moore et al., 1978). However, 
enterotoxigenic strains of B. fragilis (ETBF) are associated with human and animal disease. 
ETBF were initially identified in newborn lambs with diarrhoea (Myers et al., 1984) and 
subsequently identified in multiple animal species with diarrhoeal disease, including a report 
of a piglet with exfoliating colitis with severe neutrophilic mucosal infiltrate (Collins et al., 
1989), the first association of ETBF with inflammatory disease. In humans, ETBF was first 
isolated from eight patients with diarrhoea (Myers et al., 1987), while a later study of ETBF as 
a cause of diarrhoeal disease in children found that ETBF isolated from family members were 
genetically similar. Moreover, samples from the same patients taken months apart contained 
genetically similar ETBF, whether from diarrhoeal or normal stools, suggesting sustained 
infection (Sack et al., 1992).  
The ETBF virulence factor is a zinc metalloprotease enterotoxin, commonly referred to as the 
Bacteroides fragilis toxin (BFT). Metalloproteases are enzymes commonly produced by 
bacteria and BFT is structurally similar to other bacterial toxins important in human disease 
such as tetanus toxin and diphtheria toxin (Sears & Pardoll, 2011). 
BFT binds to a specific colonic epithelial cell membrane receptor, inducing γ-secretase-
dependent cleavage of E-cadherin (Wu et al., 2007). As detailed above, E-cadherin forms 
complexes with α-, β-, and γ-cadherins at the cell membrane. Consequently, BFT-mediated 
cleavage of E-cadherin releases β-catenin to translocate to the nucleus where it helps transcribe 




In vitro BFT-mediated E-cadherin cleavage causes increased permeability of colonic mucosa 
whereby the colonic submucosa is exposed to normally luminal bacteria (Riegler et al., 1999), 
while in vivo this results in disruption of the colonic epithelium, followed by a subsequent 
inflammatory response and colitis in mice (Rhee et al., 2009). Stimulation of immune cells by 
bacteria or bacterial antigens may create an inflammatory environment that leads to 
carcinogenesis. BFT affects the immune system in a number of ways, including regulatory T-
cell enhancement of IL-17 production (Geis et al., 2015), activation of the NF-кB pathway (J. 
M. Kim et al., 2002), generation of pro-tumoural myeloid-derived suppressor cells (Thiele 
Orberg et al., 2017) and increasing IL-8 secretion (Hwang et al., 2013).  
The B fragilis toxin is also linked to DNA damage via the induction of spermine oxidase 
(SMO), a polyamine catabolic enzyme that is highly inducible by inflammation. SMO produces 
reactive oxygen species such as superoxide and hydrogen peroxide, which in turn result in 
induction of stress response pathways and DNA damage. Intestinal SMO expression is elevated 
in mice infected with ETBF and, conversely, inhibition of SMO in ETBF-infected mice reduces 
chronic inflammation, decreases immune response upregulation and inhibits colon 
tumourigenesis (Goodwin et al., 2011). 
All these characteristics implicate ETBF in the early stages of colon carcinogenesis. Therefore, 
unsurprisingly, ETBF have been found more often in CRC patients than in healthy controls by 
multiple groups in multiple countries, providing a strong association of ETBF with CRC (J. I. 
Keenan et al., 2016; Merino et al., 2011; Ramamurthy et al., 2013; Toprak et al., 2006). Our 
findings support a direct role for ETBF in carcinogenesis (Purcell et al., 2017), and further 
evidence for ETBF involvement in colorectal carcinogenesis is found in the ability of ETBF to 
substantially increase the rate at which APCMin+/- mice develop tumours in their colons, 
compared to uninfected mice (Rhee et al., 2009). In the same study, ETBF-infected mice with 
wild type APC, while not developing tumours, developed inflammation of the colon. The 
finding that colonic carriage of ETBF causes colonic inflammation in normal mice and colonic 
tumours in mice with mutant APC, coupled with multiple findings of ETBF being positively 
associated with CRC in humans, suggest ETBF may both have a role in initiating 
carcinogenesis and be able to persist in the developing tumour environment, consistent with 
the alpha-bug model (Sears & Pardoll, 2011) described in Section 1.5.1.   
It should be noted however that asymptomatic colonic carriage of ETBF is common (J. I. 
Keenan et al., 2016; Odamaki et al., 2012). While it is currently unknown whether 
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asymptomatic carriers display any colonic inflammatory pathology, this suggests that ETBF-
mediated colon carcinogenesis occurs in a minority of carriers, and other environmental or 
lifestyle factors must be required.  
 
1.5.2 Lifestyle risk factors for CRC 
Multiple lifestyle factors may contribute to colorectal carcinogenesis; red meat consumption 
(Chan et al., 2011), smoking (Botteri et al., 2008), alcohol (Fedirko et al., 2011), obesity 
(Larsson & Wolk, 2007) and lack of physical activity (Pan & DesMeules, 2009) have all been 
associated with increased risk of CRC. However, elucidating the molecular mechanisms of 
individual risk factors is difficult as often multiple lifestyle factors such as smoking, alcohol 
and chronic inflammation are found in the same patient (Haas et al., 2012).  
Chronic alcohol consumption can result in nutritional deficiencies with reduced vitamins B1, 
B2 and B12 resulting in an increase in reactive oxygen species (Testino, 2011), while alcohol-
induced reduction in folic acid can alter the production of S-adenosyl methionine (SAM), a key 
methyl donor, leading to alterations in the epigenetic control of gene expression (Sauer et al., 
2010).  
Tobacco smoke contains numerous carcinogenic compounds that can affect multiple molecular 
pathways (Derry et al., 2013). In addition to conferring an additional risk for CRC, there is also 
evidence to suggest that smoking may be associated with a higher risk of proximal rather than 
distal cancer (Botteri et al., 2008). Smoking is also linked to microsatellite instability, CpG 
island methylator phenotype and BRAF mutant tumours (Limsui et al., 2010). This connection 
of smoking with the microsatellite instability pathway (Section 1.1.2) indicates smoking-
induced epigenetic changes may underlie smoking-associated CRC. Of particular interest, a 
recent study showed an association of smoking with hypermethylation of the APC promoter in 
colorectal cancer (Barrow et al., 2017).  
Obesity is another established risk factor for CRC (Moghaddam et al., 2007), particularly in 
men but with a lesser effect in women (Bardou et al., 2013). The mechanisms behind this 
association remain to be fully elucidated, but the association of chronic inflammation and 
obesity may increase the risk of CRC (John et al., 2007), and gut microbes may be involved in 
promoting inflammation in people with obesity (Cani et al., 2012). Additionally there is a 
strong link between diet and obesity, with diets high in rapid carbohydrates and fat being linked 
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to CRC risk in patients with obesity, while dietary fibre and polyunsaturated fats from fish 
appear protective (Johnson & Lund, 2007). 
The assertion that high levels of fibre in the diet may reduce the risk of CRC was postulated as 
far back as the 1970s, based on low rates of CRC in rural Africans who ate a high-fibre diet 
(Burkitt et al., 1974). More recent analyses have confirmed the reduced risk of CRC with 
dietary fibre intake (Aune et al., 2011).  
Another dietary risk factor for CRC is red meat intake, with high red meat consuming countries, 
including New Zealand having higher rates of CRC than countries with lower red meat intake 
(Chan et al., 2011). Although the mechanism(s) that increase CRC risk from red meat 
consumption have not been elucidated, the presence of heme iron, resulting in the production 
of nitroso compounds, has been postulated due to the lack of increased CRC risk in populations 
that eat poultry and other meats that do not contain heme iron (Bingham et al., 2002).  
 
1.5.3 Interplay of diet, gut bacteria and metabolites in CRC 
There is a growing awareness that the unique mix of different bacterial species have the 
potential to contribute to an individual’s risk of diseases through their breakdown of undigested 
food in the colon into a broad range of dietary metabolites (Louis et al., 2014). An individual 
eating a diet rich in fruit and vegetables is more likely to produce increased levels of butyrate, 
but when the same individual (colonised with the same gut microbiota) switches to a high fat, 
carbohydrate-rich diet, the types of dietary metabolites produced in the colon also change 
(O'Keefe et al., 2015).  
Fibre is fermented in the gut to produce short chain fatty acids such as butyrate and propionate 
by colonic bacteria (Louis & Flint, 2017). The short chain fatty acids may protect against CRC 
by a number of different mechanisms. Butyrate is an inhibitor of histone deacetylase, thereby 
maintaining histone acetylation, altering gene expression and arresting cell proliferation 
(Davie, 2003). Additionally, butyrate suppresses colonic inflammation by inhibition of the 
interferon-gamma and STAT1 pathways (Klampfer et al., 2003; Stempelj et al., 2007). 
In addition to the anti-tumourigenic properties described above, butyrate increases mucin 
production in colonic epithelial cells, strengthening the mucus layer of the colon, enhancing 
the adherence of beneficial Lactobacilli and Bifidobacteria, and helping to exclude pathogenic 
bacteria (Jung et al., 2015). This gains significance with evidence of a butyrate gradient in the 
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colon, with higher levels in the more proximal regions of the colon that reflect saccharolytic 
fermentation of available carbohydrate by bacteria at this site (Korpela, 2018).  
Under normal conditions protein fermentation mostly occurs in the distal colon. Many bacterial 
proteases are sensitive to acidic pH, and the more neutral pH of the distal colon favours 
digestion of protein at this site (Macfarlane et al., 1988). When present, dietary fibre decreases 
the requirement for amino acids as an energy source and reducing the pH through production 
of short chain fatty acids, thereby reducing the activity of bacterial proteases (Smith & 
Macfarlane, 1998). Conversely, diets lacking fermentable carbohydrate or diets high in protein 
can increase both the quantity and location of proteolytic fermentation in the colon (Diether & 
Willing, 2019; Korpela, 2018).  
The switch from fibre to protein fermentation is associated with a change in the relative 
abundance of fibre-degrading versus protein-degrading bacterial species of colonic bacteria. 
This is illustrated by one study, where human volunteers given an exclusively animal-based 
diet showed increased abundance of proteolytic bacteria, while those given an exclusively 
plant-based diet increased the abundance of species capable of metabolising plant 
polysaccharides (David et al., 2014). 
The significance of predominantly proteolytic fermentation in the colon is the increased 
production of metabolites with pro-oncogenic effects. Among these biologically active 
metabolites, hydrogen sulphide and nitroso compounds are toxic to intestinal cells and have 
been implicated in the development of CRC (Hughes et al., 2000). A further metabolite of 
proteolytic fermentation is p-cresol, a genotoxic compound that can cause DNA damage in 
colonocytes (Andriamihaja et al., 2015).  
Interestingly, proteolytic fermentation occurring primarily in the distal colon correlates with a 
higher incidence of CRC tumours in the distal colon, a particularly notable characteristic of 
early-onset CRC as described below, perhaps providing evidence for a link between diet, 
microbes and early-onset CRC. 
 
1.6 Early onset colorectal cancer 
In line with a worldwide increase in incidence of early-onset colorectal cancer (EOCRC) 
(Bailey et al., 2015; Hessami Arani & Kerachian, 2017), rates of the disease in patients under 
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50 years of age in New Zealand are increasing in contrast to an overall decline in CRC in recent 
years (Gandhi et al., 2017).  
In addition to the familial conditions mentioned above, other factors that may play a role in 
CRC in the young include inflammatory bowel disease, which confers a two- to three-fold 
increase in risk of CRC (Triantafillidis et al., 2009), and prior radiation therapy, such as for 
paediatric malignancies (Hill et al., 2007). However, the majority of early-onset CRC cases are 
sporadic (Connell et al., 2017) and this may, in part, reflect changing lifestyles (see Section 
1.7). 
Patients with EOCRC are not included in early screening initiatives that internationally start at 
ages between 50 and 65 years. Younger patients are less likely to seek medical advice for gut 
issues (Bleyer, 2009) and, when they do, often do not meet criteria for colonoscopy that might 
lead to a diagnosis. These factors partly explain why EOCRC patients more commonly present 
with symptomatic and late-stage cancers with poorly differentiated cancers when compared to 
CRC as a whole (26.3% vs 20%) (Chou et al., 2011; Fleming et al., 2012).  
The normal progression of colorectal cancer through the accumulation of multiple genetic 
abnormalities is a slow process, potentially taking decades. This has led to sporadic EOCRC 
being considered a specific subtype of CRC with distinct clinical and molecular features 
(Kirzin et al., 2014; Perea et al., 2014; Raman et al., 2014). Histologically, EOCRC cases more 
frequently present with mucinous tumours than older-onset CRCs, and a higher percentage of 
EOCRC tumours have presence of signet-ring cells than older-onset CRCs (Silla et al., 2014), 
both features that are common in hereditary cancers. Despite the majority of EOCRC patients 
not being found to have an inherited disorder, they are more likely than older patients to have 
a family history (Kirzin et al., 2014). 
The majority of EOCRC tumours do not show microsatellite instability and those that do are 
usually due to HNPCC. Therefore microsatellite instability in sporadic EOCRCs is relatively 
rare (Ballester et al., 2016). The V600E mutation in the BRAF gene is less common in EOCRC, 
with a large multi-cohort study finding increasing prevalence of BRAF V600E in older age 
groups, from less than 4% in under 30 year olds to 13% in over 70 year olds (Willauer et al., 
2019). The CpG island methylator phenotype is also found less in EOCRC patients than in 
older-onset CRC patients, with one study reporting the CIMP to be absent in all 47 EOCRCs, 
but present in 15/49 (31%) of CRCs in over 60 year olds (Kirzin et al., 2014). 
23 
 
Three decades ago biological differences were identified in tumours located in either the 
proximal (right-sided) or distal (left-sided) colon, leading to the proposal of distinct categories 
of colorectal cancer based on tumour location (Bufill, 1990). In particular, proximal tumours 
had characteristics similar to HNPCC, while left-sided tumours displayed characteristics more 
similar to FAP. EOCRC patients present more often with distal tumours than older CRC 
patients. One study had 32% of patients aged 35-39 diagnosed with having tumours in their 
rectum, with the percentage in subsequent age groups decreasing to 15, with 1% in those aged 
over 85 years. Conversely, only 9.3% of the 35-39 years age group had tumours in the caecum, 
rising to 23.2% in the over 85 year olds (Davis et al., 2011). Further to Bufill’s categorisation 
of CRC by tumour location, it has been suggested that EOCRC should be similarly categorised 
by location (Perea et al., 2015). 
  
1.6.1 Colorectal signet-ring cell carcinoma 
Colorectal signet-ring cell carcinoma (SRCC) is a rare form of CRC, accounting for 
approximately 1% of all cases (Kang et al., 2005). However, SRCCs are more common in 
younger patients, accounting for 3-13% of EOCRCs (Mauri et al., 2019). They are defined as 
tumours containing at least 50% of cells displaying signet-ring morphology, where large 
amounts of intracellular mucin push the nuclei to the edge of the cells (Bosman et al., 2010), 
with the subsequent loss of cell-cell contact increasing the invasiveness and metastatic potential 
of the disease. Colorectal SRCCs are associated with younger age than conventional CRCs 
(Foda et al., 2018; Hyngstrom et al., 2012), generally present at a later stage, with a worse 
tumour grade and a poorer prognosis (Barresi et al., 2017; Borger et al., 2007). Indeed the 
American Joint Committee on Cancer accept signet-ring histology as an independent 
prognostic factor for CRC (Compton et al., 2000). Moreover, there is evidence that a signet-
ring component of less than 50%, hence not enough to classify a tumour as SRCC, still has a 
negative effect on prognosis (Inamura et al., 2015; Tan et al., 2015). Colorectal SRCCs are, 
like EOCRCs in general, also predominantly found in the distal colon, particularly the sigmoid 
colon and rectum (Chang et al., 2012; Hyngstrom et al., 2012). 
The relative rarity of colorectal signet-ring cell carcinomas is reflected in a paucity of molecular 
studies, and those that have been published generally report a small number of cases. 
Accordingly, there are often conflicting conclusions regarding the characteristics of colorectal 
SRCC. This is illustrated by high rates of microsatellite instability reported in two studies 
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(Kakar & Smyrk, 2005; Ogino et al., 2006), whereas a third study found all colorectal SRCC 
samples were microsatellite stable (Nam et al., 2018). Moreover, when present, there is no 
evidence that microsatellite instability in colorectal SRCC confers an improved prognosis as 
reported for conventional colorectal adenocarcinoma (Kakar & Smyrk, 2005).  
As with HDGC, loss of E-cadherin is frequently found in colorectal SRCC (Borger et al., 2007; 
Wang et al., 2016). However, unlike HDGC, the presence of CDH1 mutations, or their role in 
the pathogenesis of colorectal SRCC, have not been established. E-cadherin loss, and 
subsequent loss of cell-cell interaction and morphology, may explain the increased 
invasiveness and metastatic potential of colorectal SRCC (Borger et al., 2007).  
 
1.7 Lifestyle factors in EOCRC 
Sporadic colorectal cancers generally emerge from an accumulation of genetic alterations that 
accumulate over many decades. However, by their very nature EOCRC cases develop in a 
shorter timeframe. It is likely that the development of tumours in this younger cohort is 
accelerated by the effects of lifestyle factors. While finding that the risk factors for CRC 
detailed above (Section 1.5.2), such as obesity and smoking, were also relevant for EOCRC, a 
recent study comparing patients diagnosed with CRC under the age of 50 with those aged over 
50, identified non-modifiable risk factors, such as sex, race, inflammatory bowel disease and a 
family history of CRC, distinguished EOCRC cases from late-onset CRC (Gausman et al., 
2019). Patients with EOCRC were more likely to be male and there were higher rates of 
EOCRC amongst African Americans and Asians. This reflects an earlier large-scale study of 
the Surveillance, Epidemiology and End Results (SEER) database that found higher rates in 
African Americans and Asians aged under 50 living in the USA, despite lower overall CRC 
rates for Asians (Rahman et al., 2015). This is in line with increasing rates of CRC in Asia, 
which is also hypothesised to be due to an increased uptake of a Western diet (Y. Deng, 2017).  
Similarly, a recent prospective study of young women found the risk of early-onset CRC in 
women with obesity (BMI>30) to be nearly double that of women with a BMI between 18.5 
and 22.9 (Liu et al., 2019), possibly reflecting earlier, and increasing exposure in recent 
decades, to Western diets and consequent risk factors such as obesity.  
Interestingly, in light of the higher risk of EOCRC in African Americans, highlighted by 
Gausman and colleagues, the large disparity in colon cancer between African Americans and 
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native Africans from South Africa has previously been noted (O'Keefe et al., 2007), and been 
associated with a high fat, low fibre diet, with African Americans displaying low levels of short 
chain fatty acids in their colons (O'Keefe et al., 2015). So, modifiable factors, such as a Western 
diet and the evidence of nutritional transition associated with an increasing uptake of Western-
style diets across the world in recent decades, may play a role in the increasing incidence of 
EOCRC.  
 
1.8 Cellular models of colorectal carcinogenesis 
While advances in genomic technologies, some of which are utilised in this thesis, have 
allowed a rapid evaluation of clinical samples and helped elucidate the molecular basis of 
disease, suitable in vitro models of disease are still required to further understand the aetiology 
of cancer, the effects of risk factors and to test possible therapeutic strategies. As such the 
cancer cell line remains a mainstay of cancer research. Many of the cell lines commonly used 
to study cancer date back 50 or more years and questions around their clinical relevance have 
arisen (Borrell, 2010).  
The resemblance of a cell line to the original tumour is not always strong. As early as the 1970s 
concerns were raised that cell lines can acquire additional modifications over time as they are 
cultured (Nelson-Rees et al., 1976). One commonly used colorectal cancer cell line, Caco-2, 
displays variability in growth characteristics with increasing passage number. Cells at passage 
number 72 reached a growth plateau quicker than passage number 22 and 33 cells and, after 21 
days growth, cells at passage 72 also had lower alkaline phosphatase expression (Briske-
Anderson et al., 1997).  
In light of these differences the clinical relevance of cell lines is an issue that needs to be raised 
when designing in vitro studies. An important consideration, is that cancer cell lines, by virtue 
of being derived from tumours, already have numerous genetic and epigenetic alterations and 
therefore likely do not represent the normal state of cells within non-neoplastic tissue. This is 
a particularly important consideration when investigating the early stages of carcinogenesis, 
where the failure to take into account the effects of stimuli on the cells, in light of the existing 
mutational background of the cells, may compromise conclusions made in relation to early 
events in carcinogenesis. This is exemplified by the response of cultured colonic epithelial cell 
lines to the B fragilis toxin. 
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Cellular approaches to research into ETBF-mediated CRC have primarily been focused on the 
HT29 cell line and its derivative, HT29/c1 (Huet et al., 1987). HT29 cells display an exquisitely 
sensitive response to BFT, with the cells rapidly losing their morphology and rounding up in 
response to toxin-mediated cleavage of E-cadherin (Sears, 2009) (Figure 1.8). This rapid 
response has led to HT29 being the cell line of choice for studying cellular reaction to the B. 
fragilis toxin (Hwang et al., 2013; J. M. Kim et al., 2002; Sears, 2009). However, our results 
show that this response is not universal amongst colon cancer cell lines, as seen in the failure 
of HCT116 cells to round up upon exposure to BFT (Figure 1.8).   
 
   
Figure 1.8 Colorectal cancer cell lines HCT116 and HT29 after incubation with B. fragilis toxin. 
A, HCT116 cells maintain their cellular morphology after addition of the toxin while, B, HT29 cells 
show characteristic rounding (arrowed) (Keenan, unpublished). 
The underlying cause of the rapid response by HT29 cells to BFT is likely to be mutations 
within critical genes that make HT29 cells particularly susceptible to the effects of ETBF. This 
illustrates the idea that the use of cells that are already highly susceptible to the effects of BFT 
may not represent the best model for studying any bacterially-induced induction of 
carcinogenesis.    
 
1.9 APC in HT29 cells 
As discussed earlier, the APC gene is mutated in the majority of sporadic colorectal cancers. 
Additionally, Miyoshi and colleagues found that 60% of colorectal tumours they studied with 
APC mutations had two mutations (Miyoshi et al., 1992). Similarly, HT29 cells contain two 
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truncated forms of the APC gene and as a result express no full length APC protein (Morin et 
al., 1996). Consequently, due to the central role of APC in the formation and maintenance of 
the cytoskeleton, it is possible that the lack of full-length APC is fundamental to the rounding 
up of cells, when E-cadherin is cleaved following exposure to BFT.  
In light of this, we sought to introduce wildtype APC into HT29 cells in order to produce a cell 
line that would be more informative when studying the effects of environmental factors such 
as bacterial toxin exposure on the early stages of colorectal carcinogenesis (Chapter 5). 
Wildtype APC has been expressed in HT29 cells previously using a plasmid containing an 
inducible APC gene (Morin et al., 1996). However, expression was under the control of a zinc-
inducible promoter. Unfortunately, given that BFT is a zinc metalloprotease (Moncrief et al., 
1995), using zinc to induce APC expression would have created uncertainty over whether 
observations were due to APC expression or the effects of zinc on BFT.  
Therefore we sought to edit an existing allele of APC in HT29 cells to correct the mutation to 
allow the expression of full-length protein. Additionally, the correction of the cell’s existing 
APC gene would allow for normal cellular expression of the protein rather than artificial 
induction of the gene, thereby better representing the natural in vivo situation. 
The CRISPR-Cas system, consisting of CRISPR (clustered regularly interspersed short 
palindromic repeats) and CRISPR-associated (Cas) genes is used by bacteria as part of their 
adaptive immunity. Briefly, viral or plasmid DNA entering a cell are recognised as foreign and 
digested into small fragments. Some of these small fragments are subsequently incorporated 
into the CRISPR array of the bacterial genome. The CRISPR array contains small fragments 
of DNA from previous infections. When the array is transcribed into RNA and subsequently 
cleaved into individual CRISPR RNAs (crRNAs) each individual crRNA will recognise a 
specific invading virus or plasmid and guide Cas nucleases that are complexed to the crRNA 
to digest the invading DNA upon re-exposure (Barrangou et al., 2007).  
Jinek and colleagues initially showed that the Cas9 nuclease could be programmed to target 
double-stranded DNA cleavage at specific DNA sites in vitro by the use of crRNAs with 
specific target sequences, known as guide RNAs (gRNAs) (Jinek et al., 2012). This 
CRISPR/Cas9 technique was subsequently used to edit genomes in mammalian cells (Cong et 
al., 2013; Mali et al., 2013). Also, in another innovation a nickase enzyme, Cas9n, was used to 
nick both strands of DNA at locations close to each other, using separate gRNA recognition 
sequences for each strand in order to minimise off-target effects, as both sites require nicking 
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for homology-directed repair to occur (Cong et al., 2013). The CRISPR/Cas9n system allows 
for the precise editing of mutated bases such as those found in the APC gene of HT29 cells. 
 
1.10 Aims of the study 
This study is divided into three parts: firstly determining the status of E-cadherin and CDH1 
mutation in a cohort of young colorectal SRCC patients; secondly investigating the CDH1 and 
APC mutation status of a New Zealand cohort of EOCRC patients, and finally correcting 
mutant APC in a CRC cell line to obtain a model for the study of factors initiating colorectal 
carcinogenesis. 
The first part of the study utilised a cohort of Pakistani early-onset colorectal SRCC samples, 
to look at the mutation status of the CDH1 gene using a next generation sequencing approach. 
This work was devised based on the similarity between colorectal SRCC and the presence of 
SRCC in hereditary diffuse gastric cancer, and the common finding of inherited CDH1 
mutations in HDGC. This was complemented by immunohistochemistry to identify expression 
of E-cadherin and mismatch repair genes. The results of this work are presented in Chapter 3. 
The second part of the study builds on Chapter 3 by looking at CDH1 mutation status in an 
archival New Zealand cohort of EOCRC patients, primarily with adenocarcinomas, using the 
same approach as in Chapter 3. Additionally we devised a similar approach to look at APC 
mutation within the same samples. Again we looked at E-cadherin expression in these samples, 
while their mismatch repair gene expression status was obtained from the pathology reports. 
Results obtained from this work were correlated with clinical data and are presented in Chapter 
4. 
The final part of the study used a CRISPR-Cas9n gene editing approach to correct one allele 
of the APC gene in HT29 cells. Correction of this gene will allow the expression of wild-type 
APC protein in these cells. The resultant cell line was then characterised in comparison to the 
parent HT29 cell line, including observation of its response to BFT. The results of these 






Chapter 2 Materials & Methods 
 
2.1 Materials 
Key reagents and kits used in this research are listed in the tables below. 
 
Table 2.1 Primary antibodies  
Antibody Raised In Product 
code 
Supplier Analysis 
E-cadherin Mouse NCH-38 Dako (Glostrup, Denmark) IHC 
MSH6 Rabbit SP93 Roche (Basel, Switzerland) IHC 
PMS2 Mouse A16-4 Roche IHC 
MLH1  Mouse M1 Roche IHC 
     
E-cadherin Mouse ab76055 AbCam (Cambridge, UK) IF 
β-catenin Mouse ab22656 AbCam IF 
     
APC (N-terminal) Mouse ab58 AbCam WB 
APC (C-terminal) Rabbit ab15270 AbCam WB 
IHC, Immunohistochemistry; IF, Immunofluorescence microscopy; WB, Western blotting. 
 
 
Table 2.2 Secondary antibodies  




A11001 Invitrogen  









A21203 Invitrogen IF 
Horseradish peroxidase-
conjugated goat anti-mouse 
 
P 0447 DAKO WB 
Horseradish peroxidase-
conjugated goat anti-rabbit 
P 0448 DAKO WB 






Table 2.3 Kits used in this study 
Name Product Code Supplier 
QIAamp DNA FFPE Tissue Kit 56404 Qiagen (Hilden, Germany) 
DNeasy Blood & Tissue Kit 69504 Qiagen 
MiSeq 500-Cycle Reagent Kit MS-102-2003 Illumina (San Diego, CA, USA) 
NucleoBond Xtra Midi Kit 740410.50 Macherey-Nagel (Düren, Germany) 
PureLink Quick Gel Extraction Kit K2100-12 Invitrogen 
Qubit dsDNA High Sensitivity Assay Kit Q23854 Thermo Fisher (Waltham, MA, USA) 
 
 
Table 2.4 Cell processing and staining reagents  
Name Product Code Supplier Used for 
Cell Conditioning 1 retrieval solution 950-124 Roche Ventana (Oro Valley, AZ, USA) IHC 
UltraView DAB  760-500 Roche Ventana IHC 
Hematoxylin II  790-2208 Roche Ventana IHC 
Bluing Reagent  760-2037 Roche Ventana IHC 
Trypan blue T6146 Sigma (St Louis, MO, USA)  
Texas Red-X phalloidin T7471 Invitrogen  IF 
Hoechst 33342 H3570 Invitrogen IF 
Antifade mountant P36930 Molecular Probes (Eugene, OR, USA) IF 
IHC, Immunohistochemistry; IF, Immunofluorescence microscopy 
 
 
Table 2.5 Bacterial and cell culture reagents 
Name Product Code Supplier 
McCoy’s 5A medium 16600108 Life Technologies (Carlsbad, CA, USA) 
Fetal bovine serum 16000044 Life Technologies 
Penicillin/streptomycin solution (100x) 10378016 Life Technologies 
TrypLE Express Trypsin solution 12605010 Invitrogen 
Luria Bertani media CM0996B Oxoid (Basingstoke, UK) 






Table 2.6 Molecular reagents 
Name Product Code Supplier 
Kapa HiFi HotStart Readymix KK2602 Kapa Biosystems (Basel, Switzerland) 
SYBRSafe Gel Stain S33102 Invitrogen 
HighPrep magnetic beads AC-60005 MagBio (Gaithersburg, MD, USA) 
Phusion High Fidelity Polymerase F530S ThermoFisher 
T4 DNA ligase 
Hyperladder DNA size marker 
XhoI restriction endonuclease 
XbaI restriction endonuclease 
BpiI restriction endonuclease 
KpnI restriction endonuclease 









Bioline (Memphis, TN, USA) 
New England Biolabs (Ipswich, MA, USA) 
New England Biolabs 
New England Biolabs 
New England Biolabs 
New England Biolabs 
 
 
Table 2.7 Western blotting reagents 
Name Product Code Supplier 
Pierce ECL Plus Western Blotting Substrate 32132 Thermo Fisher 
Amersham Hybond-P polyvinylidene fluoride 
(PVDF) membrane 
10600023 GE Healthcare (Chicago, IL, USA) 




















2.2.1 Human tissue samples 
2.2.1.1 DNA extraction from tissue  
DNA was extracted from up to three 10 µm sections of formalin-fixed paraffin-embedded 
samples using a QIAamp DNA FFPE Tissue Kit (Qiagen) according to the manufacturer’s 
protocol. Briefly, sections were placed in a 1.5 mL microcentrifuge tube and deparaffinised by 
the addition of 1 mL xylene with vigorous vortexing. Following centrifugation at 13,000 x g 
for 2 minutes, the xylene was removed and 1 mL ethanol added to remove residual xylene. 
After centrifugation at 13,000 x g for 2 minutes, removal of ethanol and air-drying of the pellet, 
lysis buffer and proteinase K were added and samples were incubated at 56°C for 1 hour. 
Further incubation at 90°C for 1 hour was done to reverse formaldehyde modification of DNA. 
Subsequently, 200 µL protein precipitation buffer and 200µl ethanol were added and mixed. 
The mixture was then centrifuged through a spin column, washed twice with wash buffers and 
eluted using a Tris-EDTA solution supplied with the kit. 
To extract DNA from frozen samples, up to 25 mg of tissue was added to 180 µL lysis buffer 
(Qiagen DNeasy Blood and Tissue kit) and homogenized in a Precellys Evolution homogenizer 
(Bertin Technologies, Montigny-le-Bretonneux, France) using 2.8 mm zirconium oxide beads 
in reinforced 2 mL microtubes for 4 x 15 s at 5800 rpm. DNA was then extracted according to 
the protocol provided with the kit. Briefly, 20 µL of proteinase K was added to the 
homogenised sample, mixed and incubated at 56°C overnight. Two hundred µL of protein 
precipitation buffer and 200 µL ethanol were then added and mixed. The mixture was 
centrifuged through a spin column, washed twice with wash buffers and eluted using a Tris-
EDTA solution. 
 
2.2.1.2 Histology  
Hematoxylin and eosin (H&E) stained sections were evaluated according to the WHO criteria. 
Adjacent sections were immunostained to identify the presence of E-cadherin, and to identify 
microsatellite markers MSH6, PMS2 and MLH1. Staining was carried out using the Roche 
Ventana BenchMark Ultra Platform stainer. Briefly, antigen retrieval for E-cadherin was for 
64 minutes at 95˚C, and for MSH6 was for 32 minutes at 100˚C. For MLH1 and PMS2, slides 
were immersed in Roche Ventana Cell Conditioning 1 (CC1) retrieval solution for 64 minutes 
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or 92 minutes respectively. Incubation in primary antibody was at 37˚C for 40 minutes (E-
cadherin), or 36˚C for 12 minutes (MSH6), 24 minutes (MLH1) or 32 minutes (PMS2). All 
sections were subsequently treated with Ventana UltraView DAB to visualise primary antibody 
staining. Counterstaining was with Roche Ventana Haematoxylin II (modified Mayer’s) for 
four minutes before the sections were blued with Roche Ventana Bluing Reagent, four minutes. 
E-cadherin staining of signet ring cells was graded as negative, weak positive or positive 
whereas microsatellite markers were assessed as positive or negative. All slides were scored 
by a pathologist blinded to the identity of the samples.  
 
2.2.2 Human cell lines 
2.2.2.1 Cell culture  
Two colonic epithelial cell lines, HT29 (ATCC HTB-38) and HCT116 (ATCC CCL-247) were 
used in this work. Both are adherent cell lines, isolated from a 44 year old Caucasian patient 
who presented with colorectal adenocarcinoma (Fogh, 1975) and an adult male diagnosed with 
colorectal carcinoma (Brattain et al., 1981), respectively.  
Both cell lines were grown in McCoy’s 5A medium supplemented with 10% (v/v) fetal bovine 
serum and 100 U/mL penicillin and 100 µg/mL streptomycin. The cells were cultured at 37°C 
and 5% CO2 in a humidified incubator, with the media changed every 72-96 hours. Cells 
nearing confluency were washed twice with PBS and lifted from the flask with 1 mL 0.25% 
TrypLE Express at 37°C and 5% CO2 for 10 minutes. Trypsinisation was stopped by the 
addition of 9 mL of medium and cells were centrifuged at 1500 x g for 5 minutes. The 
supernatant was removed and cells were either resuspended in fresh medium, or used for 
experimentation. 
 
2.2.2.2 Counting  
To count cells, 15 µL were taken from 10 mL of trypsinised cell suspension (see above) and 
added to 15 µL of trypan blue solution (0.25% w/v in PBS). Cell numbers were quantified 
using a haemocytometer. Dead cells stain blue with trypan blue, enabling the number of non-




2.2.2.3 Preservation  
For long term storage, cells were centrifuged at 1500 x g and the supernatant removed. 
Following a brief PBS wash, pelleted cells were resuspended in freezing medium (90% FBS, 
10% DMSO) to give a concentration of 1.5-3 x 106 / mL. One milliliter aliquots were frozen 
overnight in cryotubes at -80°C and then transferred to liquid nitrogen. 
 
2.2.2.4 Light microscopy  
Images of cells cultured in tissue culture plates were captured using an Olympus CK2 
microscope equipped with an Olympus DP21 digital camera (Olympus, Shinjuku, Japan). 
 
2.2.2.5 Immunofluorescence microscopy  
Cells were cultured on sterile glass coverslips (Paul Marienfeld GmbH, Lauda-Konigshofen, 
Germany) before being fixed in a pre-chilled (-20°C) 50:50 (v/v) solution of methanol:acetone 
for 45 minutes at 4°C. The cells were then washed 4 x 5 minutes with PIPES buffer (Appendix 
2) at room temperature before permeabilisation with PIPES buffer containing 0.5% (v/v) Triton 
X-100 for 15 minutes at room temperature. Following two further 5 minute washes in PIPES 
buffer, non-specific binding sites were blocked with 1% BSA in PIPES buffer for 45 minutes 
at room temperature with gentle agitation. Coverslips were then washed a further 2 x 5 minutes 
in PIPES buffer before being incubated in primary E-cadherin antibody (diluted 1:250 in PIPES 
buffer with 1% BSA) overnight at 4°C. Following four washes with PIPES buffer at room 
temperature, the coverslips were incubated for 90 minutes at room temperature in secondary 
antibody (Alexafluor conjugated secondary antibody diluted 1:1000 in PIPES with 1% BSA) 
before being washed four times with PIPES.  
Actin was detected using Texas Red-X phalloidin (5 µL/mL) by incubating overnight at 4°C 
in PIPES with 1% BSA. Nuclei were stained using Hoechst 33342 (Invitrogen) at 2.5 µg/mL 
in PIPES buffer for 30 minutes at room temperature. Coverslips were washed a further two 
times in PIPES before being mounted onto slides using antifade mountant (Molecular Probes). 
Fluorescent imaging was carried out using an AxioImager Z1 microscope (Zeiss, Oberkochen, 
Germany) with EC Plan-Neofluar lenses (Zeiss) and an Axiocam 506 color camera (Zeiss). 
Images were captured by Zen3 software (Zeiss). Exposure times for each channel (red, blue, 
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green) were kept constant in all images from each experiment to maintain an accurate 
comparison between variables. 
 
2.2.3 Next generation sequencing of CDH1 and APC 
2.2.3.1 CDH1 sequencing library construction  
All coding regions and the proximal promoter of the CDH1 gene were amplified using a two-
step PCR strategy previously described by Dr Chris Hakkaart (Hakkaart et al., 2019). Briefly, 
the targeted regions were amplified initially using primers specific to the region of interest, 
with 18 base pairs (bp) non-specific tails at 5’ ends, which acted as binding sequences for 
primers in the second round of PCRs (Figure 2.1). Seventeen different PCR reactions were 
required to provide coverage of all 16 exons and the proximal promoter sequence of CDH1. 
Each amplicon was designed to be less than 500bp to fit within the capabilities of a MiSeq 500-
cycle reagent kit (Illumina). Consideration was also given to the relative composition of 
nucleotides in the first four bases across all primers as during a MiSeq run the first four bases 
are used for fluorescence calibration. Thus, a bias toward any particular nucleotide at each base 
would result in suboptimal calibration. Primer sequences are detailed in Appendix 1. 
 
 
Figure 2.1 Two-step PCR strategy to generate amplicon sequencing libraries. A first round of PCR 
is carried out using locus-specific primers with 18bp 5’ ends as templates for second round PCR. The 
second round primers, used on pooled first round products for each sample, contain unique paired 





2.2.3.2 APC sequencing library construction  
PCR primers were designed to create amplicons spanning regions of the APC gene accounting 
for the vast majority of known mutations found in cancers. Regions of interest were identified 
using the COSMIC database of somatic mutations in cancer 
(https://cancer.sanger.ac.uk/cosmic). Fifteen amplicons were designed spanning multiple 
regions of the APC gene including the mutation cluster region. The same 18bp non-specific 5’ 
ends used for the CDH1 first round amplification primers were added to the sequences of APC-
specific first round primers. Primer sequences and target nucleotides are detailed in Appendix 
1. 
 
2.2.3.3 Primer design  
Where PCR was not performed using previously published primers, primer design was carried 
out using the Whitehead Institute web design page Primer3 (primer3.ut.ee/). Off-target binding 
was checked using the BLAST tool from the US National Center for Biotechnology 
Information (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
All primers were ordered from Integrated DNA Technologies Inc. (Singapore) and 
reconstituted to a concentration of 50 µM with Tris-EDTA (TE; Appendix 2). Working stocks 
were prepared by further dilution to 10 µM in H2O. 
 
2.2.3.4 First round amplicon generation  
Regions of interest within CDH1 and APC were amplified using amplicon-specific primers in 
10 µL reactions using Kapa HiFi HotStart Readymix (Kapa Biosystems) to maintain sequence 
fidelity. The reaction mixture is detailed in Table 2.8.  
 
Table 2.8 Mixture for amplicon-specific PCR 
Reagent Volume 
10 µM forward primer 0.6 µL 
10 µM reverse primer 0.6 µL 
Kapa HiFi HotStart 
Readymix 
5 µL 
Sterile MPW 1.8 µL 





Amplification of PCR products was carried out in a Kyratec Supercycler thermal cycler 
(Kyratec, Mansfield, QLD, Australia) using the conditions detailed in Table 2.9. 3 µL of each 
amplicon was run on a 1.5% agarose gel to check for successful amplification (Section 2.2.3.5). 
The amplicons for each sample were then pooled and cleaned using HighPrep magnetic beads 
(MagBio) (see Section 2.2.3.6).  
 
Table 2.9 Thermocycler conditions for amplicon-specific PCR 
Step Temp 
(°C) 
Time  Cycles 
Initial Denaturation 95 3 min 1 
Denaturation 98 14 sec  
35 Annealing 64 14 sec 
Extension 72 14 sec 
Final Extension 72 1 min 1 
 
 
2.2.3.5 Agarose gel electrophoresis  
PCR products were resolved in 1.5% agarose gels prepared by dissolving agarose in 1x Tris 
Borate EDTA (TBE) (Appendix 2) and supplemented with 0.4 x SYBRSafe. Appropriate 
volumes of 6 x loading buffer (Appendix 2) were added to samples prior to running gels in 1 x 
TBE at 100V for up to an hour. Two µL of 100bp Hyperladder DNA marker were run alongside 
samples as a size marker. Gels were visualized under ultraviolet light using a Q9 Alliance 
Advanced transilluminator with Q9 Alliance software (Uvitec, Cambridge, UK). 
 
2.2.3.6 Magnetic bead clean-up of PCR products  
Pooled PCR products from first or second round amplification steps for sequencing library 
construction were cleaned using HighPrep magnetic beads to remove unused primers, excess 
dinucleotides and other contaminants. Samples were mixed with 1.8 x volumes of bead solution 
by pipetting up and down at least 10 times and left at room temperature for 5 minutes. Samples 
were placed on a magnet and the beads allowed to aggregate on the walls of the tubes. 
Supernatants were discarded and the bead aggregates washed twice with 200µl 70% ethanol. 
The beads were air dried for 15-20 minutes. Sample were removed from the magnet, and the 
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DNA eluted from the beads with 40µl of the elution buffer supplied with the kit. Samples were 
replaced on the magnet to aggregate the beads and the supernatants containing the cleaned 
DNA were recovered to clean tubes.  
 
2.2.3.7 DNA quantitation by Nanodrop  
DNA and PCR products were quantified by a Nanodrop 1000 spectrophotometer (Nanodrop 
Technologies, Wilmington, DE, USA). TE, mqH2O or the respective elution buffer was used 
as a blank depending on the sample. One µL of sample was placed on the Nanodrop pedestal 
and the ratio between absorbances at 260 and 280nm used to determine the concentration and 
purity of the DNA. 
 
2.2.3.8 Adapter PCR  
Pooled and cleaned amplicons for each sample were amplified in a second reaction using 
primers with 18bp 3’ sequences complementary to the 18bp 5’ ends of the first round 
amplicons. The second round adapter primers also contain unique indices that identify 
sequences from individual samples in a pooled library, as well as sequences required to bind 
the amplicon to Illumina flow cells, and sequences for the binding of Illumina MiSeq extension 
primers (Figure 2.1). The same pairs of indexed primers were used for APC as for CDH1 for 
samples in which both genes were sequenced (NZ EOCRC cohort, Chapter 4). The reaction 
mixture is detailed in Table 2.10. Second round primer sequences are detailed in Appendix 1.  
 
Table 2.10 Adapter PCR mixture 
Reagent Volume 
10 µM forward primer 0.6 µL 
10 µM reverse primer 0.6 µL 
Kapa HiFi HotStart 
Readymix 
5 µL 
Sterile MPW 1.8 µL 
Pooled 1st rd DNA (2 ng) 2 µL 
Total 10 µL 
 
PCR conditions are detailed in Table 2.11. Adapter combinations were unique to each sample, 
allowing identification of sample for each sequence produced. It was ensured that there were 
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no similarities in adapter primers between tumour and normal tissue DNA for the same patient 
(NZ EOCRC cohort) to avoid cross-contamination and ensure that mutations common to both 
tumour and normal tissue were real. 
 
Table 2.11 Thermocycler conditions for adapter PCR 
Step Temp 
(°C) 
Time  Cycles 
Initial Denaturation 95 2 min 1 
Denaturation 98 14 sec  
10 Annealing 68 14 sec 
Extension 72 14 sec 
Final Extension 72 1 min 1 
 
 
Three µL of each reaction were run on a 1.5% agarose gel alongside the pre-amplification 
pooled input DNA to visualize the successful addition of adapter primers to the amplicons, 
evidenced by an increase in the size of the amplicons. Five µL of each adapter PCR product 
were pooled as a library in a single tube and cleaned by magnetic bead clean-up (Section 
2.2.3.6).  
 
2.2.3.9 Library preparation and sequencing in Illumina MiSeq  
Quantitation of sequencing libraries and sequencing of the libraries using MiSeq (Illumina, San 
Diego, CA, USA) were carried out by Dr Robert Day (Biochemistry Department, University 
of Otago. Dunedin), as previously described (Hakkaart et al., 2019). 
 
2.2.3.10 Quantitation of sequencing libraries  
Sequencing libraries were quantified using a Qubit dsDNA High Sensitivity Assay Kit prior to 
loading on an Illumina flow cell for sequencing. Qubit working solution was prepared freshly 
as a 1:200 dilution of Qubit reagent in Qubit buffer. Two µL of sample were added to 198 µL 
of working solution. Standards were made by adding 190 µL of working solution to 10 µL of 




2.2.3.11. Sequencing, analysis and annotation  
DNA libraries were diluted to 4 nM and run on an Illumina Miseq using V2-500 cycle reagent 
kits (Illumina). Raw paired end reads were cleaned using Trimmomatic v.0.35 (Bolger et al., 
2014) then the cleaned reads were aligned to the human reference genome (GRCh37/hg19) 
using the Burrows-Wheeler Aligner v.0.7.10 (H. Li & Durbin, 2009). Minimum read depths 
were 40 reads. Single nucleotide variants, insertions and deletions were called using the 
Genome Analysis Toolkit (GATK) v.3.6 (McKenna et al., 2010). The effects of variants were 
predicted using SnpEff v.4.2 (Cingolani et al., 2012) and putative mutations were visualised 
using the Integrated Genomics Viewer (Robinson et al., 2011). The functional consequences 
of missense variants were predicted by a variety of online tools; Polyphen2 (Adzhubei et al., 
2013) (using both HumDiv and HumVar datasets), SIFT (Kumar et al., 2009), Provean (Choi 
et al., 2012) and Mutation Assessor (Reva et al., 2011).  
 
2.2.3.12 Sanger sequencing for confirmation of next generation sequencing 
results  
Purified PCR products were prepared for sequencing by combining 1 ng of PCR product per 
100bp with 3.2 pmol of primer and mqH2O in a total volume of 5 µL. Samples were then sent 
to the Genetic Analysis Service (Department of Anatomy, University of Otago, Dunedin) 
where they were sequenced on a capillary ABI 3700xl Genetic Analyser (Applied Biosystems) 
following a sequencing reaction using BigDye chemistry (Applied Biosystems). 
 
2.2.3.13 Loss of heterozygosity at APC locus 
The APC sequences obtained in Section 2.2.3 were used to detect loss of heterozygosity (LOH) 
by comparing levels of each allele at four single nucleotide polymorphisms (SNPs) within the 
APC gene. SNPs showing heterozygosity, by presence of both alleles, in normal tissue were 
considered to have LOH if the read count of one allele was reduced in relation to the alternate 
allele in tumour tissue. A low number of alleles present for the missing allele likely reflected 
non-tumour cells, such as lymphocytes, within the tumour tissue. The four SNPs analysed were 
rs2229992, rs351771, rs1801166 and rs41115.  If all the informative SNPs within the APC 
gene in a single patient showed loss of an allele in the tumour tissue then the tumour was 




2.2.4 Using CRISPR-Cas9 to edit the human HT29 colorectal cancer 
cell line 
2.2.4.1 Design of gRNA sequences for editing of mutated APC in HT29 cells  
The APC gene in HT29 cells has compound heterozygous mutations, one of which, a 
c.2557G>T transition resulting in a premature stop codon at codon 853, was edited using the 
CRISPR-Cas9 nickase system.  
Two guide RNAs (gRNAs) were designed to target sequences around the mutation using the 
design tool on the Zhang lab website (crispr.mit.edu). This site has since been shut down 
although resources are available via the Zhang lab (https://zlab.bio/guide-design-resources). 
One gRNA overlapped the mutated base while the other was 40-60 bases upstream of the 
mutated base. 
The use of a nickase enzyme to nick individual strands of DNA at two points close to each 
other, rather than the conventional single site cutting of both strands, was done to increase the 
specificity of the process by limiting off-target effects as both gRNA molecules would need to 
bind to complementary sequences close to each other for the editing process to take place. The 
chances of this happening at non-target sequences is greatly diminished compared to systems 
requiring only one gRNA to bind as described in Section 1.9. 
 
2.2.4.2 Plasmids and bacteria used for CRISPR-Cas9n experiments  
gRNAs were generated in pSpCas9n(BB)-Puro PX642 plasmids (Addgene) containing the 
Cas9n gene and the puromycin resistance gene. pSpCas9n(BB)-2A-Puro (PX462) V2.0 was a 
gift from Feng Zhang (Addgene plasmid # 62987; http://n2t.net/addgene:62987; 
RRID:Addgene_62987) (Ran et al., 2013). pBluescript KS(+) (Stratagene) is a small plasmid 
that was used as an intermediary for manipulating the template DNA. Subsequently the 
template DNA was cut out of pBluescript KS(+) and ligated into pCDNA3.1 (Invitrogen), an 
expression vector carrying the neomycin resistance gene, to be used for the CRISPR-Cas9n 
editing. All three plasmids and subsequent engineered plasmids were amplified in and purified 




2.2.4.3 Transformation of plasmids into bacteria  
Plasmids were transformed into E.coli DH5α bacteria by thawing 100 µL aliquots of 
chemically competent cells (a kind gift from Dr Paul Pace, made by a method based on the 
Hanrahan method for preparation and transformation of Escherichia coli (Green & Sambrook, 
2018)) on ice, adding approximately 10 ng of ligation reaction or 1 ng of plasmid DNA, mixing 
gently and incubating on ice for 30 minutes. The mixture was heat shocked at 42°C for 45 
seconds then returned to ice for 2 minutes. Pre-warmed Luria Bertani (LB) broth (900 µL) was 
added and the mixture incubated, shaking at 37°C, for 1 hour. Twenty to two hundred µL of 
the transformation mix were then plated onto LB agar plates and incubated at 37°C overnight. 
Colonies were subsequently picked, grown in LB broth and plasmids extracted according to 
Section 2.2.4.4.  
 
2.2.4.4 Plasmid purification  
Following transformation, bacteria containing pSpCas9n(BB)-2A-Puro, pCDNA3.1 or 
pBluescript KS(+) plasmids were grown overnight in LB broth with 100 µg/mL ampicillin and 
harvested to generate plasmid stocks for further use in the CRISPR-Cas9 editing process. 
Plasmids were isolated using NucleoBond Xtra kits (Macherey-Nagel, Düren, Germany) 
according to the manufacturer’s protocol. Briefly, 100 mL overnight cultures were centrifuged 
at 5000 x g for 10 minutes at 4°C and the pellets resuspended in buffer containing RNase A by 
vortexing. Equal volumes of an alkaline lysis buffer were added and the mixture inverted 
several times to mix. After a 5 minute incubation, neutralisation buffer was added and the tubes 
mixed by inverting. The mixture was added to an equilibrated DNA-binding column and 
allowed to flow through by gravity. Following two washes with wash buffer, the plasmids were 
eluted with elution buffer, precipitated with isopropanol and centrifuged at 5000 x g for 30 
minutes at 4°C. The resulting pellets were washed with 70% ethanol, centrifuged and air-dried. 
The plasmids were then resuspended in TE buffer and stored at -20°C until use. 
 
2.2.4.5 Design of APC template fragment used for editing mutant APC  
To enable CRISPR nickase directed mutagenesis of genomic APC, a plasmid was designed to 
provide a homologous recombination template that contained the relevant portion of APC 
carrying the mutation to be copied into the target genome.  Briefly, a fragment of the human 
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APC gene was amplified from pCMV-Neo-Bam-APC (Morin et al., 1996) and subsequently 
cloned into pBluescript KS(+) using KpnI and NotI restriction sites incorporated into the 
primers used to amplify the fragment (Appendix 1). This fragment covered the sequence 
encompassing the two gRNA recognition sequences and approximately 100 bp of flanking 
sequence either side of the recognition sites. The PCR mixture included Phusion High Fidelity 
Polymerase to minimise misincorporation of nucleotides during the reaction. The PCR mixture, 
thermocycler conditions and primers are detailed in Appendix 1. 
The resultant amplicon and the pBluescript KS(+) plasmid were independently digested with 
KpnI and NotI restriction enzymes. The enzymes were added consecutively as they have 
different salt requirements for optimal digestion. Briefly, 20 µL DNA were added to 5 µL NEB 
buffer 1, 0.5 µL 100 x BSA and 1 µL (10 units) KpnI in a total volume of 50 µL and incubated 
at 37°C overnight. 2.5 µL 2 M NaCl (final concentration = 100 mM) were added along with 1 
µL (10 units) NotI and the digests incubated for a further 2 hours at 37°C. Digested plasmid 
was treated with calf alkaline phosphatase to prevent self-ligation and PCR fragments were run 
on a 0.8% agarose gel, the relevant bands were cut out and the DNA fragments were purified 
using a gel extraction kit (Invitrogen).   
The cleaned, digested fragment was then ligated into the cleaned, digested pBluescript KS(+) 
vector by incubating at an insert:vector ratio of 3:1 using 2 µL of 10 x ligase buffer and 1µl of 
T4 DNA ligase (Thermo Fisher) overnight at 16°C in a total volume of 20 µL. Ligated DNA 
constructs were then transformed into competent DH5α cells (see Section 2.2.4.3).  
Following growth of the transformed cells and extraction of the newly created template 
plasmid, XbaI and XhoI restriction sites were created within the gRNA recognition sequences 
that still existed on the template plasmid, so that they would no longer be recognised by the 
gRNAs, and to provide confirmation that the template mutant APC fragment had been copied 
into the target genome following transfection into HT29 cells. The mutation primers detailed 
in Appendix 1 introduce the base changes that create the restriction sites without altering the 
protein sequence. The XbaI site was introduced first, with the post-PCR mixture incubated with 
DpnI enzyme at 37°C for 1 hour to digest original methylated DNA, thereby removing 
unmutated plasmid, and to leave nascent unmethylated but mutated DNA. The mixture was 
transformed into DH5α cells (Section 2.2.4.3), individual colonies were cultured and the 
plasmid DNA from these were purified (Section 2.2.4.4). Restriction digest analyses identified 
positive incorporation of the XbaI site and then the XhoI site was introduced in the same 
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manner. Phusion High Fidelity DNA Polymerase was used to minimise misincorporation of 
nucleotides. The PCR mixture used for each mutation PCR along with thermocycler conditions 
are detailed in Appendix 1. Successful introduction of mutated bases was confirmed by Sanger 
sequencing. 
 
2.2.4.6 Gel extraction and clean-up of digested plasmids and PCR products  
DNA fragments run on 0.8% agarose gels were extracted using a PureLink Quick Gel 
Extraction Kit (Invitrogen) according to the manufacturer’s protocol. Briefly, the gel was 
solubilized at 50°C for 10 minutes in 3:1 (volume:weight) Solubilisation Buffer before 1 gel 
volume of isopropanol was added and the mixture centrifuged through a spin column at 12,000 
x g for 1 minute. The column was washed by centrifuging 500 µL Wash Buffer through at 
12,000 x g for 1 minute before drying the column and eluting with Elution Buffer by 
centrifugation. 
 
2.2.4.7 Insertion of template fragment into pCDNA3  
Following successful mutation of the template fragment in pBluescript KS(+), the fragment 
was cut out of the plasmid and ligated into pCDNA3, a larger plasmid that carries the neomycin 
resistance gene. This was to allow selection of HT29 cells that contain the template fragment 
by using geneticin, a drug that is toxic to mammalian cells but to which resistance is conferred 
by the neomycin resistance gene. Both pCDNA3 and the pBluescript KS containing the 
template fragment were digested with KpnI and NotI as previously (Section 2.2.4.5). Digested 
pCDNA3 was treated with calf alkaline phosphatase to prevent self-ligation. The template 
fragment was isolated after electrophoresis through a 0.8% agarose gel (Section 2.2.4.6) and 
ligated into the digested pCDNA3 by incubation with 1 µL T4 DNA ligase in T4 DNA ligase 
buffer in a total volume of 20 µL overnight at 16°C.  
 
2.2.4.8 Ligation of specific gRNA sequences into pSpCas9n(BB)-2A-Puro 
(PX462)  
Two separate gRNA plasmids were created to allow nicking of opposite strands of DNA either 
side of the mutated base in the APC gene.  In each case the annealed oligos, which were 
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designed to have ends compatible with BpiI cut restriction sites, were ligated into the BpiI-
linearized PX462 plasmid.  
Complementary oligonucleotides encoding the two guide RNAs required for CRISPR-Cas9 
editing of APC c.2557G>T, as detailed in Table 2.9, were annealed as follows. One µL forward 
oligonucleotide, 1 µL reverse oligonucleotide and 1 µL T4 DNA ligase were added to 7 µL 
H2O, heated to 95°C for 5 minutes then allowed to cool for 2 hours at room temperature to 
anneal together.  
The pSpCas9(BB)-2A-Puro plasmid (PX462) was digested with BpiI restriction enzyme for 2 
hours at 37°C, treated with 1 µL calf alkaline phosphatase at 37°C for 1 hour to prevent 
religation of the plasmid, the enzyme denatured at 65°C for 10 minutes, and the plasmid 
cleaned using magnetic beads (2.2.3.6). Then 2 µL of digested plasmid were separately mixed 
with 1 µL of annealed oligos for each gRNA construct, 1 µL ligase buffer, and 0.5 µL T4 DNA 
ligase in a 10 µL reaction.  They were incubated at 37°C for 1 hour, and then transformed into 
DH5α cells (Section 2.2.4.3) that were grown overnight on Luria-Bertani agar with 100µg/ml 
ampicillin. Single colonies were then grown in liquid media and plasmids were purified 
(Section 2.2.4.4). 
 
2.2.4.9 Puromycin and geneticin sensitivity of HT29 cells  
To determine the concentrations of puromycin and geneticin needed to select for HT29 cells 
containing the PX462 and template fragment plasmids, 24-well tissue culture plates were 
seeded with 5 x 104 HT29 cells/mL and grown in McCoy’s 5A medium containing 10% fetal 
bovine serum (FBS) and penicillin/streptomycin (P/S) with increasing concentrations of the 
relevant drug (see Appendix 2). Four wells were seeded for each drug concentration with cell 
numbers in one well measured each day to allow growth to be assessed (Section 2.2.2.2). Three 
replicate plates were tested for each drug.  
 
2.2.4.10 Transfection of plasmids into HT29 cells  
HT29 cells were transfected using Lipofectamine reagents (Invitrogen) according to the 
manufacturer’s protocols. Briefly, 7.5 x 105 HT29 cells were seeded in a 9.6 cm2 well of a 
tissue culture plate and grown overnight. After 24 hours the growth medium was changed to 
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growth medium without antibiotics, and 3.75 µg of template fragment plasmid and each of the 
two PX462-gRNA Cas9 plasmids were added to 500 µL lipofectamine and 11.25 µL PLUS 
Reagent, mixed gently and incubated at room temperature for 10 minutes. Then 55 µL LTX 
reagent were added, mixed gently and incubated at room temperature for 30 minutes to allow 
lipofectamine-DNA complexes to form. Subsequently, 500 µL of this complex were pipetted 
onto the cells and incubated at 37°C in 5% CO2 overnight. A control well of cells was treated 
with the transfection reagents without plasmids.  
The following day, the cells were washed with PBS, lifted with TrypLE Express and 
resuspended to 50 mL in McCoy’s medium containing 10% fetal bovine serum and 
penicillin/streptomycin. The cells were plated into three large 15 cm diameter tissue culture 
plates, topped up to 20 mL with growth medium, with a fourth plate used to grow the no 
plasmid control transfected cells. Following incubation at 37°C, in 5% CO2 for 5 hours (to 
allow the cells to adhere), a further 20 mL medium containing 1 µg/mL puromycin and 3 
mg/mL geneticin was added to each plate, and the cells were incubated for a further four days. 
The selective drugs, puromycin and geneticin, were removed by washing the cells with PBS 
and replacing the media with fresh drug-free media after approximately 90 hours of treatment. 
Following the removal of selective drugs, the cells were incubated for a further 10 days before 
96 individual colonies were each picked and transferred by pipette to a well of a 96-well tissue 
culture plate. The colonies were each incubated with 25 µL TrypLE Express for 10 minutes to 
disperse the cells, then 175 µL of medium were added and the plate was incubated at 37°C, in 
5% CO2 until the cells reached confluence. After washing, the cells were trypsinised and split 
into corresponding wells of three new 96-well plates and incubated for a further 2-3 days. Each 
plate was used for analysis of the clones, maintenance of the clones, or for freezing cells down 
for long-term storage. 
For analyses, the cells for each clone in one of the three plates were washed, trypsinised and 
recovered into a microcentrifuge tube. After pelleting (5 minutes at 1300 x g), the medium was 
removed and the cells were washed in 10 mM Tris-Cl, pH8 before being resuspended in 10 µL 
10 mM Tris-Cl and boiled for 15 min. Two microlitres of the cell suspension were then used 
in a PCR reaction to amplify a fragment encompassing the c.2557G>T mutation in the APC 
gene, using the primers used to generate the template fragment previously (Appendix 1). The 
PCR mixture and thermocycler conditions are detailed in Appendix 1. Following PCR, 10 µL 
of the PCR reaction were incubated with 0.5 µL XhoI at 37°C overnight. Digestion of the PCR 
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product into two fragments indicated successful incorporation of the template fragment into 
the genomic DNA of that clone. 
 
2.2.4.11 Immunoprecipitation of the APC protein  
Flasks of cells were washed and harvested by trypsinisation (2.2.2.1). The cells were pelleted 
by centrifugation at 3000 x g for 5 minutes and washed twice in ice-cold PBS before being 
resuspended in 2 mL of lysis buffer (Appendix 2) and sheared by passing through a 19-guage 
needle five times. The cell lysate was cleared by centrifuging at 13,000 x g for 20 minutes at 
4°C and the protein concentration of the supernatant was measured by Bradford assay. Two 
aliquots, each containing 1 mg of protein in 1 mL of volume for each lysate, were used for 
immunoprecipitation, using two antibodies, raised against the N- (ab58) and C- (ab15270) 
terminals of the APC protein respectively. 
Protein G-sepharose (GE Healthcare) was equilibrated by washing 500 µL of suspension three 
times in lysis buffer, before being resuspended in 1 mL lysis buffer to give a 50% suspension. 
For each immunoprecipitation, 40 µL of this suspension was added to 1 mL of cell lysate and 
rotated gently for 1 hour at 4°C, centrifuged at 3000 x g for 5 minutes, and the supernatant 
(cleared lysate) was transferred to a fresh microcentrifuge tube. One µg of antibody was added 
to the cleared lysate and incubated at 4°C for 1 hour.  Then 40 µL of the 50% protein G-
sepharose suspension was added and rotated at 4°C for 1 hour to capture the antibody and any 
attached immunoprecipitate to the sepharose. The lysate was centrifuged at 3000 x g at 4°C for 
5 minutes and the supernatant discarded. The sepharose was washed four times with 1 mL lysis 
buffer, centrifuged and the supernatant discarded t each time. Following the final wash, the 
sepharose was resuspended in 100 µL of SDS-PAGE loading buffer, boiled for three minutes 
and proteins were resolved on an SDS-PAGE gel for Western blotting (Section 2.2.4.12). 
 
2.2.4.12 Western blotting  
Proteins were first resolved by polyacrylamide gel electrophoresis using 4-20% 
polyacrylamide gels (Table 2.11) in a Mini-PROTEAN Tetracell tank (BioRad) at 200V for 45 
minutes, with top and bottom loading buffers as described in Appendix 2. Dual-coloured 
Precision Plus protein standards (BioRad) were run on each gel.  
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Separated proteins were transferred to polyvinylidene fluoride (PVDF) membrane (Table 2.11) 
using a Mini-Protean II transfer system (BioRad) with ice-cold transfer buffer (Appendix 2). 
Transfer was carried out at 100 V for 1 hour. A frozen plastic iceblock was added to the transfer 
tank directly from the freezer to prevent overheating during transfer. In addition, the transfer 
tank was placed on a magnetic stirrer with a magnetic flea ensuring continuous movement of 
the transfer buffer in the tank to maintain a cool temperature. Visualisation of the dual-coloured 
ladder on the PVDF membrane following transfer was used to confirm successful transfer of 
proteins. 
Non-specific binding of antibodies was blocked by incubation of the PVDF membrane with 
5% (w/v) non-fat milk in TBST (Appendix 2) for 1 hour at room temperature. After two five 
minute washes in TBST, the membrane was incubated overnight at 4°C in TBST with 2% (w/v) 
non-fat milk and primary antibody (directed against the N- or C-terminal of APC; both diluted 
1:1000; Table 2.5). Three further 5 minute washes with TBST were followed by incubation 
with an appropriate secondary antibody (anti-mouse or rabbit, both diluted 1:2,500; Table 2.6) 
in TBST with 2% (w/v) non-fat milk for 90 minutes at room temperature. After three more 5 
minute washes with TBST the membrane was exposed to chemiluminescent substrate (Table 
2.11). Protein bands were visualized using a UVITEC gel documentation system and images 
captured with Nine Alliance software (UVITEC, Cambridge, UK). 
 
2.2.5 Bacteroides fragilis toxin  
2.2.5.1 Culturing B. fragilis  
The enterotoxigenic Bacteroides fragilis (ETBF) strain 86-5443-2-2, originally isolated from 
a piglet with diarrhoeal disease and shown to produce the bft-2 toxin subtype (Franco et al., 
1997) was used for these experiments. A non-toxigenic B. fragilis (NTBF) strain NTC9343 
was used as a control. Both strains were kindly provided by Prof Cynthia Sears (Johns Hopkins 
University, Baltimore, USA).  
Both strains were maintained on sheep blood agar plates under microaerophilic conditions, 
generated using a commercial Anaero-Pouch (Mitsubishi Chemical Gas Co, Japan) added to a 




To harvest the B. fragilis toxin (BFT), the bacteria were sub-cultured into 200 mL volumes of 
B. fragilis broth (Appendix 1; Franco, 1997) and incubated in gas jars for three days at 37°C 
under constant rotation at 120 rpm. 
 
2.2.5.2 Concentrating the B. fragilis toxin (BFT)  
The B. fragilis toxin (BFT) is released from the surface of toxigenic strains of these bacteria 
during growth in broth culture (Sears, 2001). Accordingly, the three day broth cultures were 
centrifuged (2330 x g for 10 minutes), the resultant supernatant was passed through a 0.22 µm 
syringe filter (to remove any residual bacteria) and either frozen at -80°C for future use or the 
proteins were precipitated at 4°C in ammonium sulphate. Briefly, 500 µL aliquots of 
supernatant were precipitated by the addition of a saturated solution of ammonium sulphate to 
give a dilution series of ammonium sulphate concentrations ranging from 0 to 60%. Proteins 
were pelleted by centrifugation at 4°C for 30 minutes at 21,000 x g then resuspended in 1/50th 
volume PBS. Each fraction was diluted ten-fold in medium and exposed to semi-confluent 
HT29 cells. The ETBF fraction that resulted in more than 50% of cells rounding was used for 














Chapter 3 CDH1 Gene Mutation in Early-Onset, Colorectal 
Signet-ring Cell Carcinoma 
 
3.1 Introduction 
Retrospective studies of colorectal cancer databases worldwide suggest that signet-ring cell 
cancers (SRCCs) account for around 1% of all primary colorectal cancers (Dozois et al., 2008; 
Hyngstrom et al., 2012; Inamura et al., 2015; Z. Liang et al., 2018; Nitsche et al., 2013; Wang 
et al., 2016; Wei et al., 2016). These tumours usually present at a later stage, have a worse 
grade and correspondingly poor prognosis (Hyngstrom et al., 2012). Colorectal SRCCs are 
defined as tumours exhibiting at least 50% of cells displaying signet-ring morphology (Bosman 
et al., 2010) although there is increasing evidence that even a small number of signet-ring cells 
can be detrimental to prognosis (Inamura et al., 2015; Sung et al., 2008; Tan et al., 2015).  
The unique features of these cancers suggest a different pattern of genetic alterations to 
conventional CRC (Inamura et al., 2015; Kakar & Smyrk, 2005; Ogino et al., 2006; Wei et al., 
2016) although a clear consensus on the molecular characteristics of colorectal SRCC is 
lacking. This is illustrated by conflicting evidence regarding the microsatellite instability status 
of these tumours (Nam et al., 2018; Ogino et al., 2006) that may, in part reflect the lack of 
published studies to date. 
Large epidemiological studies suggest colorectal SRCCs can develop at any age in males and 
females, and throughout the colon and rectum (Hyngstrom et al., 2012; Tan et al., 2015). 
However, in young people with colorectal tumours with a signet-ring component, occurrence 
is more frequent in males (Wang et al., 2016) and the tumour site is more distal, particularly in 
the sigmoid colon and rectum (Chang et al., 2012; Wang et al., 2016).  
There is mounting evidence that increasing numbers of young people presenting with early-
onset colorectal cancer (EOCRC) are likely to have evidence of signet-ring histology (Chang 
et al., 2012; Tan et al., 2015), and that these patients have a worse prognosis than similar-aged 
patients with conventional adenocarcinoma, even with a low (<50%) signet-ring component to 
their tumour (Huang et al., 2016; Tan et al., 2015). Unlike conventional carcinomas, colorectal 
SRCCs produce large amounts of intracellular mucus that acts to push the nucleus to the edge 
of the cell resulting in the classical signet-ring appearance to the cell. One consequence of this 
altered morphology is a loss of cell-cell adhesion that, in turn, fits with the ability of colorectal 
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SRCC to diffusely infiltrate the stroma, leading to increased invasion and metastasis, and a 
poorer prognosis (H. C. Kim et al., 2002).  
E-cadherin, encoded by the gene CDH1, is essential for maintaining intercellular stability in 
the intestinal epithelium via cell-cell adhesion and cell polarity. Accordingly, the loss of E-
cadherin is considered to contribute to early stage carcinogenesis (Hirohashi, 1998). Reduced 
E-cadherin expression has been reported as a feature of colorectal CRC (Borger et al., 2007), 
and while signet-ring cells can show markedly reduced expression of this protein (H. C. Kim 
et al., 2002), this is not always the case (Chang et al., 2012; Wang et al., 2016). 
Hereditary diffuse gastric cancer (HDGC) is typified by the presence of diffuse foci of signet-
ring cancer cells (Charlton et al., 2004), with mutations in the CDH1 gene identified in gastric 
(Guilford et al., 1998; Hakkaart et al., 2019; Norero et al., 2019) as well as in other 
malignancies (Xicola et al., 2019). Against this background, our colleague Prof. Frank Frizelle 
was intrigued to notice a large number of very young patients presenting with colorectal SRCC 
while working at the Aga Khan University Hospital in Karachi, Pakistan. In this chapter I 
describe the cohort of Pakistani colorectal SRCC patients diagnosed at or under 40 years of 
age, and investigate the possibility of mutation in the CDH1 gene playing a causative, and 
possibly familial, role in for colorectal CRC in these young patients.  
 
The objectives were to: 
1. Determine the levels of E-cadherin expression in these colorectal SRCC samples. 
2. Investigate the presence of CDH1 mutations, and to correlate these with E-cadherin 
expression.  




Formalin-fixed, paraffin embedded (FFPE) tissues from 24 patients identified with colorectal 
SRCC at the Aga Khan University Hospital in Karachi, Pakistan were obtained, either as blocks 
or pre-cut sections. One sample that had no details with regards age and gender of the patient 
or location of the tumour was removed from the cohort. The study was granted ethics approval 
by the Ethics Review Committee, The Aga Khan University, Karachi, Pakistan. 
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One section from each tumour was stained with haematoxylin and eosin (H&E) for histological 
assessment by a pathologist (Section 2.2.1.2). Additional immunohistochemical staining was 
performed on sections of each sample for the mismatch repair proteins MSH6 and PMS2 in a 
2-stain method for microsatellite instability testing (Hall et al., 2010). Additionally, staining 
for MLH1, another mismatch repair protein, was carried out for samples that were negative for 
PMS2 (Section 2.2.1.2). Another slide from each tumour was also stained for E-cadherin 
(Section 2.2.1.2). 
DNA was extracted from up to three tissue sections (Section 2.2.1.1) and genomic DNA 
encompassing the promoter and all exons of the CDH1 gene was amplified by a 2-step PCR 
protocol followed by sequencing by Illumina MiSeq. All molecular and downstream analysis 
protocols are detailed in Section 2.2.3. 
 
3.3 Results 
3.3.1 Histological characterisation of the Pakistani colorectal cancer cohort 
Sections of tissue were received for nine of the 23 samples, while the remaining 14 samples 
arrived as FFPE blocks. Two and ten micron thick sections were cut from these blocks and 
used for staining of the tissues and extraction of DNA, respectively.  
The hematoxylin and eosin (H&E) stained section of each tumour was reviewed by a 
pathologist according to WHO criteria for SRCC (Bosman et al., 2010). Three samples were 
diagnosed as mucinous adenocarcinomas (MA) rather than SRCC as they exhibited 
extracellular mucin and the cells lacked the classical signet-ring appearance. Although both 
MA and SRCC overproduce mucin, they exhibit different biological behaviours and survival 
outcomes (Hyngstrom et al., 2012) therefore these three MA samples were excluded from 
further analysis. Sixteen of the remaining 20 samples met the criteria of signet ring cell cancer 
based on the finding that >50% of the tumour cells had typical signet ring morphology (Barresi 
et al., 2017), while the remaining four were classified as CRC with a partial signet ring 
component on the basis of having fewer than 50% signet rings. Males were over-represented 
in the cohort (n=16), the median age was 27.5 years (range 8-40) and, while the tumours in our 
study were found at sites throughout the colon, 75% (15 of 20) were found in or below the 




Table 3.1. Clinical characteristics of the 20 SRCC samples received as part of the Pakistani 
colorectal cancer cohort.  
 Total  
 N % 
Total 20  
Gender   
   Male 16 80 
…Female 
Age at diagnosis (years) 
  4 20 
   <21   6 30 
   21-30   6 30 
  31-40    8 40 
Tumour site   
   Proximal (right-sided)   5 25 
   Distal (left-sided) 15 75 
   
 
3.3.2 DNA extraction and amplification. 
DNA was extracted from the FFPE samples as described (Section 2.2.1.2) and the promoter 
and exons of CDH1 were amplified according to the methods described in Section 2.2.1.1. 
Nine samples sent as pre-cut sections had to be excluded due to poor DNA yields and quality 
as evidenced by inconsistent amplification resulting in only a few amplicons of varying 
intensity being visible per sample (Figure 3.1). Of note, the few amplifiable regions of CDH1 
in the samples supplied as tissue sections were similar across samples, perhaps reflecting the 
dynamics of those PCR reactions or the relative degradation of DNA at those regions of CDH1. 
In contrast the DNA extracted from the tissues received as blocks was of sufficient quality 
(Figure 3.1). This may, in part, reflect the amount of material available for extraction on the 
individual slides. Whereas ten micron sections were cut from those tissues received from 
Pakistan as blocks, the remaining nine tissues were received as pre-cut sections and were 
therefore likely to be considerably thinner. Only three sections per patient were available for 
DNA extraction for these nine samples, which meant only six microns thickness of material 
per sample was available for extraction. 
Accordingly, the number of samples available for analysis of the CDH1 gene expression was 
reduced to 11. This group consisted of nine males and two females, with a median age of 28 





Figure 3.1 PCR amplification of CDH1 promoter and exons. Amplicons from PCR reactions to 
amplify promoter region and exons 1-16 of CDH1 gene from (A), DNA extracted from a sample 
supplied as a FFPE block and (B), DNA extracted from a sample supplied as cut sections. 
 
3.3.3 Immunohistochemical staining for E-cadherin 
The remaining 11 sections were immunostained to determine the presence of E-cadherin 
(Section 2.2.1.2), with staining of signet ring cells graded as negative, weak positive or positive 
(Wang et al., 2016). As with the H&E staining, the level of staining was scored by a pathologist 
blinded to the identity of the samples.  
Immunohistochemistry revealed E-cadherin staining was absent (n=6) or notably weak (n=5) 
at the membranes of the signet-ring cells in the 11 tumours when compared to adenocarcinoma 






Table 3.2 E-cadherin staining by signet ring cell component of the 11 SRCC samples included in 
the final analysis.   
Histology Age Gender Location E-cadherin 
staining 
Colorectal SRCC  15 F anal growth negative 
(>50% signet ring 
cells) 
24 M rectosigmoid negative 
 24 M anal canal weak positive 
 28 M rectal negative 
 37 M rectosigmoid weak positive 
 39 M rectum weak positive 
 21 F gut nodule weak positive 
 35 M hepatic flexure negative 
 40 M cecum negative 
     
     
CRC (with <50% signet  20 M cecum weak positive 
ring cell component) 30 M anus weak positive 




Figure 3.2 E-cadherin staining of signet ring cell cancer. Representative immunohistochemistry with 
(A) weakly staining positive and (B) negative E-cadherin staining of signet ring cells, and (C) 
adenocarcinoma cells showing typical E-cadherin staining, alongside sequential H&E staining of the 




3.3.4 Molecular analysis of the CDH1 gene 
The CDH1 gene sequence was determined by running pooled, indexed PCR products on an 
Illumina MiSeq instrument following the protocol described by Hakkaart et al. (Hakkaart et 
al., 2019). This approach involved the generation of dual-indexed amplicon sequencing 
libraries for each of the 11 samples with amplifiable DNA, that were diagnosed as either 
colorectal SRCC or CRC with signet-ring cell component, using a two-step PCR strategy 
(Section 2.2.3).  
Briefly, 17 target sites (16 exons and the promoter region) were amplified in separate PCR 
reactions and checked by electrophoresis on a 1.5% agarose gel (Figure 3.1). Following 
successful amplification, the PCR products for each sample were pooled and further amplified 
using unique pairs of primers containing indices that would allow for the identification of each 
sample within an Illumina MiSeq sequencing run.  
Raw paired end reads were cleaned with Trimmomatic v.0.35.25. Cleaned reads were aligned 
to the human reference genome (GRCh37/hg19) using the Burrows–Wheeler Aligner v.0.7.10 
(H. Li & Durbin, 2009).  Single nucleotide variants and insertion/deletion variants were called 
using ‘The Genome Analysis Toolkit’ (GATK) v.3.6 (McKenna et al., 2010).  The effects of 
variants were predicted using SnpEff v.4.2 (Cingolani et al., 2012). The trimming of reads, 
sequence alignments, variant calling and variant effect prediction were performed by Dr 
Christopher Hakkaart using a bioinformatics pipeline developed by him. All putative mutations 
were visually inspected using the Integrative Genomics Viewer (Robinson et al., 2011). The 
functional consequences of missense variants were predicted in silico using five different 
models that included SIFT (Kumar et al., 2009), Provean (Choi et al., 2012), Mutation Assessor 
(Reva et al., 2011) and PolyPhen2  (using both HumDiv and HumVar datasets) (Adzhubei et 
al., 2013). Mutations predicted to be deleterious by at least 3/5 predictive models were 
considered of interest.  
Raw sequencing data were cleaned and aligned to the reference genome (GRCh37/hg19) as 
explained in Section 2.2.3.11. Variants were called and their effects predicted as detailed in the 
same section, with all variants visually inspected using the Integrative Genomics Viewer 
(Robinson et al., 2011). Multiple in silico models were used to predict the pathogenicity of 
mutations with a mutation being considered of interest if at least 3/5 models predicted it to be 
pathogenic (Section 2.2.3.11). 
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This analysis of the data generated using next generation sequencing of the CDH1 gene 
revealed eight mutations meeting our inclusion criteria regarding absolute (>10) and relative 
(>20%) read depth in 7 of the 11 (64%) samples that yielded DNA of sufficient quality for 
analysis (Table 3.3). These samples included five signet-ring cancers and two CRCs with a 
partial signet-ring component. 
Mutation status was not associated with the histological classification of the cancer. In line 
with the spread of reported mutations in the COSMIC (Catalogue of Somatic Mutations In 
Cancer) database, the CDH1 mutations were spread throughout the gene with no clear hotspots 
(Figure 3.3), although three out of the eight mutations occurred in the third ectodomain. All 
mutations were classified as variants of unknown significance. Six mutations had not 
previously been described. Allele counts indicated that five mutations found in four of the 
seven samples were possibly germline (Table 3.3) where the mutant allele accounted for 50% 
or more of the reads. 
 
 
Figure 3.3 Distribution of CDH1 mutations within the SRCC cohort. The locations of the mutations 
found in this study are indicated by lollipops along the length of the CDH1 protein. The mutations 
occurred in multiple different domains throughout the protein: the pre-protein (green), ectodomains 
(red) and the intracellular domain (blue). The plot was generated using Mutation Mapper 























Germline    
  
Cytoplasm c.2516G>A p.G839D 2,35 damaging negative  positive SRCC 
EC4 c.1724C>T p.A575V 25,25 damaging weak 
positive 
 positive SRCC 
EC4 c.1727C>T p.T576I 25,25 damaging 
EC3 c.1241C>A p.T414N 56,64 benign negative  positive SRCC 
EC3 c.1337C>T p.A446V 9,36 benign 
weak 
positive 
 negative mixed 
     
   
Somatic              
Cytoplasm c.2617G>T p.A873S 197,72 damaging negative  positive SRCC 
EC3 c.1322G>T p.G441V 42,14 damaging 
weak 
positive 
 positive SRCC 
Preprotein c.188G>A p.R63Q 37,18 benign 
weak 
positive 
 positive mixed 
1 (consensus allele, mutant allele), where mutant alleles present in at least 50% of reads were considered 
to be germline while those present in less than 40% of reads were determined to be somatic. 2 considered 
damaging if 3/5 or more software tools predicted the mutation to be possibly or probably damaging. 
Nonsense or frameshift mutations were all considered damaging without predictive tools. 
 
3.3.5 Clinical characteristics of samples with predicted germline mutations 
Of the four samples with putative germline mutations, three were from patients diagnosed with 
colorectal SRCCs with the other case being a CRC with partial signet-ring morphology. 
Moreover, in silico analysis of the CDH1 gene in two of these tumours suggested the mutations 
are damaging (Table 3.3).  
Sequence analysis revealed that one SRCC tumour had a germline mutation (p.G839D) that 
was universally predicted by all in silico tools to have a deleterious effect on the E-cadherin 
protein. Additionally, nearly all the reads showed the mutated form, suggesting the mutation 
may be inherited. While mutations at codon 839 have not previously been described, all 
substitutions in the COSMIC database within ten codons either side of codon 839 are predicted 
to be pathogenic, likely due to the location within the intracellular catenin-binding domain 
(Figure 3.3). Disruption of catenin binding to the intracellular domain of E-cadherin would 
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likely destabilise the cellular architecture via loss of binding of the catenin complex to actin 
filaments (Mege & Ishiyama, 2017). There was no evidence E-cadherin staining of signet ring 
cells in this tumour. 
The other two possible germline deleterious CDH1 mutations occurred in the same sample. 
Two adjacent amino acids (p.A575V, p.T576I) were mutated on the same allele, in an area 
encoding an extracellular domain (Table 3.3, Figure 3.3). In silico, these adjacent mutations 
would be considered likely to affect the ability of the mutant E-cadherin to form effective 
junctions with adjacent cells. Weak E-cadherin staining of signet-ring cells in this sample may 
equate with this predicted loss of functional activity. 
Sequence analysis of the CDH1 gene in a further SRCC sample suggested evidence of a 
p.T414N substitution. In silico, this mutation was predicted to be benign, as was the p.A446V 
mutation found in a CRC with signet-ring cell component (Table 3.3). Signet-ring cells in the 
sample with the p.A446V mutation were weakly positive for E-cadherin staining. In contrast, 
the sample with the p.T414N mutation did not stain for E-cadherin. The p.T414N mutation has 
previously been identified and designated as of unknown significance and, currently, there is 
no evidence to suggest that or the p.A446V mutations have clinical significance. If not, the loss 
of E-cadherin in the sample with the p.T414N mutation may be due to other mechanisms, such 
as epigenetic modification (Darwanto et al., 2003). 
 
3.3.6 Clinical characteristics of samples with predicted somatic mutations  
The remaining CDH1 mutations were considered somatic, given the low relative allele counts 
(<40%; Table 3.3). This discovery of multiple somatic mutations is not surprising given the 
late stage at diagnosis of these tumours where there is increased likelihood of a high and 
heterogeneous mutational load of somatic mutations.  
One of the somatic mutations, p.R63Q, has been described previously as benign 
(https://www.ncbi.nlm.nih.gov/snp/rs587780117). Codon 63 is located within the pre-protein 
so is not part of the mature active protein. Therefore, providing the mutation does not affect 
the intracellular targeting of the protein, loss of E-cadherin staining in this sample may be due 
to another mechanism. However, in the absence of evidence of another mechanism R63Q 




3.3.7 Microsatellite instability was not a common feature in this cohort 
Microsatellite instability (MSI) is found in 15-20% of sporadic colorectal cancer and 
considered to be a positive prognostic factor (F. A. Sinicrope et al., 2006). MSI is also reported 
in colorectal SRCC (Ogino et al., 2006; Rosty et al., 2014) although this is not universal (Nam 
et al., 2018) and, when present, may not have a role in cancer-related mortality (Inamura et al., 
2015). Accordingly, tissue sections were immunostained to identify microsatellite markers 
MSH6, PMS2 and, in the event of negative PMS2, MLH1 to better understand the potential 
contribution of MSI to SRCC prognosis in this cohort. Again, the stained sections were scored 
by a pathologist blinded to the identity of the samples. 
While it is standard practice in New Zealand diagnostic laboratories to stain for all four MMR 
proteins (MSH2, MSH6, MLH1 and PMS2), just MSH6 and PMS2 were stained in the first 
instance. This was for two reasons, namely cost and to maximize the number of slides available 
for DNA extraction, particularly for those samples that were only supplied as a limited number 
of pre-cut sections, and was on the advice of an anatomical pathologist although it has also 
been reported elsewhere (Hall et al., 2010). This approach is based on the observation that the 
MSH2 and MSH6 form a heterodimers during mismatch repair while PMS2 and MLH1 do 
likewise. While MSH2 can also partner with MSH3, MSH6 can only pair with MSH2 so lack 
of MSH2 staining would also lead to lack of MSH6 staining therefore MSH6 can be used as a 
proxy for MSH2. Similarly PMS2 can be used as a proxy for MLH1. Samples deficient in 
PMS2 or MSH6 staining would then have sections stained with MLH1 or MSH2 respectively, 
although all samples were MSH6 positive so no MSH2 staining was ultimately required for 
this study. This protocol is not, however, a full-proof method of assessing MMR deficiency as 
in a very small number of cases, MMR deficiency can be present despite positive MSH6 and 
PMS2 staining (Pearlman et al., 2018). However, due to the considerations mentioned above 
and the relative rarity of the 2-stain method failing to identify MMR deficiency it was decided 
to proceed with the 2-stain method.  
All of the 11 samples included in the sequence analysis above were positive for MSH6 staining, 
however two samples were negative for PMS2 (Figure 3.4), loss of which is associated with 
colorectal cancer. Interestingly, both samples (one SRCC and one CRC with signet-ring cell 
component) that stained negative for PMS2 showed staining for E-cadherin, albeit weak, 
suggesting perhaps that microsatellite instability and loss of E-cadherin represent different 
pathways of colorectal signet-ring cell development. This argument is further strengthened by 
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noting that one of these two samples had no CDH1 mutation while the other sample had a 
mutation that was predicted to be benign. Subsequent testing of these two samples for MLH1 
staining showed one sample lacking MLH1 while the other sample was inconclusive due to 
non-reactivity of the control tissue added to each slide holding a tumour section prior to 
staining.  
 
Figure 3.4. PMS2 staining of signet-ring cells. Immunohistochemistry showing (A) a sample with 




While the prevalence of colorectal SRCC in Pakistan is currently unknown, a growing number 
of studies show high incidences of early-onset CRC across the Asian continent (Chew et al., 
2009; Gupta et al., 2010; Laskar et al., 2014; Wang et al., 2016) including Pakistan where 
younger age and advanced stage of disease at diagnosis were identified in two unrelated studies 
(Amini et al., 2013; Bhurgri et al., 2011). While neither of the Pakistani studies specifically 
reported the percentage of young patients with SRCC, early-onset CRCs are more likely to 
demonstrate signet ring cell differentiation when compared to CRCs seen in patients aged over 
40 years (Chang et al., 2012; Q. Li et al., 2014). Collectively, these studies support anecdotal 
evidence of high rates of colorectal SRCC in young Pakistani people. Against that background, 
our colleague’s observance of high rates of colorectal SRCC in young Pakistani patients at a 
hospital in Karachi, provided us with an intriguing cohort in which to study this disease. 
Studies suggest the younger the age of the patient, the poorer the outcome (Huang et al., 2016; 
Poles et al., 2016). The youngest patient in the cohort was only eight years old and 35% (7 of 
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20) of the patients diagnosed with CRC with a signet ring cell component (irrespective of 
whether signet ring cells were a major (>50%) or minor (<50%) component of the tumour) 
were younger than 22 years of age, a cut-off which has been used to define CRC patient 
populations as paediatric (≤21 years) and early-onset adult (22-50 years), respectively (Poles 
et al., 2016). No family history was available for any patients in our study, but the early age of 
onset suggests that some of these cancers may be familial rather than sporadic (Wei et al., 
2016). E-cadherin loss is a well-documented feature of familial SRCC gastric cancer (Guilford 
et al., 2007), and while colorectal SRCC is far less studied, the loss of this adherens junction 
protein has been reported as a feature of this disease too (H. C. Kim et al., 2002), and may 
explain the increased invasiveness and metastatic potential of colorectal SRCCs. 
Eleven samples in our cohort of patients with colorectal SRCC had DNA of sufficiently good 
quality for molecular analysis by next generation sequencing. Using this technique, we found 
evidence of one or more mutations in the CDH1 gene in seven (64%) samples that included 
five predicted germline and three predicted somatic mutations. Unfortunately, neither matched 
normal tissue nor peripheral blood samples were available to confirm the germline status of the 
mutations. The use of allele counts to predict the germline status of is a crude and inaccurate 
method which may be affected by aneuploidy within tumour cells and the presence of non-
tumour cells. As such the assignment of possible germline status to any samples in this chapter 
is made due to the absence of normal tissue and is only speculative.  
The absence of any common mutation between patients suggests that if there are familial cases 
in our cohort it is not due to a single founder mutation within that population. It is possible 
however that multiple mutations may arise in a population, as evidenced by the discovery of 
multiple familial CDH1 mutations in New Zealand Māori (Hakkaart et al., 2019; Humar et al., 
2009). 
 It has been postulated that the occurrence of multiple germline CDH1 mutations in a 
population may reflect a selective advantage in these populations. One explanation revolves 
around Listeria monocytogenes, a food-borne pathogen causing gastroenteritis and, in serious 
cases, meningitis or miscarriage in pregnant women (da Silva Tatley et al., 2003). This 
bacterium internalizes into epithelial cells via the binding of the bacterial internalin-A protein 
to the N-terminal, extracellular domain of E-cadherin (Hamon et al., 2006). Potentially, mutant 
E-cadherin protein may interfere with the ability of L. monocytogenes to bind and internalise 
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in epithelial cells. However, whether or not there is (or was) a selective advantage conferred 
by these mutations remains to be determined. 
The low mutant allele count for some of the mutations may indicate that for some samples 
mutation of CDH1 is a late event in the development of colorectal SRCC. However, the two 
SRCC cases with seemingly deleterious germline mutations and others with high mutant allele 
counts suggest that E-cadherin loss is an important early step in a subset of SRCC. This is 
highlighted by our finding that all three paediatric patients (ranging in age from 15 to 21 y) in 
this group had evidence of mutations in their respective CDH1 genes. One tumour contained a 
predicted germline mutation, despite the signet ring cells staining weakly positive for E-
cadherin. The two other paediatric patients had tumours that were classified as colorectal 
SRCCs (>50% signet rings), each with evidence of predicted damaging somatic rather than 
germline mutations in the CDH1 gene, and again the signet ring cells in one of these tumours 
showed weak evidence of E-cadherin expression. Collectively, these findings suggest a lack of 
concordance between the molecular and phenotypic expression of E-cadherin although it is 
possible that weak E-cadherin immunoreactivity may not necessarily equate with functional 
activity (Becker et al., 1994). 
Microsatellite instability (MSI) has previously been associated with colorectal SRCC (Ogino 
et al., 2006; Rosty et al., 2014) but we found low levels (2/11, 18%) in our cohort. Furthermore, 
one of the two was identified as a mixed signet ring/mucinous adenocarcinoma sample, 
meaning the prevalence of MSI is even lower, with only one out of the seven samples (14%) 
classified as SRCC having microsatellite instability. It is to be noted, however, the evidence 
for MSI in colorectal SRCC is based on small scale studies and case reports and is not a 
universal conclusion in all studies. A recent study of five Korean SRCC patients found all cases 
were microsatellite stable (Nam et al., 2018).   
Microsatellite instability in sporadic colorectal cancer tends to be associated with proximal 
tumours (H. Kim et al., 1994; Thibodeau et al., 1993) and occurs in females more than males 
(F. Sinicrope et al., 2010), neither characteristic seen in our (admittedly small) cohort of SRCC 
patients. Additionally, MSI in sporadic CRC has a better prognosis than microsatellite stable 
(MSS) cancers, while colorectal SRCC has a very poor prognosis irrespective of MSI status. 
In light of these observations it may not be surprising that we find low levels of MSI in our 
young, predominantly male cohort with mostly distal tumours. Both our cohort and the MSS 
cohort in the Korean study of SRCC described above (Nam et al., 2018) had low median ages 
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(28y and 40y respectively) therefore it may be that our findings reflect a shift from lower to 
higher levels of MSI with increasing age and that MSI may not be a strong feature of early-
onset colorectal SRCC.  
A major limitation of this study was that clinical data for the cohort included only age, gender 
and tumour site. No other clinical variables were available and there was no follow-up or family 
history for any of the samples. The lack of this information meant that no assessment of 
outcome in relation to E-cadherin expression (Wang et al., 2016) and/or CDH1 mutation was 
possible. While limited follow-up was only ever going to be possible given the diagnoses 
ranged from 2015-2017, the poor prognosis associated with colorectal SRCC suggest that some 
useful conclusions may have been made had this information been available. 
Similarly, the lack of family history prevents any evaluation of genetic predisposition to SRCC. 
This would also be informed by access to matched normal tissue or peripheral blood samples 
that could have confirmed the germline status of any mutations found. As well as limiting this 
study, the inability to show germline mutation of CDH1 prevents any benefit to patient families 
that might be afforded by early screening or vigilance. 
Additionally, the poor quality of the samples limited the scope of the study in several ways. 
We were only able to report on 14 of the original 24 samples due to the poor quality of DNA 
recovered from tissue sections. This limited the power of the study, particularly with the small 
number of starting samples. Due to the rarity of colorectal SRCC, many of the existing studies 
have very small cohorts. Hence, a study with 24 SRCC patients had the potential to 
significantly increase current knowledge around colorectal SRCC. However, notwithstanding 
the smaller sample number, we still regard this study as a useful addition to the currently sparse 
data on this rare condition. 
In conclusion, we found E-cadherin expression to be absent (or at best very weak) in colorectal 
signet-ring cell carcinomas and that this corresponded in a small number of cases with germline 
mutation of the CDH1 gene. For these patients, testing of family members for germline 
mutation may allow screening and early detection of tumours. Other colorectal SRCC cases 
showed low levels of somatic CDH1 mutations. Collectively, these findings suggest that while 
loss of E-cadherin is a common feature of colorectal SRCC and colorectal cancers with a 
signet-ring cell component, mutation of the CDH1 gene is not an underlying cause in the 








Our finding, described in Chapter 3, that absent or weak E-cadherin expression coincided with 
multiple CDH1 mutations within the cohort of Pakistani SRCC samples, was intriguing.  
However our ability to further assess the implications of this within that cohort was limited by 
sample quality and a lack of access to further samples (such as matched normal tissue) and/or 
clinical data, including patient outcomes and family histories. Our inability to confirm the 
germline status of those mutations with high allele counts, due to lack of matched non-tumour 
tissue, prevented us from drawing any conclusions as to whether screening of family members 
may have been of benefit. In addition, the lack of any family history of affected individuals 
limits the insights that can be made from our findings.  
In light of these limitations we sought to investigate E-cadherin expression and CDH1 mutation 
in a local cohort of early-onset colorectal cancer (EOCRC) patients where clinical information 
would be more readily available and sample quality more consistent. In addition we also sought 
to determine the presence of mutations in the APC gene for two reasons. Firstly, APC mutations 
occur in 60-80% of sporadic CRCs (Rowan et al., 2000) and mutations in this gene have long 
been established as an early event in colorectal tumourigenesis (Powell et al., 1992). Secondly 
we were aware that the number of SRCC cases in our cohort of EOCRC patients was likely to 
be very low (Plunkett et al., 2014).  
 Interestingly, there are studies that report the rate of APC mutation in early-onset CRCs to be 
lower than the rate seen in older CRC patients (Kothari et al., 2016), although this is not always 
the case (Willauer et al., 2019). While this may reflect different pathways to tumourigenesis in 
these individuals, another possibility is that these differences may reflect the use of different 
methodologies to look for mutations in a gene that has a large coding sequence spanning 
multiple exons over more than 100 kilobases of genomic DNA (Luchtenborg et al., 2004).  
There have been many different approaches in assessing APC mutations, with different regions 
of APC investigated in each approach (Kothari et al., 2016; Luchtenborg et al., 2004). While 
there is a defined mutation cluster region within the final exon of the gene, there are many 
mutations occurring outside this region. Therefore, strategies that limit themselves to the 
mutation cluster region, or more widely to the final exon, will miss a proportion of mutations 
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found elsewhere in the gene. To address this we looked at regions of the APC gene 
encompassing the vast majority of mutations found in the COSMIC database. It is reasonably 
common for a tumour to have both APC alleles mutated. When this occurs there tends to be a 
3’ mutation in or near the mutation cluster region, plus a mutation further upstream on the other 
allele (Christie et al., 2013). Truncated APC proteins have different functionalities and so this 
distribution of mutations within tumour cells is not a random coincidence. Therefore screening 
for mutations upstream of the mutation cluster region is warranted and necessary for a fuller 
picture of APC-related colon carcinogenesis.  
Frozen tumours and off-tumour tissue samples, obtained from 25 patients identified with early-
onset CRC, were collected at Christchurch Hospital, New Zealand, between August 2005 and 
February 2019. None of the patients had treatment prior to surgery and known Hereditary Non-
Polyposis Colorectal Cancer (HNPCC, Lynch syndrome) or Familial Adenomatous Polyposis 
patients were not included.  
 
The objectives of this study were to: 
1. Investigate the presence of CDH1 and APC mutations in a cohort of early-onset CRC 
cases from New Zealand by next generation sequencing protocols.  
2. Determine by immunohistochemistry the level of E-cadherin expression in tumours 
from the early-onset CRC patients and compare this to the DNA sequence information. 
3. Use single nucleotide polymorphisms within the sequence obtained in objective 1 to 
assess any loss of heterozygosity within the CDH1 and APC loci. 
 
4.2 Methods 
Samples from 25 patients with early-onset colorectal cancer, diagnosed at or under the age of 
50, were obtained from the Cancer Society Tissue Bank New Zealand. The samples consisted 
of frozen tumour tissue as well as matched normal tissue taken at the same time of surgery. 
The study was granted ethics approval by the University of Otago Human Ethics Committee 
(H18/143).   
DNA was extracted from 25 mg of frozen tissue (Section 2.2.1.1) and regions of DNA 
encompassing the promoter and all exons of the CDH1 gene were amplified by a 2-step PCR 
protocol followed by sequencing on an Illumina MiSeq platform in the Department of 
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Biochemistry, University of Otago, Dunedin. All molecular and downstream analysis protocols 
are detailed in Section 2.2.3. 
FFPE tissue blocks were obtained for each sample, sections cut and one slide for each case was 
stained with haematoxylin (to reveal nuclei) and eosin (to stain the extracellular matrix and 
cytoplasm) (H&E) for histological assessment by a pathologist (Section 2.2.1.2). In addition, 
a slide from each tumour was immunostained for E-cadherin (Section 2.2.1.2). 
The microsatellite instability status of the samples, as determined by the expression of four 
mismatch repair genes, MSH2, MSH6, PMS2 and MLH1, was carried out as part of the clinical 
assessment of the tumours, using the same method detailed in Chapter 2 (section 2.2.1.2). This 
data was obtained from the clinical records.   
 
4.3 Results 
4.3.1 Characterisation of the cohort  
The cohort of 25 early-onset CRC cases consisted of 14 (56%) women and 11 (44%) men aged 
50 years or under at diagnosis (median 44 years, range 28-50 years) (Table 4.1). The tumours 
were predominantly distal and all but two were classed as adenocarcinomas by H&E staining, 
with an adenosquamous carcinoma, where tumours contain cells originating from both mucus-
producing glandular cells and flat squamous cells that line epithelia, and a signet-ring cell 
carcinoma completing the cohort (Table 4.1). While the tumours were predominantly distal 
this is likely an under-representation of the proportion of distal tumours in early-onset CRC. 
Due to protocols used by the tissue bank, following removal of the colon, the rectum is not 
opened up prior to formalin fixation in order to preserve the resection margins. Therefore it is 
not possible for the tissue bank to obtain fresh rectal tumour tissue. In addition, neoadjuvant 
therapy on rectal tumour patients prior to surgery would have excluded inclusion of many of 







Table 4.1: Clinical features of the early-onset CRC cohort. 
   
 Number % 
Total 25  
Gender   
   Male 11 44 
   Female 
Age at diagnosis (years) 
14 56 
   21-30 1 4 
   31-40 6 24 
   41-50  18 72 
Ethnicity   
   European 24 96 
   Filipino 1 4 
Stage at diagnosis   
   I                  9 36 
   II                  9 36 
   III                  6 24 
   IV                  1 4 
Tumour site      
   Caecum 1 4 
   Ascending colon 6 24 
   Hepatic flexure 1 4 
   Splenic flexure 1 4 
   Descending colon 3 12 
   Sigmoid colon 12 48 
   Rectosigmoid 1 4 
Pathology   
   Adenocarcinoma 23 92 
   Adenosquamous carcinoma 1 4 
   Signet-ring cell carcinoma 1 4 
  
 
4.3.2 Immunohistochemical staining for E-cadherin   
Sections of tumour tissue that were cut from FFPE blocks were immunostained for the E-
cadherin protein (Section 2.2.1.2) and were independently assessed by a pathologist. As with 
the Pakistani cohort (Chapter 3), the level of staining of the tumour cells was graded as 
negative, weak positive or positive.  
While frozen tissue was available for all 25 patients, FFPE blocks were not available for one 
patient, meaning that tumour tissue could not be stained for E-cadherin in this case. Of the 
remaining 24 samples only one tumour was classified as negative for E-cadherin, while a 
second sample stained weakly. Consistent with previous reports of E-cadherin status in 
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colorectal SRCC (Aitchison et al., 2020; Borger et al., 2007), the sample with negative E-
cadherin staining was the sole SRCC sample in the cohort. 
 
 
Figure 4.1. Representative immunohistochemistry for E-cadherin in EOCRC samples. A, 
positively-staining adenocarcinoma sample showing strong membrane-associated E-cadherin staining 
(brown) in tumour cells. B, an adenosquamous carcinoma sample showing weak E-cadherin staining at 
tumour cell membranes although the staining was consistent along the cell membrane. C, signet-ring 
cell carcinoma cells with small foci of E-cadherin at cell junctions within predominantly negatively 
staining cells showing classic signet-ring morphology. A pathologist classified this tumour as negative 
for E-cadherin due to the absence of E-cadherin along the membranes. Nuclei are stained blue. 
 
The sample with weak E-cadherin staining was the sole adenosquamous carcinoma, whereas 
all the 22 other tumours that stained positive for E-cadherin were adenocarcinomas. 
Interestingly, within the adenosquamous carcinoma it was the squamous cells that stained very 
weakly, whereas stronger staining was seen in the glandular cells. This suggests that the 
squamous proportion of the carcinoma contributed to the weakness of the E-cadherin signal in 
this sample. 
 
4.3.3 Molecular analysis of the CDH1 gene  
DNA was extracted from 25 mg of frozen tumour and matched normal tissue using a Qiagen 
DNeasy Blood & Tissue kit (Section 2.2.1.1). The CDH1 gene sequence was determined by 
running pooled, indexed PCR products on an Illumina MiSeq instrument following the protocol 
described in Section 2.2.3. Again, mutations predicted to be deleterious by at least 3/5 
predictive models were considered of interest while mutations with low absolute (<10) or 
relative (<20%) allele counts were excluded. 
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This analysis of the data revealed a single tumour sample from a 34 year old male that met the 
inclusion criteria. This sample yielded a c.88C>A variant in the CDH1 gene, a missense variant 
resulting in a p.P30T substitution. The proline residue encoded by codon 30 of E-cadherin is 
moderately conserved between species and is within a very conserved region of the E-cadherin 
sequence, between codons 28 and 32 (Figure 4.2). The c.88C>A variant is seen at low 
frequency in databases such as 1000Genomes (MAF 0.00040) and ExAc (MAF 0.00094), and 
multiple predictive tools suggest this variant to be deleterious. In contrast, ClinVar considers 
c.88C>A as likely benign (https://www.ncbi.nlm.nih.gov/clinvar/variation/127933/).  
 
 
Figure 4.2. Conservation of the proline residue at codon 30 of E-cadherin. A section of the E-
cadherin containing protein including the proline residue at codon 30 (red arrow) which is conserved to 
zebrafish (Danio rerio) and is adjacent to the strongly conserved glycine and phenylalanine residues at 
codons 31 and 32. Alignments created using Clustal Omega in Geneious Prime 2020.0.5 (Biomatters 
Ltd, Auckland, NZ). 
Interestingly the p.P30T substitution created by the c.88C>A variant is located in the pre-
protein, and therefore does not impact on the mature E-cadherin protein sequence. However it 
may play a role in the localisation of the protein to the cell membrane (Vogelaar et al., 2013) 
and, while proline and threonine are physiochemically similar, this change may subtly impact 
this potential targeting role.  
Sanger sequencing of tumour tissue confirmed the presence of the variant, and sequencing of 






Figure 4.3. Confirmation of germline status of CDH1 c.88C>A mutation. Sanger sequencing of the 
CDH1 c.88C>A (recognised as a heterozygous base, M, in the sequence) mutation, confirming its 
presence in both tumour and matched normal tissue. 
 
4.3.4 Molecular analysis of the APC gene 
As detailed in the introduction to this chapter, there are many different approaches to assessing 
APC mutations that can, in part, relate to the region of the gene in which they are located. 
Accordingly, an approach that is limited to investigating mutations within the defined mutation 
cluster region within the final exon of the gene is likely to miss a proportion of mutations found 
elsewhere in the gene. To address this we looked at regions of APC encompassing the vast 
majority of mutations found in the COSMIC database.  
Fifteen amplicons covering the APC sequences most commonly mutated in colorectal cancer 
were amplified for each of the 25 EOCRC samples, as detailed in Section 2.2.3 (Figure 4.4). A 
second round of PCR was performed using indexed primers as for the CDH1 sequencing 
detailed above. Pooled products for each tumour and matched normal tissue samples were then 
sequenced (Sections 2.2.3.9 to 2.2.3.11).  
Twenty four mutations meeting the inclusion criteria for absolute (>10) and relative (>20%) 
read number were found in 18/25 tumour samples. The mutations consisted of 14 nonsense 
mutations, 6 frameshift mutations, 3 missense mutations and one splice region variant (Figure 
4.5). Sequencing of matched normal tissues revealed that, while the majority of mutations were 




Figure 4.4. PCR amplification of APC sequences. Fifteen PCR reactions were used to amplify the 
regions of APC containing the most frequently mutated bases. Two amplicons each were required to 




Figure 4.5. APC mutations found in EOCRC samples mapped to their position within the protein. 
Each lollipop represents the position of a mutation with the colours of the lollipop representing different 
types of mutation: black, nonsense mutations; green, missense mutation; pink, frameshift mutation; 
yellow, splice variant. While a high proportion of mutations occur within the mutation cluster region 
(MCR, black bar), mutations are found throughout the first 1600 codons of APC including some 
upstream of exon 15 (green bar). Protein domains: green, oligomerisation; red, armadillo repeats; blue, 
15 amino acid repeats; yellow, 20 amino acid repeats; purple, SAMP motif. The plot was generated 




4.3.5 The two germline APC Variants 
p.V1125A. A c.3374T>C variant, found in one sample in the current cohort, has a low 
frequency in the general population (ExAC MAF 0.00057). This variant results in a substitution 
at codon 1125 of a valine to an alanine, and is regarded as a conservative change as they are 
closely related amino acids. Coupled with the occurrence of the variant in the general 
population (F. F. Li et al., 2015), as well as its position in a poorly conserved region of the 
gene, the c.3374T>C variant is considered benign.  
 
p.E1317Q. A c.3949G>C mutation found in one patient resulted in a glutamic acid to 
glutamine change at codon 1317 of APC, in a region of the gene poorly conserved between 
species. The c.3949G>C variant is found at low frequency in the general population (ExAC 
MAF 0.00413; 1000Genomes MAF 0.003). ClinVar has conflicting interpretations of 
pathogenicity.  
In this study this mutation was found in a 36 year old female (Patient 15310) with a stage 2 
adenocarcinoma with no lymph node involvement or metastasis. There is no reported family 
history of bowel cancer. Interestingly, while the matched normal tissue showed the mutation 
to be heterozygous, the wild type allele was barely visible in the tumour. Moreover, this 
apparent loss of heterozygosity in the tumour occurred despite the positive staining of the 
tumour for all four mismatch repair proteins deeming the tumour microsatellite stable. It is 
reasonable to suggest that this second genetic hit is required for the pathogenicity of the 
p.E1317Q to occur. This might explain the lack of family history, as the single mutant allele 
alone may not be sufficient for carcinogenesis, and is an example of the damaging potential 









Figure 4.6. Sanger sequencing of APC c.3949G>C mutation. The guanine base indicated by the red 
arrow in the wild type APC sequence is mutated to a cytosine in one allele in the normal tissue of the 
patient to give a heterozygous sequence. In the tumour tissue the wild type guanine allele is barely 
visible.  
 
4.3.6 Sporadic APC mutations 
As well as the two germline APC mutations, 22 sporadic mutations (20 unique plus one found 
in two samples) were found in the cohort (Table 4.2) and confirmed by Sanger sequencing. 
None of these mutations were seen in the matched normal tissue. All but two sporadic 
mutations were predicted to be damaging, as they caused premature truncation of the gene. The 
remaining two were missense mutations, both of which were predicted to be benign. Fifteen 















Reference DNA rsID Protein 
10006 MSI c.2626C>T rs121913333 p.R876X Nonsense Damaging (Powell et al., 1992) 
10765 MSS c.835-8A>G rs1064793022 Splice variant Truncation2 Damaging (Fostira & Yannoukakos, 2010) 
12294 MSS c.1660C>T rs137854573 p.R554X Nonsense Damaging (Friedl & Aretz, 2005) 
12961 MSS c.2853T>G rs575406600 p.Y951X Nonsense Damaging (Friedl & Aretz, 2005) 
13046 MSS 
c.4488delT n/a p.P1497fsX Frameshift Damaging This Study 
c.2805C>A rs137854575 p.Y935X Nonsense Damaging (Simbolo et al., 2015) 
13501 MSS c.2636delA n/a p.Q879fsX Frameshift Damaging This Study 
13564 MSS c.4033G>T rs1211642532 P.E1345X Nonsense Damaging (Gomez-Fernandez et al., 2009) 
14459 MSS 
c.4463delT rs1114167577 p.L1488fsX Frameshift Damaging (Miyaki et al., 1994) 
c.3826delT n/a p.S1276fsX Frameshift Damaging This Study 
15310 MSS c.4216C>T rs587782518 p.Q1406X Nonsense Damaging (Lagarde et al., 2010) 
16993 MSS 
c.4717G>T rs878853217 p.E1573X Nonsense Damaging (Aceto et al., 2005) 
c.2821G>T n/a p.E941X Nonsense Damaging (Miyaki et al., 1994) 
17871 MSS 
c.4485delT n/a p.S1459fsX Frameshift Damaging This Study 
c.2626C>T rs121913333 p.R876X Nonsense Damaging (Powell et al., 1992) 
18090 MSS c.3925G>T n/a p.E1309X Nonsense Damaging (Luchtenborg et al., 2004) 
19199 MSS c.646C>T rs62619935 p.R216X Nonsense Damaging (Gomez-Fernandez et al., 2009) 
19513 MSS 
c.3740C>T n/a p.A1247V Missense Benign This Study 
c.3340C>T rs121913331 p.R1114X Nonsense Damaging (Aceto et al., 2005) 
20039 MSS c.4230C>A n/a. p.C1410X Nonsense Damaging This Study 
















DNA rsID Protein 
21025 MSI c.2563_2564dupGA n/a p.R856fsX Frameshift Damaging This Study 
1, Missense mutations were considered damaging if 3/5 or more software tools predicted the mutation to be possibly or probably damaging. Nonsense or 
frameshift mutations were all considered damaging without predictive tools. 2, The splice variant c.835-8A>G results in a frameshift that ultimately leads to 





4.3.7 Microsatellite instability 
Of the 24 samples for which sections were available, 21 reportedly stained for all four mismatch 
repair proteins and were therefore considered microsatellite stable. All three of the remaining 
samples displayed microsatellite instability, with one negative for MSH6 staining and two 
negative for PMS2 staining. These three tumours did not cluster at any location in the colon, 
as they were found in the ascending colon, splenic flexure and the sigmoid colon respectively. 
Interestingly, one of the 21 samples that stained positively for all four mismatch repair genes 
was reported to have a BRAF mutation. This sample was the only adenosquamous carcinoma 
in the cohort and also stained weakly for E-cadherin. This combination of a BRAF mutation in 
a microsatellite stable adenosquamous colon cancer has been reported before (Ishida et al., 
2017). 
 
4.3.8 Loss of heterozygosity is associated with APC mutation near codon 1300 
Loss of heterozygosity was determined by the APC sequence data, when loss of one allele of a 
single nucleotide polymorphism was seen in the tumour sequence where two different alleles 
were seen in matched normal tissue (Section 2.2.3.13). Three out of the 25 samples in the 
cohort (12%) displayed a loss of heterozygosity. Of particular note was that these three samples 
all had APC mutations clustered around codon 1300, a phenomenon previously reported in 
sporadic CRC (Rowan et al., 2000).  
 
4.4 Discussion  
In contrast to the cohort of early-onset CRCs from Pakistan (Chapter 3) that were primarily 
characterised by the presence of signet rings, the local cohort predominantly carried colorectal 
adenocarcinomas. We found one tumour in our cohort of EOCRC tumours with evidence of a 
previously described CDH1 germline mutation. That, combined with evidence of E-cadherin 
staining in all but the single SRCC case within the cohort, leads to the conclusion that loss of 
E-cadherin is not a major factor in the pathogenesis of early-onset CRCs in New Zealand. This 
finding is in agreement with a recent study where commercially available 46- or 50-gene panels 
for Next Generation Sequencing also failed to find CDH1 to be commonly mutated in early-
onset CRCs, or indeed at any age of onset (Willauer et al., 2019). 
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The one tumour with evidence of a CDH1 germline mutation was found in a 34 year old male. 
This was a c.88C>A variant reportedly present at low frequency in the general population 
(https://www.ncbi.nlm.nih.gov/clinvar/variation/127933/). However, the very young age of 
diagnosis and the presence of mucin in the tumour suggests a similarity to hereditary diffuse 
gastric cancer patients, where CDH1 mutations are causative (Guilford et al., 1998). That, 
along with the co-occurrence of c.88C>A in other diseases such as lobular breast and gastric 
cancer (Masciari et al., 2007; Molinaro et al., 2014) and the observation  that c.88C>A affected 
the localisation of E-cadherin in vitro (Vogelaar et al., 2013), suggests that c.88C>A may be 
causative in this individual. Although the presence of strong E-cadherin staining at the cell 
membranes in the tumour reduces this possibility, the presence of this mutation may indicate 
familial risk and screening of family members should be considered. 
Only one sample was histologically classified as a SRCC and interestingly this was the same 
tumour that was classified negative for E-cadherin staining, providing further evidence that 
loss of this inter-cellular protein is an important step in the development of SRCC tumours. 
One other tumour also showed partial loss of E-cadherin. The absence of any CDH1 mutation 
in these two samples with reduced or absent E-cadherin expression suggests other forms of 
silencing of this gene are likely to have occurred. Methylation-induced silencing of CDH1 has 
been found in colorectal cancers (Lee et al., 2004; Wheeler et al., 2001), including SRCCs 
where loss of E-cadherin was associated with an increase in expression of MeCP2, a methyl-
binding protein (Darwanto et al., 2003). Promoter methylation of one allele as a second genetic 
hit may occur alongside genetic loss of the other allele as has been described for CDH1 in 
gastric cancer (Oliveira et al., 2009), providing additional argument for CDH1 methylation as 
a possible mechanism in the current cohort. Time constraints precluded methylation analyses 
of our cohort but this is considered a priority for future research. 
In contrast to the observed lack of mutations in the CDH1 gene, mutations of APC were 
identified in 18/25 (72%) of early-onset CRC cases in our cohort. This is higher than some 
other studies looking at APC mutation in early-onset CRCs (Kothari et al., 2016; Willauer et 
al., 2019) that may, in part, reflect the methodology used here. The APC gene is long, 
encompassing 8529 bases of coding sequence over multiple exons covering over 100 kilobases 
of chromosome 5, making sequencing strategies cumbersome and expensive. Therefore, many 
studies have focused on mutation hotspots in the gene, particularly the mutation cluster region 
between amino acids 1286 and 1513 (Miyoshi et al., 1992) or more widely within the final, 
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large exon which encompasses the majority of APC mutations. This has the potential to miss 
mutations that fall outside these regions.  
We developed a sequencing strategy to maximize the mutations identified while maintaining a 
manageable, cost-effective amount of sequencing. Firstly, regions of APC with very low rates 
of mutation in sporadic CRCs were identified using the Catalogue Of Somatic Mutation In 
Cancer (COSMIC) database, and excluded from our sequencing strategy. That left exons 5, 6, 
8, 9, 11, 12 and 13, as well as exon 15 from amino acids 788 to 1593. These exons encompass 
the vast majority of non-synonymous mutations of the APC gene in the COSMIC database, 
and each was sequenced. This approach identified 24 mutations in 18/25 (72%) tumour samples 
across these regions of the APC gene. Importantly, if we had only sequenced the mutation 
cluster region, this number would have dropped to 8/25 (32%). Likewise, mutations in the final 
exon of the gene were identified in only 14/25 (56%) of the samples. These findings 
convincingly highlight that protocols applied to study APC mutations are of critical importance, 
and that studies limited to “hotspot” regions of the gene may significantly under-report the 
mutation rate.  
A recent study investigating mutations in two separate cohorts of colorectal cancer gave 
considerably different rates of APC mutation between the cohorts (Willauer et al., 2019) that 
were investigated using different screening panels. For patients under 50 years of age, the APC 
mutation rates of the tumours were 41.6% and 65.2% for the two cohorts. The commercial 
panel that identified the lower rate of APC mutations only investigated mutations within the 
last exon of APC, mostly within the mutation cluster region. The second cohort was studied 
using a mixture of platforms, suggesting the method used to identify APC mutations and the 
amount of the gene covered has a large impact on the rate of mutations reported. In comparison, 
the rate of tumours with mutations in the final exon of APC within our cohort was 56% (14/25). 
Of further interest was that, with the exception of patients under 30 years old, the rates of APC 
mutation in the two cohorts detailed in the Willauer study were not very different between 
early-onset and late-onset CRCs (Willauer et al., 2019). Only one patient in our cohort was 
aged under 30, a male aged 28 with left sided adenocarcinoma. Of note this patient did not have 
an APC mutation. 
Of interest was our finding of two germline mutations in our cohort, despite familial 
adenomatous polyposis being one of the exclusion criteria. Perhaps unsurprisingly, while 21/24 
mutations were either nonsense or frameshift mutations resulting in truncated proteins, both 
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the germline variants were missense mutations. The p.V1125A variant appears to be benign, 
whereas the p.E1317Q variant that replaces a glutamic acid residue with a glutamine has 
previously been found to be significantly associated with cancer with an odds ratio of 11.17 in 
a study of 164 unrelated colorectal adenoma patients (Lamlum et al., 2000). While glutamic 
acid and glutamine are structurally similar, this alteration may have the potential to cause a 
change in the charge at that specific amino acid position that may affect folding or some other 
aspect of protein regulation or function.  
The finding that the wild type allele, while present in the patient’s normal tissue, was almost 
completely absent in the tumour of the patient with the germline p.E1317Q mutation, suggests 
that p.E1317Q acts as a susceptibility allele, only becoming pathogenic in the absence of its 
wild type partner.  
This is further evidenced in a study of a cancer-prone family in Scotland, where two family 
members with colon cancer carried the p.E1317Q mutation. In tumours from both those 
individuals, the wild type allele was lost (White et al., 1996). Interestingly, the patient in our 
cohort with evidence of this mutation presented with adenocarcinoma with adenoma, but no 
family history of adenomas, seemingly ruling out Familial Adenomatous Polyposis. However, 
a study that detailed the family histories of four unrelated CRC patients exhibiting the same 
p.E1317Q mutation, found a spectrum of risk that ranged from no known history of colorectal 
cancer or related disease in one patient, to two of the patients having a first-degree relative with 
rectal cancer (Frayling et al., 1998). This is further compounded by evidence that the number 
and rate at which polyps developed in these four patients was widely divergent, where two had 
17 and 5 metaplastic polyps respectively, while the other two had none but developed 1 and 3 
polyps in 14 and 15 years of follow-up, respectively (Frayling et al., 1998).  
These conflicting presentations suggest that p.E1317Q has wide phenotypic variation and may 
or may not indicate familial risk for relatives carrying the mutation. In light of this, screening 
of families identified with the p.E1317Q mutation may identify polyp formation or cancer at 
an earlier stage than otherwise likely.  
Furthermore, the finding of a total of three samples with loss of heterozygosity, by the loss of 
one APC allele in the tumour tissue, including the patient described above, was notable in that 
all three samples had APC mutations clustered near codon 1300, namely codons 1309, 1317 
and 1345. While this phenomenon was first identified in familial adenomatous polyposis 
patients (Lamlum et al., 1999) it was subsequently identified in sporadic CRC (Rowan et al., 
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2000). Similarly, the three samples we found with LOH associated with mutations near codon 
1300 include one germline and two sporadic mutations. Although we did not investigate the 
mechanism of LOH in these samples, whether due to specific loss of an APC allele or a wider 
loss of a chromosomal region or arm, our findings of LOH in samples with mutations around 
codon 1300 add further evidence to this intriguing observation and expand it to include early-
onset CRC. 
In a review of 1025 CRC patients under 50 years of age, tumours were found to be 
predominantly distal (49.1% rectal, 29.1% left-sided) with a minority (21.9%) being right sided 
(Dozois et al., 2008). Similarly, the current cohort was generally distal (68%) with almost half 
(48%) being located in the sigmoid colon. There were some gender differences in location with 
6/11 (54.5%) of males having distal tumours in contrast to 11/14 (78.6%) of females. Despite 
our cohort ranging in age from 28 to 50 there was no tendency for younger patients to have 
distal cancers with the mean age of those with proximal cancers being 40.7 years as opposed 
to 44.5 years for those with distal tumours. Interestingly, although 17/25 (68%) of the cohort 
had distal tumours, among those tumours with APC mutations, 11/18 (61.1%) were distal while 
6/7 (85.7%) of tumours lacking APC mutation were distal. 
Levels of microsatellite instability have been reported to be higher in early-onset CRC than in 
older patients with rates amongst patients aged under 50 years of age ranging between 19.8% 
and 31% (Cheong et al., 2019; Perea et al., 2010) while older patients display lower rates 
(Cheong et al., 2019). In our cohort we found only 3/25 (12%) of cases with microsatellite 
instability. The lower rate may be partly attributed to the exclusion of Lynch syndrome patients, 
in whom a germline mutation in a DNA mismatch repair gene results in a defective mismatch 
repair process. This is exemplified by an unrelated study of microsatellite instability in CRC 
patients aged under 45 years old, where 11 (24%) of the 45 patients had microsatellite 
instability but when patients with germline mutations in mismatch repair genes were removed, 
this reduced to 6/40 (15%) (Salovaara et al., 2000). We saw no association of microsatellite 
instability with tumour location, with the three microsatellite instability tumours being found 
in the ascending colon, splenic flexure and sigmoid colon respectively. 
 When EOCRC patients are further stratified by age, it is clear that the younger the age at 
diagnosis, the higher the likelihood of microsatellite instability. Studies looking at younger age 
groups show higher rates of microsatellite instability that include 40.5% in a cohort of under-
40s (J. T. Liang et al., 2003), 47.5% in under-30s (Farrington et al., 1998) and 72.7% in under-
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25s (Durno et al., 2005). The median age of the cohort in our study is 44 years which may 
additionally explain the lower microsatellite instability rate. In support of this hypothesis is the 
finding that two of the six patients (33%) under the age of 40 in the cohort displayed 
microsatellite instability. 
Like CDH1, APC promoter methylation has long been associated with colorectal cancer 
(Esteller et al., 2000). With the high rate of APC mutation in our cohort, it is possible that 
promoter methylation may be involved as the second-hit in some of these cases. Unlike CDH1, 
where most mutations are loss-of-function mutations, the truncated APC proteins that arise 
from many of the mutations still retain some functionality (Chandra et al., 2012; Christie et al., 
2013), and indeed the altered functionality of the truncated forms appears to promote 
carcinogenesis (Albuquerque et al., 2002). Promoter methylation, which results in loss of 
expression, would preclude a silenced allele from performing these altered functions, thus it 
may be that methylation of the APC gene occurs in cells where the other allele is already 
truncated and performing the oncogenic role required by the cells. Allelic loss of APC has been 
shown to occur more often in tandem with a truncation at around codon 1300 (Rowan et al., 
2000) and accordingly it may be that protein loss via promoter methylation may occur 
alongside similarly positioned APC truncations. 
 
4.4.1 Conclusions 
The absence of any pathogenic CDH1 mutations in all the adenocarcinoma samples in our 
early-onset CRC cohort suggests that, unlike the early-onset SRCC tumours from Pakistan, 
mutation of this gene is not a common cause of CRC in under 50 year-olds in New Zealand. 
This is further evidenced by the strong E-cadherin staining in all the adenocarcinoma samples 
tested. This includes strong E-cadherin staining in the sample with a p.P30T variant, which is 
in keeping with the bulk of evidence in the literature that p.P30T is not pathogenic. The 
negative E-cadherin staining in the sole SRCC sample concurs with our conclusions from the 
previous chapter that loss of E-cadherin is, however, a common factor in the development of 
colorectal SRCC, even when due to other mechanisms than CDH1 mutation. The weak E-
cadherin staining found in the only adenosquamous tumour in our cohort may indicate a 
different aetiology to the more common adenocarcinomas.  
The presence of a high number of APC mutations in our cohort compared to other studies of 
early-onset CRC may reflect the methodology used, particularly the extent of the gene that is 
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investigated in different studies and that, particularly with recent advances in sequencing 
technology, greater coverage of the APC gene is desirable when looking for possibly 
pathogenic APC mutations. Whereas the association of loss of heterozygosity at the APC locus 
with mutations around codon 1300 is not a novel discovery, it does add to existing evidence 
























Chapter 5 Gene editing of mutant APC in HT29 cells 
 
5.1 Introduction 
While Chapter 3 described a role for E-cadherin silencing in the development of early-onset 
colorectal signet-ring cell carcinomas, Chapter 4 showed that this was not as prevalent in the 
cohort of early-onset, colorectal adenocarcinomas, where only the sole SRCC case showed 
negative staining for E-cadherin. Instead, the finding of high rates of APC mutation in this 
cohort suggests that early-onset colorectal adenocarcinomas in our community may have 
similar aetiologies to tumours in older patients, where there is considerable existing evidence 
of APC mutation as an early event in carcinogenesis (Powell et al., 1992).  
While current thinking is that the development of sporadic cancers may be driven by 
environmental and/or lifestyle factors (J. Keenan et al., 2017; Richardson et al., 2016), there is 
also increasing evidence to suggest a role for an individual’s gut microbiota in the aetiology of 
these cancers. Specifically, long-term carriage of toxin-producing strains of gut bacteria is 
considered to have the potential to initiate colorectal carcinogenesis (Tjalsma et al., 2012).  
Bacteroides species are highly abundant in the gut microbiota (Wick & Sears, 2010) and are 
generally considered to contribute to human health (Mazmanian et al., 2005). However, select 
strains of B. fragilis can express a toxin capable of triggering colonic inflammation in mice 
(Rhee et al., 2009) and damaging cellular DNA (Goodwin et al., 2011). Carriage of these 
enterotoxigenic strains of B. fragilis (ETBF) is reportedly increased in patients with colorectal 
cancer (J. I. Keenan et al., 2016; Toprak et al., 2006), and long-term colonic carriage of ETBF 
is associated with significant risk of low-grade colonic dysplasia (Purcell et al., 2017). 
To date, in vitro studies of mechanisms that might underlie B. fragilis toxin (BFT)-mediated 
carcinogenesis have been performed using the human colonic cancer HT29 cell line or its 
derivative HT29/c1 (Huet et al., 1987). Numerous studies have demonstrated the ability of 
purified BFT to cause these cells to round up, reportedly as a result of toxin-mediated cleavage 
of extracellular E-cadherin (Sears, 2009). However, when BFT is added to the human 
colorectal carcinoma HCT116 cell line, these cells retain their normal morphology.  
The APC gene in HT29 cells carries mutations that allow expression of only truncated APC, 
whereas the gene in HCT116 cells expresses full length wild type APC (El-Bahrawy et al., 
2004) (Figure 5.1), raising the possibility that the reported “exquisite sensitivity” of HT29 cells 
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to BFT may reflect their APC genotype rather than toxin-mediated loss of E-cadherin per se. 
If so, using cell culture models where the cells are already partly along the pathway to cancer 
(and drawing conclusions regarding the effects of environmental factors on colonic epithelial 
cells) has the potential to misrepresent the risk long-term carriage of ETBF has on the 
development of carcinogenesis in an infected individual. As such, HT29 cells may not represent 
a useful cell line in which to model the effects of BFT on normal epithelial cells in the gut, in 
order to better understand how this bacterial toxin might drive colon carcinogenesis.  
 
 
Figure 5.1 APC functional domains and isoforms in HT29 cells. Top: Full length wild type APC 
protein with functional domains annotated. Middle and bottom: Truncated APC protein isoforms found 
in HT29 cells. The shortest truncated APC at the bottom is the isoform corrected in this chapter. MCR, 
mutation cluster region. 
 
One option is to study HCT116 cells as they carry an intact APC gene. HCT116 cells, however, 
also carry an activating mutation in the CTNNB1 gene, which encodes β-catenin and, like cells 
with mutated APC, also have a defective Wnt signaling pathway (El-Bahrawy et al., 2004).  
An alternative option is to express full-length APC protein in HT29 cells and use these cells to 
measure the effects of the toxin on colonic epithelial cells with correctly regulated Wnt 
signalling pathways. APC has been expressed in HT29 cells previously (Morin et al., 1996), 
with the inducible APC-expressing cells used to elucidate downstream targets of Wnt signaling 
(T. C. He et al., 1998). However, Morin and colleagues used a zinc-inducible promoter to 
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express APC. The B. fragilis toxin is a zinc metalloprotease (Moncrief et al., 1995), meaning 
the use of a zinc-inducible promoter was not an option for our study. Instead we sought to edit 
the APC gene in HT29 cells using a CRISPR-Cas9n (nickase) approach (Ran et al., 2013) as a 
means to enable wild type APC expression from the HT29 cells’ genomic DNA. 
While both APC alleles are mutated in HT29 cells it was felt that maintaining one mutant allele 
would be the prudent option in the first instance as truncated APC isoforms are known to be 
critical for the proliferation of CRC cells (Chandra et al., 2012). In other words the removal of 
both truncated forms may have been too detrimental to the cells. Editing of the second allele 
could be considered after the establishment of a stable cell line with one corrected APC allele. 
It was decided to correct the c.2557G>T mutation which would leave the c.4666_4667insA 
mutation unaltered, thereby leaving a truncated isoform with β-catenin binding domains that 
may be critical in the function of the truncated isoform (Figure 5.1).   
This chapter details the development of a derivative of the HT29 cell line expressing full-length 
APC as a model for investigating a role for BFT in the initiation of colon carcinogenesis. 
 The aims of the chapter were to: 
1. Edit genomic APC using a CRISPR-Cas9 system to allow endogenous expression of 
wild type APC from HT29 cells. 
2. Characterise the resultant cell line in comparison with the original HT29 cell line. 




CRISPR-Cas9n editing of the mutated APC gene in HT29 cells was carried out using the 
methods described in Chapter 2.2.4. Briefly, plasmids carrying antibiotic resistance genes as 
well as containing the gene for the Cas9 nickase enzyme, targeted to the c.2557G>T mutation 
in the APC gene, and a template fragment encompassing the relevant genomic region of wild 
type APC to copy, were transformed into HT29 cells and cultured in the presence of selective 
antibiotics. Colonies of surviving cells were then tested to identify clones with APC 
successfully edited at the c.2557 locus. Putative edited clones were confirmed by both Sanger 
and next-generation sequencing. The other mutant allele, c.4666_4667insA, was not corrected. 
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The growth rate of a clone containing corrected APC was compared to those of the parent HT29 
cell line and the colonic epithelial cell line HCT116, both of which have defective Wnt 
signalling, caused by mutated APC (HT29) or β-catenin (HCT116). This was done by growing 
the cell lines in appropriate media for 96 hours at 37°C, and counting the number of cells per 
well at 24 hour intervals (Section 2.2.2.2).  
Immunofluorescence microscopy was used to show the expression and localization of E-
cadherin, β-catenin and actin, while protein expression was investigated by Western blotting 
of cell lysates, using materials (Table 2.7) and methods (Section 2.2.4.12) as described in 
Chapter 2.  
Immunoprecipitation of the APC protein in cell lysates was carried out using specific N- and 
C-terminal antibodies (section 2.2.4.11). Precipitated proteins were run on 4-20% gradient 




5.3.1 HT29 cells contain three alleles encoding truncated forms of the APC 
protein. 
A previous study utilizing spectral karyotyping to assess chromosomal abnormalities amongst 
commonly studied colonic epithelial cells found that there were three copies of the long arm of 
chromosome 5 in the HT29 cell line (Abdel-Rahman et al., 2001). HT29 cells are known to 
exhibit two truncated forms of APC, a single base pair change, c.2557G>T, introducing a stop 
codon resulting in a p.853X truncation, and a single base pair insertion, c.4666_4667insA, 
resulting in a p.T1556fsX3 frameshift and subsequent truncation.  
To date there are no reports of relative allelic ratios of these truncations in light of the additional 
chromosome. In the previous chapter, next generation sequencing was described as a way to 
screen the APC gene for evidence of mutations in patient samples (Section 2.2.3). Using a 
similar approach to sequence the APC gene in the HT29 cells allowed an assessment of the 
relative proportions of each mutant allele within HT29 cells. Accordingly, when HT29 cells 
were sequenced in this way, 1477/2166 (68%) of reads for the c.2557G>T mutation exhibited 
the G allele while the remaining 689/2166 (32%) displayed the mutant T allele. We concluded 
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therefore that 1/3 alleles contain the c.2557G>T mutated APC, while 2/3 alleles contain the 
c.4666_4667insA mutation.  
 
5.3.2 CRISPR-Cas9n editing can incorporate errors into target sequences. 
A CRISPR-Cas9n approach was used to correct the c.2557G>T mutation in the APC gene of 
HT29 cells. The CRISPR-Cas9n editing process can however result in both on (or near)-target 
and off-target errors. Accordingly, Next Generation Sequencing was used again to confirm that 
CRISPR-Cas9n editing of selected clones resulted in clones with just the c.2557G>T mutation 
corrected. The importance of including this step is highlighted by the finding that one of the 




Figure 5.2. Short deletion incorporated during CRISPR editing of APC gene. Sequence reads as 
viewed on the Integrative Genomics Viewer showing the failure of CRISPR-Cas9n to incorporate the 
correct sequence in one of the 96 selected clones. The top of the figure shows chromosome 5 with the 
highlighted region of 5q22.2 containing the APC gene. Below that the mutant thymine, highlighted on 
the right of the sequence reads, has not been edited while a 24 base pair sequence has erroneously been 





5.3.3 Confirmation of APC editing in HT29 
Once individual clones from the CRISPR-Cas9n editing experiment (described above in 
Section 5.2) had grown to approximately 80% confluency in wells of a 96-well plate, the cells 
were harvested. For each clone some cells were seeded into a new plate, while others were used 
to confirm that editing of the APC gene had occurred. 
Cells from 96 individual CRISPR-Cas9n edited clones were centrifuged, washed and 
resuspended in 10mM Tris-CL pH8, boiled for 15 min and centrifuged. The supernatant was 
then used for PCR of the APC sequence spanning the mutated base at c.2557, with XhoI 
digestion of the PCR product (see Section 2.2.4.5) to confirm the incorporation of template 
DNA into the HT29 genome (Figure 5.3). Sanger sequencing of one clone, referred to as  Clone 
30, was carried out to confirm incorporation of the corrected base and restriction sites (Figure 
5.4). This was later confirmed by Next Generation Sequencing as described in Section 2.2.3 
(not shown).  Due to its confirmed genomic correction, Clone 30 was subsequently referred to 
as HT29 APC+/-. 
 
 
Figure 5.3. Digestion of PCR products from CRISPR-Cas9n edited clones. PCR products spanning 
the edited region of the APC gene were digested with XhoI. The undigested PCR product is indicated 
by the blue arrow, with the two XhoI digestion products obtained from Clone 30 indicated by red 
arrows. Template plasmid DNA was used as a positive control (+) and water was used as a no template 







Figure 5.4. Sanger sequence of APC confirming incorporation of template fragment correction of 
the c.2557G>T mutation. The APC sequence of Clone 30 shows incorporation of XbaI and XhoI sites 
indicating that the Cas9n enzyme has incorporated the template fragment DNA into the genomic APC 
DNA. Black arrows indicate bases altered to incorporate restriction sites; red arrow indicates the base 
edited from the mutant thymine to the wild type guanine base. 
 
5.3.4 Correction of the APC gene in HT29 cells slows their growth rate 
HT29 cells and HT29 APC+/- cells (derived from Clone 30 and shown to have one corrected 
APC allele) (5 x 104 cells) were grown in 1 mL of media in 24 well plates for four days. Their 
growth rate was assessed at 24 hour intervals by lifting and counting the number of cells per 
well. HT29 cells showed rapid growth as expected for poorly differentiated cancerous cells. 
However, the HT29 APC+/- cells showed a growth rate that was significantly slower than that 
of their parent cell line (Figure 5.5). 
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Figure 5.5. Growth rates of HT29 and HT29 APC+/-. Cell counts were measured over 96 hours at 24 
hour intervals for each cell line with the CRISPR-edited cell line showing a lower growth rate than its 
parent cell line HT29. The results shown are from three independent experiments, analysed using Two-
Way ANOVA with Sidak’s multiple comparisons test. ****; P<0.0001 
 
Interestingly, the number of non-viable cells, as determined by trypan blue staining (Section 
2.2.2.2), was significantly higher in HT29 APC+/- than in the parent HT29 cell line (Figure 5.6) 
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Figure 5.6. Percentage of non-viable cells during growth of cell lines. Dead cells stained with trypan 
blue were counted and were calculated as a proportion of total cells. A greater proportion of cells with 
corrected APC stain with trypan blue than HT29 cells. The results shown are from three independent 
experiments, analysed using Two-Way ANOVA with Sidak’s multiple comparisons test. *; P<0.05. 
 
5.3.5 HT29 APC+/- cells maintain morphology after incubation with BFT-enriched 
supernatant. 
Based on the growth curves in Figure 5.5, cells of each of the three cell lines (HT29, HT29 
APC+/- and HCT116) were seeded in 24 well plates at concentrations between 5 x104 and 1 x 
105 cells/well with the aim of reaching similar levels of confluence after 48 hours of growth. 
Concentrated enterotoxigenic B. fragilis broth culture supernatants, prepared by ammonium 
sulphate precipitation of broth following bacterial culture (Section 2.2.5.1) and demonstrated 
to have measureable toxigenic activity (Section 2.2.5.2) were then added to the cells. After 6 
hours of incubation with the BFT-enriched supernatant the HT29 cells showed distinctive 
rounding in response to the toxin, as reported elsewhere (Sears, 2009), while the concentrated 
NTBF supernatant (used as a negative control) had no effect on cell morphology over the same 
period of time (Figure 5.7).  
Likewise little to no rounding occurred in HT29 APC+/- cells in response to the concentrated 
ETBF supernatant, with the morphology of the toxin-treated cells observed to closely resemble 





Figure 5.7. Cell morphology following incubation with BFT-enriched ETBF supernatant. The 
effect of BFT on HT29 cells can be seen by the rounding up of cells (arrowed), whereas no rounding 
up occurs with supernatant from NTBF. Cellular morphology is barely affected in both HT29 APC+/- 
and HCT116 cells. Images are representative of three independent experiments. BFT, B. fragilis toxin, 
ETBF, enterotoxigenic Bacteroides fragilis; NTBF, non-toxigenic Bacteroides fragilis. The cells were 
viewed under 40x magnification. 
 
5.3.6 Bacteroides fragilis toxin-mediated loss of E-cadherin occurs in HT29 
APC+/- cells  
HT29 and HT29 APC+/- cells were grown on coverslips for 48 hours (Section 2.2.2.5), after 
which ETBF or NTBF supernatant was added to the medium and the cells were incubated for 
a further 6 hours. The cells on coverslips were, fixed, permeabilised, washed and incubated 
with an anti-E-cadherin antibody overnight at 4°C, before incubation with an AlexaFluor-
tagged secondary antibody directed  to the E-cadherin antibody (Section 2.2.2.5) for 2 hours at 
room temperature. Cells were also incubated overnight in Texas-Red Phalloidin, a 
fluorescently-tagged toxin that binds to actin. Nuclei were then stained with Hoechst 33342 for 
30 minutes, and coverslips were washed and mounted on slides for fluorescence microscopy. 
94 
 
E-cadherin was cleaved in both HT29 and HT29 APC+/- cells after incubation with the toxin-
enriched ETBF supernatant but the loss of actin staining was much greater in HT29 cells than 
in HT29 APC+/- cells (Figure 5.8). This finding supports the idea that full-length APC has a 
role in maintaining the integrity of the actin cytoskeleton following exposure to BFT, via its 
association with the cytoskeleton (Moseley et al., 2007; Narayan & Roy, 2003) and thus cell 
morphology, as seen in Figure 5.7. 
Collectively these results support the hypothesis that toxin-mediated loss of epithelial cell 
morphology is largely due to the absence of full-length APC protein as opposed to simply loss 
of inter-cellular E-cadherin. 
 
Figure 5.8. Immunofluorescence staining of HT29, HT29 APC+/- cells with and without BFT-
enriched supernatant treatment. E-cadherin staining (green) is markedly reduced in both cell lines 
following incubation with BFT-enriched supernatant. Actin staining (red) reduces in HT29 cells with 
BFT-enriched supernatant but is maintained in HT29 APC+/- cells. Nuclei are stained blue. The cells 




5.3.7 Full length APC is not identifiable in Western blots of HT29 APC+/-. 
HT29, HT29 APC+/- and HCT116 cells were grown to confluency and Western blots were 
performed on cell lysates to identify the APC protein. Probing with an antibody raised against 
the N-terminal region of APC produced a band at the expected level in the HCT116 cell lysate 
but not in either the HT29 or HT29 APC+/- lysates, despite the expectation that it would be 
present in HT29 APC+/- (Figure 5.9). Instead, lower molecular weight bands were seen in HT29 
and HT29 APC+/- lysates at approximately 100 kDa and 200 kDa, which are the expected sizes 
of the truncated proteins in HT29 (Cristofaro et al., 2015). The 200 kDa protein in the HT29 
APC+/- lysate was of much lower intensity than in HT29 whereas the lower band at 100 kDa 
appeared stronger. This was unexpected, given that the more 5’ APC mutation was corrected, 
meaning the lower 100 kDa band should have been the one to disappear in the edited cell line. 
 
 
Figure 5.9. Expression of APC in CRC cell lines. Western blotting of cell lysates with an N-terminal 
antibody recognising APC. A long exposure was used to ensure any APC present in the lysates was 
seen thus there is considerable background. A band is seen in the HCT116 lane at the expected size of 
312 kDa (blue arrow) but is absent in both the HT29 and HT20 APC+/- cell lysates. Bands at 
approximately 200 kDa and 100 kDa (black arrows) represent the truncated versions of APC found in 




Cell lysates were also blotted and probed with an antibody against the C-terminal region of 
APC. In this case, only those cell lines with full-length APC would be expected to give a signal 
(Figure 5.10). However, all cell lysates showed a band above 250 kDa irrespective of their APC 
status. Similarly all cell lysates gave a signal just above the 150 kDa band, which was not 
expected for any APC isoform. Previously, C-terminal antibodies that recognize the APC 
protein have been found to bind to an unrelated protein of approximately 150 kDa (Davies et 
al., 2007). This may be what is occurring here and, if so, this suggests that the C-terminal 
antibodies may be prone to non-specific binding.   
 
Figure 5.10. Western blotting of cell lysates with a C-terminal APC antibody. All cell lines gave 
strong signals for a band in excess of 250 kDa irrespective of their expected APC genomic status. Non-
specific signal was also seen strongly in all lysates at about 150 kDa. Clone 50 was included as a 
possible APC-corrected cell line but was subsequently found to have suffered an eight amino acid in-
frame deletion upstream of the targeted mutation. 
 
5.3.8 Immunoprecipitation of proteins reveals specificity of APC antibodies. 
To ascertain the specificity of the antibodies being used for probing for APC, N-terminal and 
C-terminal APC antibodies were used to immunoprecipitate the proteins they bind to by 
incubating the antibodies with HT29, HT29 APC+/- and HCT116 cell lysates. The precipitated 
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proteins were then separated by SDS-PAGE, transferred to PVDF membrane and probed with 
APC-specific antibodies. When the C-terminal antibody was used, no signal was obtained from 
the proteins precipitated with the N-terminal antibody (not shown). When the blot was probed 
with the N-terminal antibody, there was evidence of a large band in the HCT116 cell line lane 
precipitated by the C-terminal antibody (Figure 5.11). However, the same antibody failed to 
precipitate bands in either of the other two cell lines suggesting that the C-terminal bands for 
HT29 and HT29 APC+/- seen in Figure 5.10 above are non-specific. Thus while the C-terminal 
antibody can recognize full-length APC, it also has strong association with something other 
than APC and is therefore not a good antibody to use in our research.  
It was also noted that there was only a faint band in the HCT116 cell line lane that was 
precipitated with N-terminal antibody, suggesting that the N-terminal antibody has reduced 
affinity for full-length APC (when compared to the strength of the band in the C-terminal 
precipitated HCT116). This also reflects the relative strengths of the bands seen in Figure 5.9 
where whole lysates were stained with N-terminal antibody. There the full-length APC band 
in the HCT116 cell line was markedly less intense than the bands for truncated APC in the 
other lanes. Thus the N-terminal antibody we used may not be an ideal antibody for identifying 
full-length APC. 
 
Figure 5.11. APC N-terminal probing of immunoprecipitated cell lysates. Proteins 
immunoprecipitated with either N-terminal or C-terminal antibodies were probed with the N-terminal 







The use of colonic epithelial cell lines to study environmental factors affecting colon 
carcinogenesis is well established. For example, HT29 and its derivative HT29/c1 are the 
predominant cell lines used in the study of ETBF infection (Sears, 2009). However, HT29 cells 
have only truncated forms of the APC protein due to mutation of the gene and we hypothesised 
that the absence of full length APC in HT29 cells may play a part in the marked sensitivity of 
HT29 cells to BFT toxin, a reason these cells are attractive to researchers studying ETBF in 
CRC. If loss of APC is indeed a factor in the response of colonic epithelial cells to 
environmental factors in the development of CRC, then HT29 cells are not ideal for the study 
of the earliest events in colorectal carcinogenesis. 
We reasoned it would be intriguing to look at the same responses in the same cells with full 
length APC. To this end, we attempted to edit one allele of APC in HT29 cells using a CRISPR-
Cas9n system and to characterise the resultant cell line. We successfully corrected the 
c.2557G>T mutation in APC by inducing single strand breaks close to each other on each DNA 
strand around the mutated base with a nickase enzyme, and then incorporating correct DNA 
sequence via homology-directed repair from template DNA inserted into the cell in a plasmid 
(Ran et al., 2013). The use of a nickase enzyme to create two nearby nicks on opposite strands, 
rather than a single double-strand break created by conventional Cas9, is thought to limit the 
chance of off-target effects, due to the reduced likelihood of both guide RNA recognition 
sequences annealing close to each other at non-specific sites (Ran et al., 2013).  
The efficiency of the editing was low, with one successful clone being produced from 96 tested 
clones. This may be partly due to our use of separate Cas9n plasmids for each gRNA 
recognition site. These plasmids contain the same puromycin resistance gene for selection, 
potentially resulting in survival of cells containing one or both plasmids. Single strand nicks 
are readily fixed by repair processes in mammalian cells, and therefore the presence of only 
one guide RNA would result in Cas9n nicking one DNA strand, but this nick would be fixed 
by the cell in the absence of the second gRNA targeting Cas9 to create the second nick. Thus 
clones surviving antibiotic selection due to the presence of only one guide RNA encoding 
plasmid are unlikely to result in editing of APC, and this likely accounts for the high number 
of failed clones. An alternative strategy would be to include both guide RNA coding sequences 
in the same plasmid as has recently been done by others (Adikusuma et al., 2017).   
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We also encountered issues with the editing process where a clone (Clone 50) contained a 24-
bp in-frame deletion directly upstream of the mutant base. This is likely to have resulted 
following successful nicking of the APC gene followed by incorporation of the deletion during 
the homology-directed repair process (Figure 5.2). Mistakes like these are common during 
CRISPR-Cas9 gene editing (van Overbeek et al., 2016) and therefore sequence analysis of the 
DNA around the edited bases is essential.  
Our finding via Next Generation Sequencing that HT29 cells contain three copies of APC 
comprising two separate alleles, two copies of one allele with the c.4666-4667insA mutation 
and one copy of a second allele with the c.2557G>T mutation, while incidental to our project 
aims, is a noteworthy discovery. It fits with the previous finding that HT29 contains 3 copies 
of most of chromosome 5 (Abdel-Rahman et al., 2001) and will inform those working on APC 
in HT29 cells. Indeed with regard to the current project it is useful to know that the allele we 
attempted to correct represents only a third of the mutated APC alleles in HT29 cells, which 
may have relevance when considering the behaviour of successfully edited clones. Our finding 
that HT29 APC+/- cells have a markedly slower growth rate than the parent HT29 cells is in 
line with the study by Morin et al (Morin et al., 1996). This finding of a slower growth rate in 
cells expressing full length APC can be explained by the observation of a gradient of increasing 
APC expression levels in colonic epithelial cells undergoing crypt-to-villus differentiation, 
while highly proliferating cells at the bottom of the crypt express relatively little (Boman & 
Fields, 2013). APC mutation results in a shift in this gradient and a resulting dysregulation of 
cell proliferation up the crypt. The observed increase in the proportion of non-viable HT29 
APC+/- cells (as measured by trypan blue staining) likely reflects the turnover of fully-
differentiated cells occurring at the colonic epithelial surface.  
The most striking property of the CRISPR-edited HT29 APC+/- cell line was its apparent 
resistance to the toxin-mediated loss of morphology that is widely reported in the HT29 cell 
line (Sears, 2009). Instead, after 6 hours of incubation with the concentrated toxin-containing 
ETBF supernatant, the HT29 APC+/- cell line showed no evidence of cell rounding, retaining 
morphology that was similar to that seen in a similar number of HCT116 cells (that are APC+/+) 
(El-Bahrawy et al., 2004), treated with the same concentration of toxin and for the same length 
of time. Fluorescence microscopy confirmed that the resistance to morphological change upon 
exposure to ETBF supernatant exhibited by the edited HT29 APC+/- cell line was not due to 
any inability of BFT to cleave E-cadherin in these cells, suggesting that the mechanism by 
which HT29 cells round up following E-cadherin cleavage was prevented in the edited cells.   
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APC is a multi-functional protein and is known to interact with actin to stabilise the 
cytoskeleton (Moseley et al., 2007). Actin filaments are formed by the polymerisation of actin 
monomers in the cytoplasm. This process is started by specific proteins acting as actin 
nucleolators, an important one of which is APC. Actin filaments are polymerised by an 
interaction of APC and mDia1, a formin protein, with actin via the APC basic domain 
(Breitsprecher et al., 2012). APC is also key to maintaining the cytoskeleton through its binding 
to actin filaments via β-, and α-catenins (Narayan & Roy, 2003). Thus, while cells exposed to 
BFT have E-cadherin cleaved, the structure of the cells may be maintained in cells where APC 
can preserve the connections with the cytoskeleton, such as seen in BFT-treated HCT116 cells.  
The truncated versions of APC present in HT29 cells both lack the C-terminal half of the 
protein which contains the basic domain required for actin filament assembly as well as 
catenin-binding sites. In particular, the c.2557G>T APC mutation that we have attempted to 
correct results in a protein with no catenin binding sites. Therefore HT29 cells may be more 
susceptible to rounding up upon BFT-mediated E-cadherin cleavage due to the inability of 
truncated APC to form actin filaments, and the presence of a full-length APC protein may 
restore this function.  
In addition, APC forms a complex with EB1, via a binding site at the C-terminus of APC 
(Figure 5.1) and this APC/EB1 complex binds to the ends of microtubules which can then be 
coupled to the cell cortex (Mimori-Kiyosue et al., 2000). Reciprocal interaction between 
microtubules and the actin cytoskeleton has been shown to be necessary for the establishment 
and maintenance of cell shape (Akhmanova & Hoogenraad, 2015), and therefore the roles of 
the C-terminal half of APC in both of these interacting structures suggest the re-introduction 
of full-length APC to HT29 cells would likely have a stabilising effect on cell morphology 
(Figure 5.7) and actin cytoskeleton (Figure 5.8), even in the event of E-cadherin cleavage as 
seen in this study.  
Cleavage of E-cadherin by BFT leads to release of membrane-associated β-catenin into the 
cytoplasm, where it can migrate to the nucleus, bind the transcription factor TCF4 and 
dysregulate Wnt-signalling target genes (Clevers, 2006). This promotes epithelial-
mesenchymal transition (EMT) in the cell, a key step in colorectal carcinogenesis (Polyak & 
Weinberg, 2009). Where full-length APC exists in the cytoplasm, this excess β-catenin can be 
mopped up by the APC protein complex, phosphorylated, ubiquitinated and targeted for 
degradation (Clevers, 2006), thereby slowing the EMT process. In contrast, where full-length 
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APC is absent or partially absent (as in APCMin+/- mice), EMT and subsequent tumour 
development can occur rapidly following exposure to B. fragilis toxin (Rhee et al., 2009). Our 
finding of a slower growth rate of HT29 APC+/- cells, compared to the parent HT29 cells, also 
supports the assertion that APC slows down or reverses EMT within these cells, as the rate of 
proliferation is considerably decreased. 
The proportion of non-viable cells was also considerably higher in the edited cell line than 
either HT29 or HCT116 cells. While the reason for increased cell death was not investigated 
here, Morin and colleagues observed the same phenomenon when full-length APC was induced 
and, by visualising condensed chromatin or micronuclei with Hoechst 33258 stain in the 
floating cells, concluded that cell death was due to apoptosis (Morin et al., 1996). 
The failure to identify APC protein expression in the edited HT29 APC+/- cell line is 
concerning. The change in cell growth rate and the resistance of the edited cells to 
morphological change upon exposure to ETBF supernatant were predicted outcomes of 
successful expression of full-length APC  generated by the editing process. Induced expression 
of APC in HT29 led to a substantial decrease in the growth rate of the cells (Morin et al., 1996) 
and HCT116 cells are resistant to morphological change despite loss of E-cadherin. 
Accordingly, showing expression of full-length APC in the edited cell line will be critical to 
proving our hypothesis that BFT-mediated morphological change in HT29 cells is enabled by 
the lack of full-length APC, and the resistance to this shown by the edited cells is not due to an 
as yet unidentified factor. Despite the choice of antibodies in this chapter being based on a 
review of previously published research, there does seem to be a question mark over the 
reliability of both C-terminal and N-terminal APC antibodies (Davies et al., 2007). This lack 
of availability of APC antibodies that can consistently immunoprecipitate and immunoblot 
effectively may limit progress.  One additional way to investigate this could be to investigate 
expression of Wnt-signalling target genes such as MYC, which encodes the c-myc transcription 
factor, based on an early study that reports expression of full-length APC should result in a 
decrease in c-myc (T. C. He et al., 1998).  
Alternatively, or additionally, the inability to detect wild-type APC in the edited cell line could 
be due to the initial clone containing unedited HT29 cells, possibly protected from puromycin 
selection by surrounding edited cells. Upon removal of puromycin, the faster growth of these 
cells may have led to them be over-represented in subsequent culture and therefore making 
wild-type APC harder to find. Both next generation and Sanger sequencing of early cultures of 
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Clone 30 indicate successful editing of the APC gene and the growth and behaviour of the cell 
line seem to indicate that full-length APC is present. Later failure to show full-length APC 
protein may be due to poor antibodies, the presence of unedited HT29 cells or a combination 
of both. 
In conclusion, the editing of the c.2557G>T mutation in APC in HT29 cells resulted in a cell 
line that is apparently resistant to the BFT-mediated loss of cell morphology that is seen in 
toxin-treated HT29 cells. While our results suggest this may relate to the association of APC 
to E-cadherin via actin and the catenins, further experiments are necessary to prove this 
hypothesis. Nevertheless, the altered response of the edited cells to BFT-enriched supernatant 
indicates this newly derived cell line will be a useful tool in increasing our understanding of 
















Chapter 6 Discussion and future directions 
 
6.1 General Discussion 
Early-onset CRC incidence is increasing worldwide despite a reduction in overall incidence of 
CRC, and New Zealand has among the steepest rises in incidence among young adults (Siegel 
et al., 2019). It has been postulated that early-onset CRC constitutes a separate subset of CRC 
(Silla et al., 2014), therefore a greater understanding about the aetiology of these cancers, 
including factors that potentially influence early-stage carcinogenesis, is paramount to 
treatment, detection and prevention strategies. 
To this end, the research detailed in this thesis comprised three distinct yet related studies. 
Firstly, the CDH1 gene was sequenced and the expression of its product, E-cadherin, was 
investigated by immunohistochemistry in a cohort of colorectal signet ring cell carcinomas 
from Pakistanis aged 40 years or under. The rationale for this was based on the similarities 
between colorectal SRCCs and SRCCs in hereditary diffuse gastric cancer, and the strong link 
between mutation of CDH1 and HDGCs (Guilford et al., 1998). While colorectal SRCCs make 
up approximately 1% of all primary CRCs (Kang et al., 2005), they are frequently found in 
younger patients with one study of 29 SRCC patients having 18 (62%) aged under 50 years old 
(Anthony et al., 1996). 
Secondly, this study was expanded to a local New Zealand cohort of early-onset colorectal 
tumours, primarily adenocarcinomas. In addition to CDH1 we also sequenced APC, a gene 
mutated in 60-80% of colorectal cancers but with reportedly lower levels in younger patients 
(Willauer et al., 2019). The early-onset CRC cohort contained only one SRCC and one 
adenosquamous carcinoma while the rest were conventional adenocarcinomas, suggestive of a 
lower level of CDH1 mutations and E-cadherin loss. Due to its frequent occurrence in CRC, 
APC mutation was likely to be present more frequently than CDH1 mutation. Moreover, the 
reported rate of APC mutation in EOCRC compared to older colorectal tumours made this an 
interesting gene to investigate.  
Finally, a mutated APC gene in a commonly used colorectal cell line, HT29, was edited using 
a CRISPR/Cas9n approach, to produce a cell line which expresses full length APC protein. The 
rationale for this was the growing awareness that early-life exposures potentially influence 
colon carcinogenesis (Siegel et al., 2019). To that end, we exposed the wild-type and 
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CRISPR/Cas9n edited cells to a bacterial toxin linked to the development of pre-cancerous 
lesions in the colon (Purcell et al., 2017), to better understand the role of APC in early colorectal 
carcinogenesis. 
 
6.1.1 CDH1 mutations in SRCC 
The finding, described in Chapter 1, of multiple CDH1 mutations in the colorectal SRCC 
samples from Pakistan (Aitchison et al., 2020), was not surprising due to the histological 
similarities between colorectal SRCC and HDGC, where CDH1 mutations are the predominant 
cause (Guilford et al., 1998). The loss of functional E-cadherin leads to loss of cell to cell 
contact and, coupled with the accumulation of large volumes of intracellular mucin, results in 
the classic signet-ring morphology where the nucleus is pushed to the edge of a rounded cell 
(Gopalan et al., 2011).  
With the samples coming from a region of the world where consanguineous marriages are 
common, the high rates of early-onset SRCCs observed may have suggested an autosomal 
recessive disorder involving CDH1. However, the presence of wild type alleles alongside the 
mutant forms suggested this was not the case. 
There was also no evidence of a founder mutation effect in the cohort, as no common mutations 
were seen in this cohort. This absence of a single founder mutation effect is also notable 
amongst New Zealand Māori, with high rates of HDGC caused by inherited CDH1 mutations, 
where many different mutations are found (Hakkaart et al., 2019), whereas a founder CDH1 
mutation has been identified in several Newfoundland families with HDGC (Kaurah et al., 
2007). The finding of multiple different CDH1 mutations in a population, if germline, as in the 
New Zealand Māori cohort, would suggest aberrant E-cadherin has offered a selective 
advantage at some point. The nature of any selective advantage is unknown. E-cadherin is 
however a target for adhesion of Candida albicans (Phan et al., 2007), Listeria monocytogenes 
(Mengaud et al., 1996) and Streptococcus pneumonia (Anderton et al., 2007). Thus aberrant E-
cadherin protein structure and/or expression may offer some resistance to adhesion of these 
(and potentially other) pathogenic microorganisms. 
Despite the lack of a founder effect or autosomal recessive inheritance, the possibility that some 
of the mutations found in the colorectal SRCC cohort were inherited was intriguing. However, 
the absence of family history for any of the Pakistani patients that could have provided evidence 
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of germline mutation in some of the cases precluded further investigation of this aspect of the 
study. Additionally, the lack of clinical follow-up data prevented assessment of any prognostic 
significance of loss of E-cadherin (Wang et al., 2016). 
It was noted that there was not a complete concordance of CDH1 mutation status with E-
cadherin expression in the SRCC samples. Tumours lacking CDH1 mutations, but also with 
weak or absent E-cadherin expression, represent alternative mechanisms of E-cadherin 
silencing, such as allelic loss or epigenetic silencing. Epigenetic silencing in the form of 
promoter methylation, where methyl binding proteins such as MeCP2 bind to methylated 
cytosine residues in the promoter preventing transcription factors from binding to the DNA, is 
a likely possibility as has been seen in HDGC either on its own or as a second-hit following 
CDH1 mutation (Grady et al., 2000). CDH1 promoter methylation in colorectal SRCCs has 
previously been shown in colorectal cancers (Darwanto et al., 2003) however methylation 
analysis of the Pakistani samples was not possible due to the poor yield and quality of DNA. 
Allelic loss at the CDH1 locus is another possibility for the two tumours showing a majority 
of alleles to be mutant. Loss of heterozygosity has been reported as a common feature of 
colorectal SRCCs (Kakar & Smyrk, 2005) and may account for the lack of wild type CDH1 
sequences for both the E-cadherin negative staining sample with a predicted damaging 
p.G839D mutation, and the weakly E-cadherin positive sample with a predicted benign 
p.A446V mutation. Unfortunately, as with methylation analyses, the yield and quality of the 
DNA recovered from the FFPE samples precluded an investigation of LOH in these samples. 
Similarly, PCR investigations of microsatellite instability would not have been possible in these 
samples. However, immunohistological assessment of MSI was possible by staining for the 
mismatch repair proteins MSH6 and PMS2. While some previous reports have suggested MSI 
may be a feature of SRCCs, there is no consensus on the association of MSI with SRCC (Nam 
et al., 2018; Ogino et al., 2006; Rosty et al., 2014). Interestingly, the finding of only two 
samples in this study having MSI, of which only one was a SRCC, the other being an 
adenocarcinoma with a signet ring component less than 50%, adds to the evidence of MSI not 
being a feature of SRCC (Nam et al., 2018). Furthermore, the two samples that lacked 
detectable PMS2 expression both showed positive, although weak, E-cadherin staining, 




The different levels of E-cadherin staining may also reflect differences in the phenotype 
associated with the particular mutation. A recent study looking at different CDH1 mutations 
suggested the location and type of CDH1 mutation may play a role in the phenotype displayed, 
with differences seen between patients with cleft lip or palate and those with HDGC 
(Selvanathan et al., 2020).  
Overall, the results detailed in Chapter 3 reinforce that E-cadherin loss is a key feature in 
colorectal SRCCs, but suggest that this loss can be due to a number of different factors 
including, in some but not all cases, CDH1 mutation. Further insight into potential causes, 
however, was precluded by two significant issues which were the quality of the FFPE samples 
and the lack of any data relating to the clinical outcome of each case, or to their individual 
family history of CRC. 
 
6.1.2 CDH1 and APC mutation in early-onset CRC 
Finding multiple CDH1 mutations in colorectal SRCC tumours from young people, we 
hypothesized that CDH1 mutation may contribute to the early-onset of colorectal cancer in 
young patients in New Zealand. However, this hypothesis did not stand up to testing as only 
one sample from our cohort was found to have a mutation and this was predicted to be benign. 
In addition E-cadherin staining was positive in all but one sample. Indeed the sample negative 
for E-cadherin was the only SRCC sample in the New Zealand cohort, reinforcing that loss of 
E-cadherin is a feature of colorectal SRCCs but not colorectal adenocarcinomas. Interestingly, 
this SRCC sample had no CDH1 mutation, was microsatellite stable and had no family history 
of cancers suggesting the lack of E-cadherin could be due to methylation of the CDH1 promoter 
(Darwanto et al., 2003). This remains to be investigated.  
While CDH1 mutation was not found to be a feature of early-onset CRC in this cohort, it should 
be noted that the ethnic make-up of the cohort was almost exclusively European except for a 
single Filipino patient. The lack of Māori in the cohort prevents the investigation of CDH1 
mutation as a cause of early-onset CRC in that group which gains significance in the light of 
CDH1 mutation as a cause of HDGC in Māori (Guilford et al., 1998). This may be remedied 
by studying a larger cohort including samples from regions of New Zealand where Māori 
populations are higher to create a cohort more representative of the New Zealand population 
as a whole. 
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An earlier study of 50 New Zealand colorectal cancer patients under the age of 25 years 
reported five tumours (10%) as SRCCs (Plunkett et al., 2014), whereas only one SRCC was 
found in the cohort detailed in chapter 4. This difference may, in part, reflect the ages of the 
two groups (median age 23.6 and 44 years, respectively).  A higher incidence of SRCC in a 
younger patient cohort may reflect the observation that the younger the patient, the poorer the 
outcome of CRC (Poles et al., 2016), as SRCC generally confers a poor prognosis (Barresi et 
al., 2017). A further distinction of CRC in patients of  a very young age is a reduced APC 
mutation rate only being found in the under 30 year age bracket, in a recent study looking at 
molecular differences in CRC at different age brackets (Willauer et al., 2019). These contrasts 
between age groups suggest the assertion, that early-onset CRCs are a subset of CRCs (Silla et 
al., 2014), may be particularly relevant for those patients under 30 years. 
The finding of APC mutations in the New Zealand cohort was not in itself surprising, but the 
rate of mutations (72%) was higher than previously reported in early-onset CRCs (Kothari et 
al., 2016; Willauer et al., 2019). This is likely to be due to the sequencing strategy used. Many 
studies have focused on the mutation cluster region as this is where the bulk of mutations are 
located, particularly in sporadic CRCs (Fearon, 2011). However, our strategy looked, and 
found, mutations at many locations upstream of the mutation cluster region. If only the 
mutations found in the mutation cluster region were considered then our rate of APC mutation, 
32% within the mutation cluster region and 56% within the final exon, would have been similar 
to previous reports. Two different cohorts investigated in one study had APC mutation rates 
for under 50 year olds of 41.6% and 65.2% respectively, with each cohort being studied using 
different protocols (Willauer et al., 2019). Accordingly, our high rate of APC mutations in 
upstream regions of the gene could be due to other studies confining their search. However, 
our finding also raises the possibility of an association between upstream APC mutations and 
early-onset CRCs. In FAP, germline APC mutations in the 5’ portion of the gene are associated 
with an attenuated form of the disease, whereas mutations within the mutation cluster led to 
conventional FAP, indicating phenotypic differences depending on the site of an APC mutation 
(Christie et al., 2013). These days modern sequencing techniques allow the investigation of 
large regions of DNA relatively cheaply. Accordingly, sequencing of the whole APC gene in 
future studies would ensure APC mutations were not missed, and expand the understanding of 
the full scale of APC mutations in early-onset CRCs. 
While the majority of APC mutations found in our cohort were sporadic and resulted in 
truncated proteins as expected, the discovery of a p.E1317Q missense mutation was of 
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particular interest. This mutation has been described before and appears to have incomplete 
penetrance of CRC (Frayling et al., 1998; White et al., 1996), suggesting environmental factors 
may determine whether individuals with p.E1317Q develop tumours. The patient in this study 
with the p.E1317Q mutation had a great aunt with bowel cancer, both parents had non-GI 
cancers and the patient was subsequently referred for testing for HNPCC. However, testing for 
FAP was not requested, presumably based on the absence of polyps.  The absence of polyps in 
this case may be due to the mutation being a missense mutation, rather than the more common 
truncating mutation observed in APC. As FAP is caused by mutations in the APC gene and 
codon 1317 is situated within the mutation cluster region, testing would have uncovered the 
mutation.  
 
6.1.3 Gene editing of mutant APC in HT29 cells 
The APC gene is mutated in most colorectal cancers (Kinzler & Vogelstein, 1996) and mutation 
is thought to be an early event in the adenoma-carcinoma pathway of colorectal carcinogenesis 
(Fearon & Vogelstein, 1990). The finding, described in Chapter 4, that 72% of early-onset CRC 
patients carried a mutation in APC, underlies the importance of understanding how the APC 
protein prevents carcinogenesis, and how mutation of APC is key to the cascade of changes 
that result in CRC. 
The HT29 colon cancer cell line has two truncated isoforms of APC and exhibits a strong 
response to the toxigenic bacterium ETBF, resulting in cell rounding. This has been attributed 
to the toxin-mediated loss of E-cadherin (Sears, 2009), but our observation that introducing 
full length APC protein to HT29 cells allowed the cells to maintain their structure after 6 hours 
of exposure to ETBF supernatant, suggests a role for APC in preserving cell structure. 
Fluorescent immunohistochemistry showed that E-cadherin was cleaved by the toxin in the 
edited cell line just as in the parent HT29 cells, so the maintenance of cell shape was due to 
some internal process involving APC and not resistance to E-cadherin cleavage. 
While the behaviour of the edited cell line suggested that full length APC was being expressed, 
and the sequence of the edited APC gene suggested successful correction of the mutated base, 
it was not possible to visualize full length APC. This may be due to non-specificity of APC 
antibodies. While the antibodies were chosen based on the literature they failed to work 
consistently in this study. The N-terminal antibody failed to consistently immunoprecipitate 
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and immunoblot (Figure 5.11), while the C-terminal APC antibody consistently picked up non-
specific protein, as reported elsewhere (Davies et al., 2007).  
 
6.2 Future Directions 
The increase in recent years in the number of people under 50 years of age in New Zealand 
(Gandhi et al., 2017) and around the world (Vuik et al., 2019) being diagnosed with sporadic 
CRC, while the rates of CRC in older patients decline, is an as yet unexplained phenomenon. 
The aim of this and future research is to better understand whether early onset CRC constitutes 
a subset with a unique biology, or whether it presents a continuum of older onset CRC, perhaps 
exacerbated by increasing and younger exposure to environmental and/or modern lifestyles (J. 
Keenan et al., 2017; Richardson et al., 2016). The worldwide increase in early onset CRC, 
coupled with the finding that a family history of CRC is not necessarily a risk factor for this 
disease, increasingly supports the idea that modifiable risk factors such as diet, obesity and lack 
of exercise are likely to have a role (Connell et al., 2017), and this is reinforced by studies on 
people who migrate from low- to high-risk areas of the world (Flood et al., 2000).  
Accordingly, considering lifestyle factors in conjunction with clinical factors and genetic 
analyses may help shed light on the reasons for the increase in early onset CRC. For example, 
patients with tumours exhibiting APC mutations have been found to have higher alcohol 
consumption, and red and processed meat consumption, than patients with APC wild type 
tumours (Gay et al., 2012). While the research described in this thesis compared APC mutation 
status with clinical data, such as tumour location and age, further research with access to 
lifestyle factors including diet, exercise, smoking and alcohol consumption, could provide 
important insights into environmental factors affecting cancer risk. 
An important factor not considered in this work, with regard to CDH1 and APC, is promoter 
methylation as a form of epigenetic silencing (Darwanto et al., 2003; Esteller et al., 2000). 
While the quality of the samples in Chapter 3 precluded study of methylation, the samples 
studied in Chapter 4 are suitable for methylation analysis and only time constraints prevented 
their inclusion in this thesis. Gene expression analysis of CDH1, APC and downstream targets, 
such as MYC and SMO in these tumours, will complement the methylation studies. In addition 
to the direct correlation of promoter methylation to gene expression, methylation analysis of 
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these and other genes may also link with lifestyle and the other environmental factors discussed 
above as a future area of research (Gay et al., 2012; Wong et al., 2007).  
The choice to investigate only CDH1 in the Pakistani cohort, and CDH1 and APC in the NZ 
cohort, rather than looking more widely throughout the genome was taken for a number of 
reasons. Firstly, there were solid hypotheses around looking at CDH1 and APC within these 
cohorts based on previous work by other groups. Secondly, there was an existing protocol for 
CDH1 sequencing (Hakkaart et al., 2019), which it was possible to use and adapt to sequence 
the APC gene as well. Thirdly, by using unique combinations of indexed primers for each 
sample, the number of flow cells run was kept to a minimum allowing the studies to be carried 
out at low cost. Despite the reducing costs of whole genome sequencing, and potential 
additional information that might have been obtained, that approach would have been 
prohibitively expensive in this case.  
The correction of one allele of APC by gene editing resulted in a colon cancer cell line (HT-
29) that showed resistance to morphological change when incubated with a B. fragilis toxin-
enriched supernatant, suggestive of the expression of full-length APC. However, the failure to 
detect APC protein in the edited cells leaves questions as to whether the stability of cell 
morphology is indeed due to the proposed mechanisms. Showing that full-length APC is indeed 
expressed will be an important first step in using these cells as a model of bacterially-induced 
carcinogenesis. Our finding that APC antibodies may not be reliable, reflecting previous 
findings (Davies et al., 2007), means that finding a robust APC antibody will be a priority for 
the next step in this research. An alternative antibody, FE-9, raised against the amino terminal 
of APC, was used successfully to detect full-length APC in HT29 cells containing a plasmid 
with an inducible APC gene (Morin et al., 1996). Additionally, sequencing of mRNA from the 
edited cell line should show no APC transcripts with the c.2557C>G mutation if the APC gene 
has been successfully edited. A further sequencing approach would be to use the long reads 
possible with Nanopore sequencing to show single DNA amplicons with both wildtype c.2557 
and wildtype c.4666 which would provide further proof that the editing has been successful. It 
was noted that in their paper discussing inducible expression of full-length APC in HT29 cells, 
Morin and colleagues mention that their attempts to constitutively express APC in HT29 cells 
were unsuccessful (Morin et al., 1996). This, combined with our inability to detect full-length 
APC in the edited cell line, suggests that HT29 cells may be unable to express APC, or that 
cells expressing APC are swiftly outgrown by cells with only truncated forms of APC. If this 
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were the case it might be expected that wildtype APC expression is being silenced, perhaps by 
some epigenetic mechanism. This is an area of ongoing investigation. 
APC has a key role in control of the Wnt/β-catenin signalling pathway, forming a complex 
with axin and glycogen synthase kinase 3β, to phosphorylate β-catenin and target it for 
ubiquitination and subsequent lysosomal degradation (Nathke, 2006). Expression of full-length 
APC in HT29 cells should therefore result in a reduction of Wnt-signalling target gene 
expression, particularly MYC, as seen when an inducible form of APC is expressed in HT29 
cells (T. C. He et al., 1998). Analysis of RNA expression will be an important future task, not 
just for MYC but also other genes. We would expect to see expression changes in the presence 
of full-length APC, such as reduced SMO, a mediator of DNA damage through generation of 
reactive oxygen species, that is frequently upregulated in CRC (Goodwin et al., 2011), and 
proteins in the Notch signalling pathway, which display crosstalk with Wnt signalling in the 
control of cell proliferation (Vinson et al., 2016).  
The epithelium of the colon consists of a polarised monolayer of cells that form along crypts. 
We have proposed using the HT29 APC+/- cells as a model of intestinal epithelial cells to study 
the role of ETBF in colorectal carcinogenesis. Colorectal neoplastic cells develop from 
differentiated epithelial cells before spreading along the crypt in a top-down morphogenetic 
process (Shih et al., 2001). However, HT29 cells, and the edited HT29 APC+/- cells are 
undifferentiated epithelial cells. HT29 cells can be differentiated by growth in glucose-free 
medium, where glucose is replaced as a carbohydrate source by galactose (Huet et al., 1987). 
These HT29 derivative cells, known as HT29/c1, grow as polarised differentiated cells. If the 
HT29 APC+/- cells can be similarly differentiated by growth in glucose-free media, the effects 
of ETBF on polarised monolayers containing full length APC can be studied. 
An alternative approach to CRISPR-editing of APC in HT29 cells that was considered involved 
using the approach of Huet and colleagues mentioned above to differentiate the HCT116 
colonic epithelial cell line that has full-length APC. Despite being able to reproduce the 
published differentiation in HT29 cells using this approach, we were unable to obtain the same 
results with HCT116 cells. A second approach using sodium butyrate to differentiate HCT116 
cells  (Fung et al., 2009) also failed, despite verifying the process in HT29 cells. These failures 
to differentiate HCT116 cells by methods successful in HT29 cells emphasise the differences 
between these CRC cell lines, and that understanding the mechanisms underlying the 
sensitivity of HT29 cells to BFT is critical to understanding any role of BFT in inducing 
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carcinogenesis. This gains significance when considering almost all cellular work on BFT-
induced carcinogenesis has been carried out on HT29 cells. 
Another alternative approach to studying the role of BFT in the initiation of CRC would be to 
grow primary colonic epithelial cells isolated from normal-looking mucosa of patients, and to 
assess the morphological, gene expression  and protein responses following exposure to BFT. 
BFT exposure of primary colonic tumour cells has been studied previously (Sanfilippo et al., 
1998) and adaptation of this protocol to study normal colonic cells as a model of normal 
epithelium could be a useful tool in investigating CRC initiation.  
In summary, disruption of E-cadherin was found to occur frequently in colorectal SRCC, 
whether by CDH1 mutation or by other mechanisms, but this was not the case with early-onset 
CRC, where all non-SRCC tumours expressed E-cadherin. Conversely, APC mutation is 
widespread in early-onset CRC, primarily sporadic but can be germline, even in a cohort where 
known familial cases have been excluded, suggesting that criteria for testing for familial 
syndromes may exclude some families.  
Rates of APC mutation were higher than other reports of early-onset CRC. Whereas this may 
be due to methodological difference, future strategies should look at the whole APC gene rather 
than just the mutation cluster region or other hotspots. This gains further significance with our 
novel observation that establishment of a derivative cell line of HT29 expressing full-length 
APC provided evidence that this protein appears to have an underappreciated role in stabilising 
cellular morphology. Accordingly, the derivative cell line is likely to prove a useful tool for 
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Appendix 1 PCR Primer Sequences 
 
Table A1. CDH1 amplicon specific primers for next generation sequencing 
Name Sequence (5’-3’) Product 
Size (bp) 
CDH1 Prom F 
CDH1 Prom R 
CDH1 Exon 1 F 
CDH1 Exon 1 R 
CDH1 Exon 2 F 
CDH1 Exon 2 R 
CDH1 Exon 3 F 
CDH1 Exon 3 R 
CDH1 Exon 4 F        
CDH1 Exon 4 R 
CDH1 Exon 5 F 
CDH1 Exon 5 R 
CDH1 Exon 6 F 
CDH1 Exon 6 R 
CDH1 Exon 7 F 
CDH1 Exon 7 R 
CDH1 Exon 8 F 
CDH1 Exon 8 R 
CDH1 Exon 9 F 
CDH1 Exon 9 R 
CDH1 Exon 10 F 
CDH1 Exon 10 R 
CDH1 Exon 11 F 
CDH1 Exon 11 R 
CDH1 Exon 12 F 
CDH1 Exon 12 R 
CDH1 Exon 13 F 
CDH1 Exon 13 R 
CDH1 Exon 14 F 
CDH1 Exon 14 R 
CDH1 Exon 15 F 
CDH1 Exon 15 R 
CDH1 Exon 16 F 





































































Amplicon-specific primers (black bases) designed with non-specific 18bp sequences at the 5’ end of 
primers (red bases). Two non-specific sequences used, one for forward primers, one for reverse primers. 
bp, base pairs. 
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Table A2. APC amplicon specific primers for next generation sequencing 
Name Sequence (5’-3’) Product 
Size (bp) 
APC Exon 5 F 
APC Exon 5 R 
APC Exon 6 F 
APC Exon 6 R 
APC Exon 8 F 
APC Exon 8 R 
APC Exon 9 F1 
APC Exon 9 R1 
APC Exon 9 F2 
APC Exon 9 R2 
APC Exon 11 F1 
APC Exon 11 R1 
APC Exon 11 F2 
APC Exon 11 R2 
APC Exon 12 F 
APC Exon 12 R 
APC Exon 13 F 
APC Exon 13 R 
APC Exon 15 F1 
APC Exon 15 R1 
APC Exon 15 F2 
APC Exon 15 R2 
APC Exon 15 F3 
APC Exon 15 R3 
APC Exon 15 F4 
APC Exon 15 R4 
APC Exon 15 F5 
APC Exon 15 R5 
APC Exon 15 F6 




























































Amplicon-specific primers (black bases) designed with non-specific 18bp sequences at the 5’ end of 
primers (red bases). Two non-specific sequences used, one for forward primers, one for reverse primers. 










Table A3. Forward adapter primers for creating next generation sequencing libraries 


















AAT GAT ACG GCG ACC ACC GAG ATC TAC AC CGTGAT ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC ACATCG ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC GCCTAA ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC TGGTCA ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC CACTGT ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC ATTGGC ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC GATCTG ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC TCAAGT ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC CTGATC ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC AAGCTA ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC GTAGCC ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC TACAAG ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC TTGACT ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC GGAACT ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC TGACAT ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
AAT GAT ACG GCG ACC ACC GAG ATC TAC AC GGACGG ACAC T CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
  







Table A4. Reverse adapter primers for creating next generation sequencing libraries 



















CAA GCA GAA GAC GGC ATA CGA GAT CGTGAT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT ACATCG GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT GCCTAA GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT TGGTCA GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT CACTGT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT ATTGGC GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT GATCTG GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT TCAAGT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT CTGATC GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT AAGCTA GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT GTAGCC GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT TACAAG GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT TTGACT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT GGAACT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT TGACAT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
CAA GCA GAA GAC GGC ATA CGA GAT GGACGG GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC 
 
Reverse adapter primers with unique index sequences shown in red.
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Table A5 Primers for generating template for CRISPR/Cas9n editing 







Primers to amplify the region of APC surrounding the mutation to be corrected. Primers incorporate 





Table A6 Primers for mutating template for CRISPR/Cas9n editing 
Name Sequence (5’-3’) Restriction Site 
APC template1 mut1F 
APC template1 mut1R 
APC template1 mut2F 








Primers designed to introduce XbaI and XhoI restriction sites, respectively, into the template plasmid 




Table A7 Primers for generating gRNA recognition sequences 









Pairs of primers with complementary sequences that anneal to form gRNA recognition sequences that 
recognise APC sequences in the region of the mutated base. Green bases denote sequences that 
recognize BpiI digested DNA, brown bases were added as the Cas9n system requires recognition 










Appendix 2 Buffers and Solutions 
 
2 x protein loading buffer (reducing): 0.4 g of sodium dodecyl sulphate (SDS) was dissolved 
in 7 mL of 0.125 M Tris solution (pH6.8). Two mL of glycerol and 0.002 g of bromophenol 
blue were added along with 1 mL of β-mercaptoethanol. The buffer was stored in 1 mL aliquots 
at -20°C. 
6 x DNA loading buffer: A 40 % (w/v) solution of sucrose was made with 0.25% (w/v) 
bromophenol blue and xylene cyanol. 1 mL aliquots were stored at -20°C. 
Phosphate Buffered Saline (PBS): A 10 x stock solution was made by dissolving 80 g sodium 
chloride, 2 g potassium chloride, 28.42 g di-sodium hydrogen phosphate and 2 g potassium 
dihydrogen phosphate in 1 L MPW. The stock was diluted 1:10 in mqH2O as required. 
PIPES buffer: 9.07 g of 1,4-piperazinediethanesulfonic acid (PIPES) were dissolved in 400 
mL MPW. The pH was adjusted to 6.8 with sodium hydroxide and the total volume adjusted 
to 500 mL.  
Polyacrylamide gel loading buffer (top): A 10 x stock solution was made by dissolving 60 g 
of Tris base, 286 g of glycine and 20 g of SDS in MPW to a total volume of 2 L. A working 
solution was made by diluting the stock 1:10 in MPW. 
Polyacrylamide gel loading buffer (bottom): A 2 L working solution was made up by 
dissolving 20 g of Tris base in MPW.  
Protein lysis buffer: A solution of 100 mM sodium chloride, 5mM EDTA, 1% (v/v) Nonidet 
P-40, 0.2% (w/v) SDS, 1 mM phenylmethanesulfonyl fluoride (PMSF), 1 mM sodium 
orthovanadate, and 0.5% (w/v) sodium deoxycholate was made in 50 mM tris-HCl to a total 
volume of 10 mL. One cOmplete mini protease inhibitor cocktail tablet was dissolved in the 
buffer which was then stored in 1 mL aliquots at -20°C until use. 
TBE (Tris Borate EDTA): A 10 x stock solution was made up by dissolving 108 g of Tris 
base 55 g of boric acid and 7.5 g of EDTA in MPW to a total volume of 1 L. The stock was 
diluted 1:10 in MPW as required.  
TBST: A 10 x stock solution of Tris buffered saline (TBS) was made by dissolving 15.125 g 
of Tris base and 44 g of sodium chloride in 450 mL of MPW, the pH adjusted to 7.5 with 
hydrochloric acid and the volume adjusted to 500 mL. The solution was diluted 1:10 in MPW 
and 1 mL Tween 20 detergent added to make a working solution. 
Transfer buffer: A 10 x stock solution was made by dissolving 60.4 g of Tris base and 288 g 
of glycine in MPW to a total volume of 2 L. Working solutions were made by adding 100 mL 
of 10 x stock solution to 800 mL of MPW and 100 mL of methanol. Working solution was 
stored at 4°C. 
Tris-HCl buffer: A 0.5M Tris solution was made up by dissolving 3 g of Tris base in 40 mL 
of mqH2O and the pH adjusted to 6.8 with hydrochloric acid. The final volume was adjusted 
to 50 mL with MPW. 
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Tris-EDTA buffer: Ten microliters of 0.5 M EDTA solution was added to 5 mL of 0.5 M 
Tris-HCl buffer (pH6.8) and the final volume adjusted to 50 mL to give final concentrations of 




Figure A1. Drug concentrations for selective drug sensitivity testing. To test the sensitivity of HT29 
cells to the selective drugs puromycin (A) and geneticin (B), cells were grown in wells of a 24-well 
culture plate in the presence of drugs at the above concentrations (Section 2.2.4.9). Note the differences 
in units between puromycin and geneticin.  
 
